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Abstract 
Secretion of mucins (e. g. MUC5AC) by the airway epithelium into the respiratory tract 
mucus layer is an important homeostatic mechanism which safeguards the lung from 
invasive pathogens and harmful particles. Airway mucus hypersecretion features in the 
pathophysiology of inflammatory-based airway diseases such as chronic obstructive 
pulmonary disease (COPD) and asthma. Signalling of the ErbB receptor tyrosine kinase 
subfamily, particularly the ErbBI and ErbB2 receptor subtypes, has been implicated in the 
process of airway mucus hypersecretion, and upregulation of ErbB 1 receptor occurs in the 
lungs of asthmatics, COPD sufferers, and cigarette smokers. Thus, ErbB receptor tyrosine 
kinase inhibitors (RTKIs) offer a potential treatment for airway mucus hypersecretion. This 
thesis studied the effects of five such inhibitors; an ErbBI, an ErbB2, and three dual 
ErbB 1+B2 inhibitors, in an in vitro system of mucin synthesis using NCI-H292 cells -a 
carcinoma-based lung epithelial cell line. After pharmacological characterisation of the 
NCI-H292 cell in vitro system, Taqman RT-qPCR was used to measure the effect of the 
five inhibitors on EGF-induced MUC5AC mRNA expression (as a marker of mucin 
synthesis). The effect of the five ErbB RTKIs on cell proliferation was also measured (as a 
positive control) by analysing DNA synthesis. All five inhibitors attenuated DNA synthesis 
with similar potencies suggesting all drugs were pharmacologically active, but only the 
single ErbBI RTK inhibitor attenuated EGF-induced MUC5AC mRNA expression. To 
address the discrepancy in pharmacological activity between the five ErbB RTKIs, activity 
of the ERKI /2 -dependent signal pathway involved in ErbB receptor-mediated MUC5AC 
synthesis was analysed by measuring ErbB receptor autophosphorylation (measuring 
phosphorylation of four specific tyrosine residues involved in ERKI/2 induction) and 
ERK1/2 phosphorylation by Western blot or ELISA. Although all five ErbB RTKI 
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compounds inhibited ErbBl and ErbB2 receptor autophosphorylation to some extent 
(particularly at 10 MM), only the single ErbBl RTK inhibitor convincingly inhibited 
autophosphorylation of all four tyrosine residues implicated in ERKI/2 signalling. Most 
importantly, the single ErbB 1 RTK inhibitor was the only inhibitor to block downstream 
phosphorylation of ERK1/2. The reason for the varying potencies exhibited by the five 
ErbBl RTK inhibitors was unclear but most likely reflects a difference in the 
pharmacological properties (for example, the receptor dissociation rate) of each compound. 
These data indicate that selective ErbB I RTK inhibitors would be of therapeutic benefit for 
the airway mucus hypersecretion of asthma and COPD. 
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CHAPTER 1 
INTRODUCTION 
The production of airway mucus is an essential homeostatic function of the lung epithelium 
that, under normal circumstances, provides protection against inhaled irritants including 
noxious gases, particulates and bacteria. The secretion of mucus traps foreign particles, and, 
coupled with the ciliated epithelium, removes them from the lung -a process referred to as 
mucociliary clearance. However, in diseases such as asthma, chronic obstruction 
pulmonary disease (COPD) and cystic fibrosis, mucus production can increase excessively 
and contributes to pathophysiology. 
1.1 COPD 
COPD is an increasing global health problem predicted to become the fifth most common 
cause of death by 2020 (Lopez and Murray, 1998). Cigarette smoking is the main 
environmental factor contributing to the development of COPD. COPD is a chronic, 
inflammatory disease which leads to narrowing of small airways (bronchiolitis), the 
destruction of lung parenchyma (emphysema) and mucus hypersecretion (Barnes et al., 
2003). The relative contribution of each of these components to the pathophysiology of 
COPD in any one patient is uncertain (Rogers, 2000). Cigarette smoke and the related 
oxidants that it produces have been shown to induce mucus hypersecretion in a variety of in 
vitro and in vivo models, and activation of the epidermal growth factor receptor (EGFR) 
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has been implicated in some of the pathways involved in this process (sections 1.6 and 1.7) 
(Richter et al., 2002; Shao et al., 2004; Takeyama et al., 2001b). 
1.1.1 Mucus hypersecretion in COPD 
COPD patients exhibit some of the classic characteristics of airway mucus hypersecretion 
(Fig. 1.1). The pathophysiology of mucus hypersecretion involves abnormalities that are 
thought to lead to an increase in the number of mucus-secreting cells in the airway 
epithelium and in the sub-mucosal glands (Leikauf et al., 2002; Maestrelli et al., 2001) and, 
hence, an increase in mucin production. There is an increase in both the goblet cell number 
in the bronchial epithelium (hyperplasia) and an increase in mucous cells of the peripheral 
airways (metaplasia). One of the possible contributing factors to the process of goblet cell 
hyperplasia is the activation of the EGFR (sections 1.6 and 1.7). 
The impact of mucus hypersecretion on airflow limitation in COPD remains unclear. Early 
studies suggested mucus hypersecretion and airflow obstruction were unrelated disease 
processes in COPD (Peto et al., 1983), but more recent epidemiological studies highlight 
the contrary (Vestbo et al., 1996). Consequently, the recommendation for the use of 
mucolytics (section 1.5) is now included in the latest guidelines for clinical management of 
COPD (National Collaborating Centre for Chronic Conditions, 2004). The subject has been 
recently reviewed (Vestbo and Hogg, 2006). 
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Figure 1.1: Mucus pathophysiology in asthma and COPD: differences and similarities. In 
asthmatics, there is increased luminal mucus, a similar or increased ratio of MUC5B to 
MUC5AC, small amounts of MUC2, epithelial fragility, marked goblet cell hyperplasia, 
submucosal gland hypertrophy (with a normal mucous to serous cell ratio), `tethering' of mucus 
to goblet cells, and plasma exudation. Airway inflammation involves T lymphocytes and 
eosinophils. In COPD, there is increased luminal mucus, an increased MUC5B to MUC5AC 
ratio, small amounts of MUC2, goblet cell hyperplasia, submucosal gland hypertrophy (with an 
increased proportion of mucous to serous cells), and respiratory infection. Pulmonary 
inflammation involves an influx of macrophages and neutrophils. Adapted and redrawn from 
(Rogers, 2004). 
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1.2 Asthma 
The increasing prevalence of asthma in many parts of the world continues to make the 
disease a global health concern (Masoli et al., 2004). Asthma, whatever the severity, is a 
chronic inflammatory disorder of the airway, manifesting itself in symptoms including; 
airway hyperresponsiveness, bronchoconstriction, oedema, airway remodelling and mucus 
hypersecretion (section 1.2.1). The airway obstruction in asthma arises through bronchial 
smooth muscle contraction, airway wall thickening and the formation of intraluminal 
mucus and debris. Airway wall thickening is characterised by submucosal oedema, 
vasodilatation, and the infiltration of inflammatory cells, predominantly lymphocytes 
(particularly Th2 lymphocytes) and eosinophils (Carroll et al., 1997). 
1.2.2 Mucus hypersecretion in asthma 
As mentioned above, airway mucus hypersecretion, sputum production and goblet cell 
hyperplasia are characteristic features of asthma (Fig. l. 1). The airways of many asthmatic 
patients can become obstructed by plugs of plasma exudate and mucus, which are difficult 
to eliminate by cough. Under less extreme conditions, asthmatics usually produce sputum 
either during or just after an asthma attack and, like COPD, this is associated with airway 
goblet cell hyperplasia and submucosal gland hypertrophy (Aikawa et al., 1992). The 
airway epithelium typically shows sloughing of cilated cells, with goblet cell and squamous 
cell metaplasia as manifestations of airway epithelial repair. The number of goblet cells 
(Fahy, 2002) and submucosal mucous glands is increased (Dunnill et al., 1969). The lumen 
contains mucus plugs, shed epithelium (Creola bodies) and Charcot-Leyden crystals 
(crystallised eosinophil derived major basic protein). Mucus is relatively dehydrated, and so 
viscid. The variety of remodelling events which occur in asthma lead to an increased 
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secretion of mucins into the mucus layer (Rogers, 2004). Large quantities of mucin 
proteins in the mucus layer greatly increase its viscosity leading to airway obstruction and, 
in severe cases, complete blockage through the formation of mucus plugs (Tillie-Leblond et 
al., 2005). As in COPD, activation of EGFR has been implicated in goblet cell hyperplasia 
and therefore may impact on the mucus hypersecretory phenotype associated with asthma 
(sections 1.6 and 1.7). 
1.3 Airway mucus 
Mucus is a complex aqueous solution consisting of a variety of lipids, proteins and 
electrolytes which protects the underlying epithelium from dehydration, pathogens, and 
chemical and particulate irritants. Airway mucus exists as a lower sol (aqueous) and an 
upper gel phase, with the sol phase bathing the base of the ciliated cells and the cilia, and 
the gel phase being transported along the mucociliary escalator to the throat where mucus is 
either coughed out or swallowed and delivered to the gastrointestinal tract for degradation 
(Knowles and Boucher, 2002). Thus, any inhaled particles trapped in the sticky mucus layer 
are removed from the airways by mucociliary clearance. The viscous consistency of mucus 
is a crucial property required for its function and is provided by the presence of a particular 
group of glycoproteins called mucins. 
1.3.1 Mucins and respiratory tract mucins 
Mucin proteins are large glycosylated proteins assembled from disulphide linkage of 
monomers and, in normal individuals, make up approximately 2% of airway mucus. These 
macromolecules are complex glycoconjugates, consisting of a protein backbone 
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(apomucin), encoded by MUC genes, to which hundreds of carbohydrate chains are added 
by post-transitional N- and O-linked glycosylation (Perez-Vilar and Hill, 1999) (Fig 1.2). 
Within the main core are variable numbers of tandemly-repeated serine- and/or threonine- 
rich regions which are unique in size and sequence for each different mucin species, and 
represent sites for mucin glycosylation (Lamblin et al., 2001). Mature mucins exist as two, 
structurally different classes; monomeric, membrane-bound mucins and oligomeric, 
secreted mucins. Membrane-bound mucins have transmembrane and cytosolic domains that 
allow them to be localised to the plasma membrane surface where they participate in such 
events as cellular adhesion, pathogen-binding and signal transduction. Membrane-bound 
mucins are not the subject of this thesis, and are thus not discussed further. 
r t44ijj$ffi}11: 
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VWF-D-like domain Y N-Glycan 
VWF-C-like domain f 0-Glycan 
Figure 1.2: Example of mucin structure - schematic diagram of the well characterised gel- 
forming mucin, MUC2. The numerous tandem repeats rich in proline, threonine and/or serine 
amino acids making up the peptide backbone in mucin proteins are often referred to collectively as 
the PTS-domain (although in the case of MUC2, serine residues are not present). As well as 
cysteine rich domains, mucin proteins also contain von Willebrand factor (VWF) homologous 
domains (also rich in cysteine) at their amino and carboxy termini. The high number of cysteine 
residues allows separate protein monomers to form disulphide-linked multimers. The N- and 0- 
glycans contribute to the stiffness of the molecule. Adapted and redrawn from (Dekker et al., 2002). 
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In contrast to membrane-bound mucins, secreted mucins contribute heavily to the 
viscoelastic properties of extracellular mucus layers. Most secreted mucins are much larger 
than the membrane-bound mucins (> 1000 kD) and contain cysteine-rich domains located 
at both the amino and carboxyl termini (homologous to von Willebrand factor D and C 
domains) (Fig 1.2). These cysteine-rich domains form disulphide bonds and link covalently 
to form mucin dimers which are then heavily glycosylated to form mature mucin dimers. 
These dimers further multimerize to form the long linear oligomers that provide the 
adhesive and space-occupying properties of the mucous gel layer (Sheehan et al., 2004). 
Although a number of mucin genes are expressed in human airways, the predominant gel- 
forming mucins secreted into airway mucus are thought to be MUC5B (which is itself 
found in a number of glycoforms) (Thornton et al., 1997), MUC5AC and, to a lesser extent, 
MUC2 (Hovenberg et al., 1996b). However, new gel-forming mucins such as MUC19 
(Chen et al., 2004) have recently been identified and our understanding of airway mucin 
secretions may alter in the future. 
The cellular sources of mucins secreted into airway mucus are goblet cells in the surface 
epithelium, that predominantly produce MUC5AC (Hovenberg et al., 1996a), and mucous 
cells in the submucosal gland that predominantly produce MUC5B and MUC2 (Finkbeiner, 
1999). After synthesis and post-translational processing, secreted mucins are stored within 
intracellular granules until stimulated for release by regulated exocytosis (Shimura, 2000; 
Rogers, 2003b). The production and secretion of mucins from both goblet cells and 
submucosal glands is a heavily regulated process influenced by many chemical mediators 
and neuronal activity (Rogers, 2001). 
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1.3.2 Mucin (MUC) genes 
Mucins are classified by their MUC protein backbone which, in turn, is encoded for by a 
specific mucin or 'MUC gene. However, the definition of what actually determines a 
mucin gene is not particularly consistent since over 20 MUC genes have been deposited in 
GenBank but only 18 actually encode for products containing the characteristic tandem 
repeats (rich in proline, theorine and/or serine) found in mucin proteins (Rose and Voynow, 
2006). Of these 18 human MUC genes, there are five that encode for oligomeric, gel- 
forming mucins (identified by recombinant DNA technology) which include: MUC2, 
MUC5AC, MUCSB, MUC6 and the recently identified MUC19. Four of these gel-forming 
mucins, namely MUC2, MUC5AC, MUC5B and MUC6, are all present in tandem as a 
conserved cluster on human chromosome 11p15. MUC19 is situated on chromosome 
12p12. 
The human respiratory tract expresses a number of MUC genes including: MUC1, MUC2, 
MUC4, MUC5AC, MUCSB, MUC7, MUC8, MUC11 and MUC13 (Morcillo and Cortijo, 
2006). Despite this eclectic range of expression, the predominant MUC gene products 
found in airway mucus, and thus thought to play a role in mucus hypersecretion, are 
MUC5AC, MUC5B and, to a lesser extent, MUC2. MUC5AC is the airway mucin of 
particular interest to the present thesis and is described below (section 1.3.2.1). 
1.3.2.1 MUC5AC 
`Tracheobroncial mucin' protein was first isolated from tracheobroncial lung mucosa (Rose 
et al., 1989) then subsequently cloned and identified as MUC5 (Meezaman et al., 1994). 
Originally, it was proposed that three MUC genes, MUCSA, MUC5B and MUC5C, existed 
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as separate entities. However, work by a French group (Guyonnet, V et al., 1995) identified 
MUCSA and MUC5C as part of the same gene, distinct from MUCSB, and were both 
renamed as the encompassing "MUC5AC". 
MUC5AC cDNA is approximately 16.6 kb long and encodes for a peptide sequence 
consisting of around 5525 amino acids (Fig. 1.3). The central core of the MUC5AC gene 
product containing the PTS-rich domain (see Fig 1.2) is interrupted by nine cysteine-rich 
domains responsible for formation of the disulphide bond required for mucin 
oligomerisation (Guyonnet, Vet al., 1995; Moniaux et al., 2001). 
Cys-rich 
4g _r AT / r/j 
von Willebrand PTS Domain (central core) C-terminal 
Factor containing domain 
N-terminus 
Figure 13: Simplified schematic representation of the amino acid sequence for MUC5AC. The 
5' end of the sequence contains various types of von Willebrand factor (VWF -a protein binding 
motif)-D-like domains (D1-3 and D'). The proline, threonine and serine rich (PTS) domain forms 
the core of the protein where, like other gel-forming mucins (e. g. MUC2 and MUC5B), 
glycosylation occurs. The central core is made up of both PTS-rich sequences (light blue) and four 
tandem repeated amino acid sequences (TR1-4 - dark blue) which are interspersed with nine 
cysteine rich sequences (red). The C-terminal, 3', region contains another VWF-D-like domain 
(D4) and also a VWF-C-like domain (yellow), culminating with a terminal peptide sequence (pink). 
PS: peptide signal. 
Compared with information on the amino acid and nucleotide sequence of MUC5AC, less 
is known about its signal promotor. The upstream sequence contains a TATA box located 
30 
P 
s1 
between bases -23 and -29, as well as a nuclear factor-kappaB (NFiB), Sp 1, GRE, AP-2, 
and a CACCC box (Li et al., 1998; Van, I et al., 2001). Since mucin synthesis is a heavily 
regulated process (section 1.3.1), the specific transcription factors involved in MUC5AC 
gene expression are most likely specific to the stimulus (or indeed pathological pathway) 
instigating transcription. 
The goblet cell hyperplasia associated with airway inflammatory diseases correlates with an 
increased expression of MUC5AC (both mRNA and protein) in the airways of patients with 
COPD (Caramori et al., 2004) and asthma (Kirkham et al., 2002; Ordonez et al., 2001), 
suggesting MUC5AC may contribute to the pathology of airway inflammatory diseases. 
MUC5AC is the main mucin produced by the goblet cells in the tracheobronchial surface 
epithelium. However, MUCSAC can be found highly expressed not only in human 
bronchial epithelium, but also in bronchial submucosal glands, nasal mucosa, gastric 
epithelium, endocervix epithelium and submucosal glands. 
1.4 Current therapeutic treatments for airway mucus hypersecretion 
The current selection of therapeutic drugs targeted specifically at mucus hypersecretion 
remains inadequate (Rogers and Barnes, 2006). Whilst research continues to discover new 
pathophysiological factors that influence mucus hypersecretion, the clinical outcome of this 
remains barren. Despite this, clinical management of asthma involves administration of 132- 
adrenoceptor agonists (e. g. salbutamol), which act as bronchodilators, and glucocorticoids, 
which effectively suppress expression of pro-inflammatory genes (Pelaia et al., 2003; 
Rogers, 2004). Increased mucin secretion is associated with the activity of various 
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inflammatory mediators such as leukotrienes and cytokines. Glucocorticoids can inhibit 
mucin secretion indirectly by suppression of these inflammatory mediators and directly by 
repressing MUC gene expression (e. g. MUC5AC) (Chen et al., 2005; Kai et al., 1996). 
On the other hand, the mucus hypersecretory phenotype in COPD patients is poorly treated 
by the use of glucocorticoids, due to the resistance COPD shows towards the anti- 
inflammatory effects of glucocorticoids (Barnes et al., 2004). The poor efficacy of current 
treatments in COPD is helping drive the development of new compounds. 
1.5 New treatments for airway mucus hypersecretion 
A host of possible, new therapeutic targets exist for treatment of mucus hypersecretion, 
although their effectiveness varies (Rogers, 2003a; Donnelly and Rogers, 2003). 
Inflammatory mediator antagonists, anticholinergics, mucoactive agents, phosphodiesterase 
4 inhibitors, MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) inhibitors, 
macrolide antibiotics, protease inhibitors, calcium-activated chloride channel inhibitors and 
P2Y2 agonists all warrant interest. 
The relatively recent recognition that EGFR may play a role in airway mucus production in 
COPD and asthma (section 1.6.4) has generated interest in the application of ErbB receptor 
tyrosine kinase inhibitors (RTKIs - already available as a therapeutic regime for the 
treatment of breast cancer) as possible therapeutic agents for the mucus hypersecretory 
phenotype associated with both these diseases. 
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1.6 ErbB receptors 
RTKs allow cells to translate information from a myriad of peptide ligands into an 
intracellular message which ultimately controls gene expression and biological outcome 
(Schlessinger, 2000). Epidermal growth factor (EGF) and its related peptides (>10 in total- 
section 1.6.2) are an example of a group of ligands that activate a subfamily of type I 
receptor tyrosine kinases called the ErbB receptors (Jorissen et al., 2003). The receptor 
subfamily was originally named according to their homology with the erythroblastoma viral 
gene product, v-erb. The ErbB receptor network is one of the most extensively studied 
areas of signal transduction due to the broad array of responses that occur as a result of 
ErbB receptor signalling. 
The ErbB receptor family contains four members (Fig. 1.3) and their biological functions 
are specific to cell type but mainly involve cell development, proliferation and survival. 
One of the prominent features of ErbB receptor signalling is that single receptors 
themselves are essentially non-functional - the process of ligand-induced dimerisation with 
other ErbB receptors is requisite for signal activation. The permutations of ErbB receptor 
dimer combinations and the number of ligands involved in the process underline the 
complexity of signalling within this subfamily of receptors and explain how they are 
capable of regulating so many biological processes. 
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1.6.1 ErbB receptor subtypes and structure 
The ErbB subfamily includes four RTKs; EGFR/ErbB1/HERI, ErbB2/HER2/Neu, 
ErbB3/HER3 and ErbB4/HER4 (referred to as their "ErbB" prefix herein) which are 
activated selectively by members of an epidermal growth factor (EGF)-related peptide 
growth factor family ofcytokines (summarised in Fig. 1.3) (Riese and Stern, 1998). 
There is strong homology within the ErbB receptor family and all four receptors share the 
same structure consisting of four extracellular domains (ECD I- IV) connected to a 
cytosolic, protein tyrosine kinase domain by a single, transmembrane spanning helix (Fig. 
1.3). Both the ECD (- 620 residues) and the protein tyrosine kinase domain (- 260 
residues) are highly conserved amongst the ErbB receptor family. ECD I and III (also 
known as LI and L2) are leucine rich repeats involved in ligand binding whereas ECD II 
and N (also known as CRI and CR2) are rich in cysteine residues and are involved in the 
dimerisation process (section 1.6.3). The extracellular component of the receptors is 
bridged with the intracellular component by a short transmembrane spanning helix (-. 23 
residues). A juxtamembrane stalk (-' 40 residues) then attaches the tyrosine kinase domain 
- which is flanked by a carboxy-terminal tail (- 232 residues) - to the transmembrane 
helix. The carboxy-terminal contains various tyrosine autophosphorylation sites specific to 
each ErbB receptor and provides the `substrate' for the kinase domain. Whilst the kinase 
domain provides the `machinery' for signal transduction, the four ECDs of ErbB receptors 
are responsible for ligand binding and dimerisation and are thus also instrumental in 
receptor function. 
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Figure 13: The ErbB receptor subfamily: structure and corresponding ligands. Structurally, 
the N-terminal, extracellular component of all four ErbB receptors is comprised of four extracellular 
domains (ECD) - denoted I, II, III and IV - linked to an intracellular protein tyrosine kinase (PTK) 
domain by a single transmembrane-spanning helix and a juxtamembrane stalk. The PTK domain is 
flanked by the carboxy-terminal tail which houses the sites of tyrosine autophosphorylation specific 
to each receptor. Despite similarity in structure, variation exists within the subfamily as the ECD I 
and III (denoted with an `X') of ErbB2 are constitutively locked together preventing ligand binding 
(hence ErbB2 is sometimes referred to as an orphan receptor) and ErbB3 has no intrinsic kinase 
ability (kinase dead - denoted with an `X'). However, since the activation of ErbB signalling 
requires receptor dimerisation, both these receptors remain functional (section 1.6.3). EGF: 
epidermal growth factor, TGF-cx transforming growth factor a, AR: amphiregulin, BTC: 
betacellulin, HB-EGF: heparin-binding epidermal-like growth factor, EPR: epiregulin and NRG- 
1/2/3/4: neuregulin-1/2/3/4. 
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Only ErbBI and ErbB4 are fully functional in terms of ligand binding and kinase activity. 
ErbB3 has impaired kinase activity (Guy et al., 1994) and relies on the kinase action of its 
heterodimerisation partners for signal transduction and activation (Kim et al., 1998). ErbB2 
fails to bind any of the known ErbB ligands but contributes its potent kinase activity to all 
possible heterodimers. Solving the 3D, crystal structure of ErbB2 revealed that there are 
specific differences in the ECD I and III compared with other ErbB receptors which 
obstructs ligand binding but at the same time encourages dimerisation (Garrett et al., 2003). 
For this reason, Erb2 receptors dimerise readily with other ligand-bound ErbB receptors 
and are commonly found in ErbB signalling complexes. The presence of ErbB2 in ErbB 
receptor heterodimers acts as a general signal amplifier, and heterodimers of ErbB2 and 
ErbB3 are the most potent ErbB pair in mitogenic signalling (Pinkas-Kramarski et al., 
1996). 
Interestingly, some transmembrane mucins such as MUC4 have been associated with 
modulating ErbB receptor signalling. MUC4 is a multi-domained mucin containing three 
EGF-like regions and can play a role in the expression levels of ErbB2 in pancreatic cancer 
cells (Singh et al., 2004). The precise mechanism driving this interaction is unclear, but 
there is evidence to suggest that Muc4 induces the relocalisation of ErbB2 (and ErbB3) 
receptors from intracellular compartments to the plasma membrane (Funes et al., 2006). 
Although transmembrane mucins are not the focus of the current thesis, the emerging 
modulatory effects of these mucins on ErbB receptor signalling remain an interesting 
phenomenon, and is providing a future focus for research into diagnostic and therapeutic 
targets in cancer (Singh et al., 2007). 
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1.6.2 ErbB receptor ligands 
Mammalian members of the EGF-like factor family include EGF, transforming growth 
factor a (TGFa), heparin-binding epidermal-like growth factor (HB-EGF), betacellulin 
(BTC), epiregulin (ER), amphiregulin (AR), epigen and a complex subfamily of 
neuregulins (NRG 1- 6), often referred to as heregulins. There is a large degree of receptor 
specificity amongst the ErbB receptor ligands (Jones et al., 1999) and it is possible to class 
them according to which receptors they bind to (Fig. 1.3). All ErbB receptor ligands share 
an EGF-like domain of around 50 amino acids that are required and indeed sufficient for 
activation (Barbacci et al., 1995; Jones et al., 1999). Within this domain, there are six, 
spatially-conserved cysteines and several semi-conserved residues that form disulphide 
bridges and produce the three-looped structure found in all EGF-like growth factors 
(Wouters et al., 2005) (Fig. 1.4). All ErbB receptor ligands exist as plasma membrane 
bound precursors that are proteolytically cleaved (shed) by metalloproteases in a process 
termed "ectodomain shedding" (section 1.6.2.1). 
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Figure 1.4: Schematic representation of the 3-loop structure common to all EGF-like and 
other growth factor ligands - exemplified by TGFa. A sequence of approximately 50 amino acid 
residues with conserved cysteine residues (turquoise) and other semi-conserved residues (yellow) 
manifests itself into a 3-looped structure through the formation of disulphide bridges. Adapted and 
redrawn from (Dunbar and Goddard, 2000). 
1.6.2.1 Generation of endogenous ErbB receptor ligands 
Another point of regulation governing the function of ErbB receptor signalling is the 
generation of the endogenous ligands that activate the receptors. As previously mentioned 
(section 1.6.2), ErbB receptor ligands exist as plasma membrane bound precursors that are 
proteolytically cleaved by proteases (or sheddases) to release a soluble mature growth 
factor in a process termed "ectodomain shedding" (Fig. 1.5) -a process common to many 
other growth factors and cytokines (Arribas and Borroto, 2002). Interestingly, since the 
cleavage sites are different for the various pro-peptide substrates, and there no similarities 
in the amino acid sequences surrounding the cleavage sites, the mechanism by which these 
sheddases recognise the appropriate substrate remains a mystery. In the case of pro-EGF- 
like factors, proteolysis occurs at a cleavage site within the precursor juxtamembrane stalk 
38 
region to release mature, soluble ligand which can signal in an autocrine or paracrine 
fashion. There is also evidence to suggest that EGF-like factors are capable of mediating 
biological effects whilst they are in their precursor, transmembrane immature state 
(Iwamoto and Mekada, 2000). 
The sheddases responsible for the generation of soluble ErbB ligands depend on the ligand 
being cleaved. However, ADAM 17 (A Disintegrin And Metalloprotease 17), otherwise 
known as TNFa Converting Enzyme (TACE), is the major protease involved in EGF 
peptide ligand shedding and is responsible for cleaving ligands such as TGF-a, HB-EGF 
and amphiregulin (Sunnarborg et al., 2002; Merlos-Suarez et al., 2001) (Fig 1.5). EGF itself 
and betacellulin are converted into the mature, soluble ligand form by ADAM 10 (Sahin et 
al., 2004; Higashiyama and Nanba, 2005; Sanderson et al., 2005). TACE is readily 
activated by a number of pharmacological stimuli including calcium ionophores, 
phosphatase inhibitors, serum factors and phorbol esters including phorbol 12-myristate 13- 
acetate (PMA). PMA was used (Chapter 3) as an indirect stimulant for ErbB receptor 
signalling, acting via TACE. TACE is also activated by a number of pathological stimuli 
and thus can contribute to the phenotypes of airway diseases such as asthma and COPD 
(see section 1.7.3). 
In addition to activators of TACE, there are also inhibitory compounds available, for 
example TAPI-2 (Arribas et al., 1996b) (Fig 1.5). TAPI-2 was used herein to investigate the 
relative contribution of PMA-induced, TACE-mediated ErbBI ligand ectodomain shedding 
to MUC5AC gene expression (Chapter 3). 
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Figure 1.5: Schematic representation of the ectodomain shedding of EGF-like factor. From left 
to right, TNF r Converting Enzyme (TACE) is activated by agents such as the phorbol ester, PMA, 
and inhibited by compounds such as TAPI-2. Upon activation, TACE cleaves a specific proteolytic 
site on the extracellular portion of the EGF-like factor precursor peptide sequence (1) releasing 
mature, soluble ligand e. g. TGFa (2). This soluble ligand can then activate ErbB receptors in either 
a paracrine or autocrine fashion. 
1.6.3 ErbB receptor ligand-induced dimerisation 
ErbB receptor ligand-induced dimerisation is a complex but mandatory procedure for ErbB 
receptor signalling (Fig 1.6). The ErbB family members are distinguished from all other 
known receptor tyrosine kinases in possessing constitutive kinase activity without the need 
of a phosphorylation event within their kinase domains (Stamos et al., 2002). The process 
of ligand-induced dimerisation serves as a highly specialised mechanism of introducing the 
constitutively active kinase domain of one ErbB receptor to the carboxy-terminal tail 
Mature 
Soluble 
Ligand 
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`substrate' of another receptor (the substrate being the tyrosine autophosphorylation sites) 
(Fig 1.6). 
A salient feature of the ErbB receptor dimerisation system is that the ErbB2 monomer 
(which has no affinity with any of the EGF-like factors) exists in a "preactivated" state, 
making it the preferred dimerisation partner for all ErbB receptors (Graus-Porta et al., 
1997) (Fig. 1.6). 
Once all the conformational requirements favourable for receptor activation have been met 
(Fig. 1.6), specific tyrosine residues are autophosphorylated, rendering the ErbB receptor 
dimer primed for signal transduction. 
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Figure 1.6: Schematic representation of ErbB receptor ligand-induced dimerisation - 
dimerisation of ErbB2 to other ligand-bound ErbB receptors. The extracellular domain (ECD) 
I and III of the native ErbB2 receptor are in close proximity to each other (like that of ligand-bound 
ErbB receptors), exposing the putative dimerisation arm located in ECD 11. This locks ErbB2 in a 
structural conformation `primed' to dimerise with other ErbB receptors. Dimerisation with other 
such receptors occurs in the absence of bound ligand, but without the presence of an EGF-like 
factor, this conformation is unstable and is not capable of initiating signalling. However, binding of 
ligand to the ECD I and III of the non-ErbB2 receptor present in the unstable dimer complex 
stabilises the conformation. Further conformational changes involving the transmembrane spanning 
domain and the cytoplasmic domain allow the C-terminal tails of the receptors, which house the 
tyrosine autophosphorylation sites (P), to be presented to the kinase domains. 
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1.6.4 ErbB signal transduction 
The process of ligand-induced dimerisation and autophosphorylation of carboxy-terminal 
tyrosine residues common to all receptor tyrosine kinase signalling systems results in the 
recruitment of phospho-tyrosine binding adapter molecules (Holbro and Hynes, 2004). 
However, regulation of the nature, duration, and potency of the intracellular signalling 
pathways activated by ErbB receptors is, unsurprisingly, very complex. The ligand, the 
receptor composition on a cell, the availability of intracellular adapter molecules, as well as 
negative effectors down-regulating the signal are some crucial parameters that determine 
the final outcome of ErbB activation. 
1.6.4.1 Carboxy-terminal tyrosine autophosphorylation 
The autophosphorylation of ErbB receptor carboxy-terminal tyrosine residues is the starting 
point of signal transduction. Each ErbB receptor carboxy-terminal contains a number of 
tyrosine residues that offer themselves as substrates for the kinase domain (residues 
involved in mucin synthesis are discussed in sections 1.6.4.3 and 1.6.5 and Fig. 1.8). Once 
autophosphorylated these residues become targets for specific intracellular adapter 
molecules which activate individual signal transduction pathways (section 1.6.4.2). The 
ErbB ligand-receptor dimer complex is a key component for determining the pattern of 
tyrosine autophosphorylation and thus the characteristics of ErbB receptor signal 
transduction (Sweeney and Carraway, III, 2000). Uncovering how the process of 
autophosphorylation of specific tyrosine residues on ErbB receptors is coordinated with the 
recruitment of intracellular adapter proteins has been a crucial step in our understanding of 
ErbB receptor signalling mechanisms. 
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Evidently, it is not just the autophosphorylated tyrosine residue itself that determines which 
signal molecule is recruited, but the 5-8 amino acid residues surrounding the tyrosine 
autophosphorylation site (Songyang et al., 1995). The small peptide sequences within 
which the tyrosine autophosphorylation sites are housed provide a substrate for the ErbB 
kinase domain and show specificity towards particular receptor kinase domains (Di Fiore et 
al., 1990; Fan et al., 2004). The ErbB ligand-receptor dimer conformation alters the affinity 
of the catalytic kinase domain to individual peptide substrates, effectively creating a system 
of implementing specificity over which carboxy-terminal tyrosine residues (encompassed 
within the peptide substrates) are autophosphorylated. Once autophosphorylated, the 
phospho-tyro sine residues become docking sites for specific adapter molecules that 
translate the signal into a response (section 1.6.4.2). By employing such a system, the 
permutations of signal generation in the ErbB receptor signalling network can be 
distinguished and allocated into distinct pathways. The diversity and sheer number of 
signalling possibilities is reflected by the ErbB receptors capability of manifesting control 
over so many biological processes. 
1.6.4.2 Adapter molecules and ErbB receptor signal transduction 
The autophosphorylation of specific ErbB receptor tyrosine residues effectively "turns the 
ignition key" of ErbB signal transduction and instigates the next stage - recruitment of 
adapter molecules (Fig. 1.7). Intracellular adapter proteins mediate the linkage of the 
ligand-receptor-induced phosphorylation events to kinase cascades that ultimately activate 
transcription factors to induce gene transcription. It is the structural components of these 
adapter proteins which allow them to play a role in translating receptor activation into gene 
transcription. 
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Adapter molecules possess a number of structural motits that recognise and bind to specific 
sequences on other proteins or enzymes. Examples of structural motifs or interaction 
modules found in many cytoplasmic mediators include the Src-homology 2 (SH2) domain, 
which recognises and binds to phosphorylated tyrosine residues (Pawson, 2004) (Fig. 1.7), 
the phospho-tyrosine binding (PTB) domain (Yan et al., 2002) and the Src-homology 3 
(SH3) domain, a motif which binds to proline rich peptide sequences (Li, 2005) (Fig. 1.7). 
Through the utilisation of PTB, SH2 and SH3 domains, adapter proteins facilitate the 
fin-nation of phospho-protein-protein interactions, hence a translational bridge between 
tyro sine-phosphoiylated proteins and downstream effectors can be created (Koch et al., 
1991; Shoelson, 1997) (Fig. 1.7) 
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Figure 1.7: Adapter molecules: playing the middle man. The dual presence of phospho-tyrosine 
binding domains (e. g. S112 domain) and protein binding domains (Sfi3 domain) in the structure of 
adapter proteins allows them to link two otherwise unrelated proteins during signal processes. 
Upon activation, individual ErbB receptors bind a distinct subset of signalling molecules, 
which, as previously mentioned (section 1.6.3), is influenced by the composition of the 
ligand-receptor dimer complex. Adapter molecules such as growth factor receptor-bound 
protein 2 (Grb2) (Lowenstein et al., 1992; Rojas et al., 1996), phospholipase Cy (PLCy) 
(Kim et al., 1990; Wahl et al., 1990) and Src homology containing (Shc) protein (Pelicci et 
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al., 1992) have all been associated with ErbB intracellular signalling and are summarised in 
Figure. 1.8. 
Grb2 and She interact with ErbB autophosphorylated tyrosine residues via their SH2 
domains (Batzer et al., 1994). As well as binding to the phosphorylated receptor, Shc can 
also undergo ErbB I -mediated tyrosine phosphorylation itself, allowing it to complex with 
the SH2 domain of Grb2. (Rozakis-Adcock et al., 1992). In either scenario, Grb2 interacts 
with the guanine-nucleotide-exchange factor (GEF) son of sevenless (Sos) via its SH3 
domain. Thus, the interaction of the Grb2-Sos or the Shc-Grb2-Sos complexes with the 
autophosphorylated ErbB receptor results in targeting of Sos to the plasma membrane, 
which is the location of Ras -a guanine nucleotide triphosphatase or GTPase (Batzer et al., 
1994). The presentation of Sos to Ras instigates its conversion from an inactive, GDP 
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Figure 1.8: ErbBl and ErbB2 autophosphorylation sites involved in the induction of the 
MEK/ERK (MEK - mitogen activated protein kinase kinase, ERK - extracellular-signal 
regulated kinase) cascade. The tyrosine phosphorylation sites on the ErbBl and ErbB2 receptors 
which are integral to ERK signal transduction are summarised. On the ErbBl receptor, tyr1068 is 
the major Grb2 binding site and interacts with the phosphorylated residue via its SH2 domain 
(Okutani et al., 1994) whereas tyrl 148 and 1173 are major sites for interaction with Shc via both its 
PTB and SH2 domains (Okabayashi et al., 1994; Sakaguchi et al., 1998). PLC1 has two phospho- 
tyrosine binding sites: tyr992 (Rotin et al., 1992) and tyrl173 (Chattopadhyay et al., 1999). The 
ErbB2 receptor has two tyrosine autophosphorylation sites that are associated with ERK activation. 
Tyr1139 and tyrl221 /2 bind to Grb2 and Shc respectively via the SH2 domain motif. PLCy - 
phospholipase Cy, Grb2 - growth hormone receptor binding protein 2, Shc - Src homology 
containing protein, SHP I- SH2 containing tyrosine phosphatase and PKC - protein kinase C. 
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bound conformation, to an active, GTP-bound form which subsequently initiates the 
activation of the ERK/MAPK (extracellular signal-regulated kinase/mitogen activated 
protein kinase) cascade (Fig. 1.8) and ultimately gene transcription (Kyriakis et al., 1992; 
Crews et al., 1992). 
1.6.4.3 ErbB signalling and the ERK cascade 
ErbB receptor activation is associated with the induction of a variety of gene transcription- 
inducing kinases such as c-Jun N-terminal kinase - JNK, protein kinase C- PKC, Akt and 
ERK (Prenzel et al., 2001). However, ErbB receptor-induced mucin synthesis (section 
1.6.5) is administered by a MAPK cascade (Van, I et al., 2001; Perrais et al., 2002), and is 
discussed in this section (Fig. 1.9). 
The MAPK pathway is a phospho-relay cascade system composed of three, sequentially 
activated kinases: MAPK kinase kinase (MKKK), MAPK kinase (MKK) and the terminal 
enzyme - MAPK. Multicellular organisms possess three major MAPK pathway modules: 
ERK, JNK and p38 (Chang and Karin, 2001). Like their substrates, these kinases are 
regulated by serine, threonine, or tyrosine phosphorylation events. ERK is the predominant 
MAPK pathway utilised in ErbB receptor signal transduction and exists as two subtypes, 
ERK1 and ERK2 (ERK1/2 - also known as p44 and p42 respectively) (Bogoyevitch and 
Court NW, 2004). ERKI/2 are co-activated by upstream kinases, MEK1 and MEK2 
(MEK1/2). To date, there are no specific inhibitors of ERK1/2, but pharmacological 
intervention of the ERK-MAPK pathway can be achieved through the inhibition of 
MEK1/2 by small molecule inhibitors such as PD98059 (Chapter 5) (Fig. 1.9) (Dudley et 
al., 1995). 
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Figure 1.9: Schematic representation of the ERKIMAPK signal cascade. Upon receptor 
activation, guanine-exchange-factors (GEF, e. g. Sos) convert the inactive, GDP-bound Ras protein, 
located on the inner side of the cell membrane to the active, GTP-bound form. Ras-GTP then 
mobilises the MKKK Raf-1 from the cytoplasm to form a Ras-GTP-Raf-1 complex at the cell 
membrane. Raf-1 is subsequently phosphorylated, denoting the start of the three-tiered ERKI/2- 
MAPK phospho-relay: Raf-1 (MKKK), MEK1/2 (MKK) and ERKI/2 (MAPK). Finally, 
phosphorylation of the terminal kinase ERK1/2 allows it to be translocated to the nucleus, where it 
activates various transcription factors and induces gene transcription. The ERK/MAPK pathway can 
be inhibited pharmacologically by small molecule inhibitors of MEK1/2 such as PD 98059. 
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1.6.5 ErbB receptor signalling and mucin gene expression 
The association of ErbB receptor signalling with the induction of mucin expression has 
only relatively recently been recognised (Fig. 1.10). Many of the stimuli reported to evoke 
ErbB receptor-induced mucin expression in human airways are a result of pathological 
events (section 1.6.6). For example, neutrophil elastase (NE) promotes the ectodomain 
shedding of EGF-like factors in human airway epithelial cells, resulting in increased ErbB 
receptor-induced mucin expression (Kohri et al., 2002a). 
The signalling pathway through which ErbB receptors drive the induction of human mucin 
expression (specifically MUCSAC) involves the Ras/Raf/MEK/ERK cascade and the 
transcription factor Sp l (Perrais et al., 2002; Hewson et al., 2004). Other studies suggest 
that ErbB receptor signalling employs the transcription factor NF-KB in the induction of 
MUC5AC gene expression (Song et al., 2005a). 
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Figure 1.10: Schematic representation of ErbB receptor signalling and mucin production. 1. 
Activation of TACE (e. g. by PMA) leads to proteolytic cleavage of membrane bound ligand 
precursor (see 1.7.3). 2. Release of mature, soluble ligand. 3. ErbB receptor dimer formation. 4. 
Ligand binding to extracellular portion of ErbB receptor stabilises homo-/hetero-dimer 
conformation allowing for ATP binding, autophosphorylation (P) of tyrosine residues and 
recruitment of adapter proteins. 5. Sos presentation to cell membrane bound Ras initiates GDP-GTP 
exchange and activates the Ras/Raf/MEK/ERKI/2 signal pathway. 6. Upon activation, ERK 
translocates to the nucleus initiating transcription of the MUC5AC gene via the transcription factor, 
Spl. 
51 
1.7 ErbB receptors and airway inflammatory diseases 
Our airways are persistently exposed to inhaled environmental insults which cause damage 
to the epithelium and maintains a constant cycle of repair and maintenance which 
necessitates processes such as cell differentiation, DNA synthesis and alterations in cell 
adhesion and motility - all regulated by ErbB signalling. 
The number of pathological pathways identified as inducing mucin expression through 
ErbB receptor signalling is constantly increasing, providing an excellent rationale for the 
development of ErbB RTKIs (section 1.9) as a treatment for mucus hypersecretion in 
airway diseases. The salient features of ErbB receptor signalling during pathogenesis of 
airway diseases are described in the following sections (1.7.1-1.7.3). 
1.7.1 Expression of ErbB receptors and ligands in the airways 
In normal, healthy individuals, ErbB1, ErbB2, ErbB3 receptors and ErbB1 receptor ligands; 
EGF, TGFo HB-EGF and amphiregulin, are co-expressed in the bronchial mucosa of the 
upper and lower airways (Prigent et al., 1992; Aida et al., 1994; Polosa et al., 1999). The 
expression of the ErbB4 receptor in respiratory tissue is unclear since some studies support 
its presence (Srinivasan et al., 1998) whilst others do not (Polosa et al., 1999). The ErbB 1, 
ErbB2 and ErbB3 receptors are all co-expressed in the lateral intracellular cell membrane 
of the basal cells of the bronchial epithelium, but not in the basal membrane attached to the 
basement membrane. The greatest immunoreactivity for EGF-like ligands is found in the 
serous acinar cells of the mucosal glands. 
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Studies examining the ErbB receptor expression profiles (and their ligands) during airway 
inflammatory diseases are fairly limited. Nevertheless, the upregulation of these receptors, 
particularly ErbBI, has been associated with the pathogenesis of COPD and asthma, as well 
as a history of smoking. ErbBl expression, but not ErbB2 nor ErbB3, is increased in the 
epithelium of human asthmatic airways (Amishima et al., 1998; Polosa et al., 2002) and 
correlates with the severity of asthma (Puddicombe et al., 2000). In addition to ErbBl 
receptor upregulation, there is also an increased expression of EGF in the asthmatic airway 
(Vignola et al., 1997; Amishima et al., 1998), but studies investigating the expression of 
other EGF-like ligands are sparse. However, available evidence suggests there is no 
significant upregulation of other ErbBl receptor ligands such as TGFa or HB-EGF in 
asthmatics (Polosa et al., 2002). 
Cigarette smoke is a major environmental factor that contributes to the development of 
COPD (section 1.1) and was first associated with an upregulation of ErbBl receptor 
expression in the bronchial epithelium in a study examining the histopathological effects of 
smoking illicit drugs as well as tobacco (Barsky et al., 1998). In current smokers, 
upregulation of ErbB 1 and ErbB3 receptors occurs as a response to smoking but with no 
detectable relationship with COPD severity (O'Donnell et al., 2004). However, this study 
suggested that the effects of current smoking obscured the COPD related changes in ErbB 
receptor expression and did not necessarily indicate a lack of association between 
upregulation of ErbB receptors and the pathophysiology of airflow obstruction in COPD. 
This was corroborated by de Boer's group who confirmed an increase in ErbBl receptor 
expression in COPD patients compared with those without COPD, but only within the ex- 
smoker subgroup (and in damaged, not intact, epithelium) (de Boer et al., 2006). No such 
increase was observed in the current smoker subgroups indicating that the effect of current 
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smoking obscures intrinsically higher ErbB receptor expression in COPD. One explanation 
for the increase in ErbB receptor expression associated with smoking may be related to the 
increased receptor autophosphorylation caused by oxidative stress (intrinsically linked with 
cigarette smoke inhalation). Oxidative stress increases the autophosphorylation of ErbBl 
receptors and prolongs their activity by localising them to the plasma membrane (Ravid et 
al., 2002). Activated receptors are otherwise internalised shortly after phosphorylation, but 
in the presence of oxidative stress, ErbB receptors lose the ability to target the adapter 
molecule c-Cbl which prepares receptors for ubiquitination and subsequent degradation. A 
loss of this function, coupled with increased receptor autophosphorylation, results in 
inhibition of receptor down-regulation and a prolonging of receptor signalling - possibly 
contributing to disease pathogenesis. 
1.7.2 Goblet cell hyperplasia 
Goblet cell hyperplasia (GCH) is a remodelling event common to both COPD and asthma 
(sections 1.1.1 and 1.2.1) and has been linked to a vast number of signalling pathways 
including ErbB receptor signalling (Fahy, 2002; Rogers, 2003b). It is noted that, due to the 
numerous pathways implicated in this pathological process, GCH is unlikely to be 
manifested through ErbB signalling alone. However, the studies investigating the influence 
of ErbB signalling on GCH have identified some interesting interactions with other disease- 
related pathways, suggesting the relationship between ErbB signalling and GCH is 
pathologically relevant. 
Ovalbumin sensitised rats (a model of asthma associated with GCH and increased ErbBI 
receptor expression) and rats exposed to cigarette smoke (model of COPD) pretreated with 
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the ErbBI tyrosine kinase inhibitor, BIBX1522, showed a decrease in GCH (as well as 
mucin production) (Takeyama et al., 1999; Takeyama et al., 2001b). Furthermore, the 
goblet cells found in bronchial mucosal biopsies of asthmatic patients demonstrated 
increased ErbB 1 receptor immunoreactivity compared with normal specimens, which 
correlated positively with the area of MUC5AC staining (Takeyama et al., 2001a). 
Oxidative stress, a process associated with airway inflammatory disease pathogenesis and a 
consequence of environmental factors such as smoking, also plays a role in ErbB I receptor 
signalling-mediated GCH. Bronchial epithelial cells exposed to reactive oxygen species 
(ROS) showed increased activation of both the ErbBl receptor and the downstream kinase, 
ERKI/2, coupled with an increase in GCH (Casalino-Matsuda et al., 2006). The mechanism 
by which ROS evoked this ErbB 1-induced GCH was attributed to the increased cleavage of 
pro-EGF by the protease tissue kallikrein. ROS-induced GCH was attenuated by inhibitors 
of both the ErbBl receptor and tissue kallikrein, outlining just one pathway by which 
oxidative stress can influence disease pathology through ErbB signalling. 
Interleukin (IL)-13 has also been implicated in the induction of GCH in chronically 
inflamed airways (Atherton et al., 2003) and recent work has linked this pathological 
process with ErbB1 receptor activation (Tyner et al., 2006). The anti-apoptotic activity of 
ErbBI signalling (a mechanism of cell survival) blocked the apoptosis of goblet cells 
which, driven by viral-induced IL-13 signalling, had differentiated from ciliated cells, 
resulting in overall GCH (Tyner et al., 2006). This IL-13-induced GCH process can be 
attenuated by inhibiting either the release of EGF-like factor or ectodomain shedding 
(sections 1.7.2.1 and 1.8.3) (Yoshisue and Hasegawa, 2004). 
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1.7.3 Ectodomain shedding and mucin expression 
The process of ectodomain shedding is orchestrated by protease enzymes such as TACE 
(section 1.6.2.1), which are susceptible to activation by a host of mediators, for example 
NE (section 1.6.5). Neutrophils undergo excessive recruitment to the lung during chronic 
airway inflammation (in COPD and during asthma exacerbations) (Beeh and Beier, 2006). 
The recruited neutrophils have increased protease activity (Burnett et al., 1987) and release 
NE, a protease capable of activating TACE. The importance of NE on the airway mucus 
hypersecretory phenotype was initially recognised through its stimulatory effect on GCH 
and mucin hypersecretion (Takeyama et al., 1998; Nadel et al., 1999). The effects mediated 
through NE appear to be oxidant-dependent (Fakeyama et al., 2000; Fischer and Voynow, 
2002) and involve an increase in proteolytic cleavage (by TACE) of proTGFa (Kohn et 
al., 2002a). More specifically, the pathological induction of mucin synthesis by NE is a 
result of the activation of protein kinase C, which generates the production of ROS. ROS 
activate TACE and induce cleavage of pro-TGFa, releasing soluble ligand which induces 
signalling through ErbB receptors and finally, expression of MUC5AC (Shao and Nadel, 
2005). Cigarette smoke has also been implicated in the activation of TACE whereby 
epithelial cells subjected to cigarette smoke solution show increased TGFa release, a 
process inhibited by the presence of antioxidants (Shao et al., 2004). 
The eosinophil may also play a role in ectodomain shedding. The supernatants of activated 
human eosinophils (incubated with IL-3 and IL-5) contained increased concentrations of 
TGFa and, when cultured with bronchial epithelial cells, caused upregulation of TGFa and 
induced its release, as well as increasing MUC5AC synthesis (Burgel et al., 2001). 
Similarly, in ovalbumin sensitised mice, a monoclonal antibody to the eotaxin receptor 
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(CCR3) inhibited eosinphilic chemotaxis, reduced goblet cell hyperplasia and mucus 
production and also reduced ErbB 1 mRNA expression (Shen et al., 2006). 
Another pathological event that significantly contributes to morbidity in COPD sufferers is 
bacterial colonization of the airways (Wilson, 2001). Bacterial products such as 
lipopolysaccharide (LPS) from Gram-negative bacteria (Kohri et al., 2002b; Shao et al., 
2003) and lipoteichoic acid (LTA) from Gram-positive bacteria (Lemjabbar and Basbaum, 
2002) can stimulate pro-EGF-like peptide ectodomain shedding by activating the 
corresponding ADAM protease (either ADAM 17 - TACE - or ADAM 10). 
1.8 ErbB receptor antagonists: ErbB receptor tyrosine kinase inhibitors 
(RTKIs) 
The continuing discovery of novel pathological pathways implicating EIbB receptor 
signalling with increased mucin expression provides a strong rationale for the inhibition of 
these receptors as a therapeutic strategy for alleviating airway mucus hypersecretion. 
Protein kinases contain a structurally conserved catalytic region, further subdivided into 
two domains. These two domains are separated by a single polypeptide strand (or linker) 
which allows them to rotate with respect to one another upon binding of ATP and/or 
substrate (Huse and Kuriyan, 2002) (section 1.6.1). ErbB receptor dimerisation and ligand 
binding promotes the intracellular conformational changes required for ATP recruitment 
and phosphorylation of target substrate (section 1.6.3 and 1.6.4). The dependence on ATP 
binding to provide the phosphate moiety for downstream phosphorylation suggests a 
rationale for development of protein kinase inhibitors (Hynes and Lane, 2005). The 
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majority of protein kinase inhibitors are based around an adenine core (Table 1.1) and, 
consequently, compete with ATP for occupation of the ATP binding site, thereby 
obstructing kinase activity and, more importantly, downstream signalling. 
Inhibition of ErbB receptor signalling was initially achieved by monoclonal antibodies 
which bind to the readily accessible extracellular domain of the receptor and compete for 
ligand binding (Sato et al., 1983; Schreiber et al., 1981). Although ErbB receptor 
monoclonal antibodies remain a realistic strategy for pharmacological intervention of ErbB 
signalling, the focus of this thesis is inhibitors of kinase activity. 
The development ErbB RTKIs were largely spurred by recognition of the fact that ErbB 
receptors play a vital role in the signalling pathways of several cancers (particularly breast 
cancer). Early ErbB RTKIs were originally named Tyrphostins and were developed by 
Levitski et al. (Gazit et al., 1989; Yaish et al., 1988), based on the observation that a 
mutation in the ErbB 1 receptor kinase domain blocked its biological activity (Honegger et 
al., 1987a; Honegger et al., 1987b). Subsequent computational modelling defined the 
salient stereochemical properties required for efficient ErbB receptor selection (Furet et al., 
1995). Optimisation of various lead structures including quinazolines, pyrrolopyrimidines, 
and phenylaminopyrimidines has generated a repertoire of ErbB receptor kinase inhibitors. 
Drugs such as erlotinib (a. k. a. Tarceva, OSI-774), gefitinib (a. k. a. Iressa, ZD1839) and 
lapatinib (GW572016), are all examples of ErbB RTKIs that are in clinical trials or already 
approved as cancer treatments (Hynes and Lane, 2005) (Table 1.1). 
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COMPOUND 
(INHIBITOR STRUCTURE AND S TA TUS 
TYPE and CHEMICAL SPECIES 
COMPANY) 
Adenine 
DNA base/purine 
nucleotide 
-F Approved for the 
treatment of NSCLC after 
GEFITINIB HN cr failure on other available 
ErbB1 
O 
N treatments; ongoing trials 
AstraZenecca ~o N --: 
5 in HNSCC, 
gastrointestinal cancer 
Quinazoline 
and breast cancer 
Phase III trial underway 
LAPATINIB ° on breast cancer patients 
ErbB1 and 2 o y who are refractory 
to 
GSK /b trastuzumab and 
chemotherapy 
Quinazoline 
ed for the A ER LOT INIB pprov 
O treatment of NSCLC after 
ErbB1 
failure on other available 
Genetech/OSI I treatments; ongoing trials 
Pharmceuticals in many cancer types Quinazoline 
Table 1.1: Table showing three well known, reversible, ErbB receptor tyrosine kinase 
inhibitors. For each drug, information on the receptor(s) inhibited, the chemical structure/species 
and the current status of development are included. NSCLC: non-small cell lung cancer, HNSCC: 
head and neck squamous cell carcinoma. The structure of adenine is present as a reference. Adapted 
from (Hynes and Lane, 2005). 
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The relatively successful application of ErbB RTKIs in the clinical treatment of cancer has 
paved the way for the development of these drugs in other diseases involving aberrant ErbB 
receptor signalling. Recent research has implicated ErbB receptor signalling with the 
process of goblet cell hyperplasia (a remodelling event that occurs in asthma and COPD 
and contributes to mucus hypersecretion) and also with direct induction of MUC5AC gene 
expression in vitro (sections 1.7.2 and 1.6.5 respectively). The current therapeutic options 
specifically for the management of airway mucus hypersecretion are rarely effective 
(section 1.4), hence targeting ErbB receptor signalling may potentially provide a new 
therapeutic avenue for eleviating airway mucus hypersecretion. 
A number of studies (both in vitro and in vivo) have highlighted the induction of MUC5AC 
synthesis and GCH by ErbB receptor signalling and shown reversibility of these processes 
through the use of ErbB RTKIs such as ZD1839 (gefitinib) and BIBX1522 (sections 1.7 - 
1.7.3). Hence, successful development of ErbB RTKIs as a therapeutic regimen for airway 
mucus hypersecretion not only requires a greater understanding of the ErbB signal 
pathways involved in disease pathogenesis, but also an in-depth understanding of the effect 
these inhibitors have on ErbB receptors themselves. 
1.9 Techniques available for measuring changes in airway mucus 
hypersecretion by ErbB RTKIs 
Airway mucus production can be divided into distinct stages: mucin gene expression 
(mRNA production), mucin synthesis, and mucin secretion (exocytosis of mucin granules), 
therefore advocating a number of approaches for investigating the process experimentally. 
It is also possible to examine features of the airway mucus hypersecretory phenotype such 
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as GCH which contribute to overproduction of mucin (although this is generally done 
through an in vivo investigatory platform). 
To examine the effects of ErbB RTKIs on airway mucus hypersecretion using in vitro 
models (section 1.9.1), measurements need to be taken during a relevant stage of the mucin 
secretory pathway. Ideally, this would involve an end-point measurement of the amount of 
secreted MUC5AC protein, but unfortunately, consistency in the methods used to measure 
comparative levels of secreted mucins is poor (due to the nature of the protein and 
variability of diagnostic antibodies) (Rose and Voynow, 2006), and preliminary methods 
undertaken in the present thesis (using an enzyme-linked lectin assay) failed to reliably 
detect secreted MUC5AC using both different cell lines and different stimuli (data not 
shown). For this reason, the effects of ErbB RTKIs on MUC5AC gene expression was 
measured, the rationale being that since ErbB receptor signalling initiates gene transcription 
which ultimately results in protein production, measuring MUC5AC mRNA expression 
levels would provide a suitable marker for mucin production as a whole. Moreover, the 
mucus produced during inflammatory airway diseases likely reflect increased expression of 
MUC genes (Basbaum et al., 1999), suggesting that elevated MUC gene expression may 
indicate an increase in mucin production. 
In the present thesis, changes in MUC5AC gene expression (mRNA levels) were used as an 
end-point for assessment of ErbB RTKI activity. Expression was assessed in respiratory 
epithelial cells (section 1.9.1) using the real-time quantitative polymerase chain reaction 
(RT-qPCR) (section 1.9.2). 
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1.9.1 Respiratory epithelial cell lines 
An in vitro approach was taken herein to measure the effect of ErbB RTKIs on mucin 
synthesis as the studies undertaken were preliminary experiments using novel inhibitors 
and thus not yet appropriate for in vivo investigation. 
The A549 and NCI-H292 lines were selected from a number of respiratory epithelial cell 
lines available for the study of mucin synthesis, as they both provide a good, cell-based 
model of this process. The A549 cell line was initiated through explant culture of lung 
carcinoma tissue (Giard et al., 1973) and the NCI-H292 cell line is derived from a lymph 
node metastasis of a mucoepidermoid carcinoma (Carney et al., 1985). Both cell lines 
express mRNA for MUC1 and MUC5AC (but only A549 cells express MUC5B mRNA) 
and secrete mucin protein (Berger et al., 1999). Most importantly, many of the findings 
from studies using primary cells (e. g. Normal Human Bronchial Epithelial - NHBE - cells) 
are also corroborated in A549 and NCI-H292 cells, indicating the same phenotype is 
demonstrated both in lung cancer cell lines and in primary cells. For example, neutrophil 
elastase increases MUC5AC expression in A549 and NHBE cells (Fischer and Voynow, 
2002); IL-9 increases MUC5AC expression in NCI-H292 and NHBE cells (Longphre et al., 
1999). 
1.9.2 Real-time quantitative polymerase chain reaction (RT-qPCR) 
RT-qPCR is a powerful and accurate technique used, amongst other applications, to 
quantify the expression of specific genes. By converting mRNA sequences to cDNA, it is 
possible to measure the expression of specific genes in comparison to control samples and 
accompanying analytical techniques such as comparative cross-over threshold analysis 
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(section 2.3.4). The major advantage of RT-qPCR is that the PCR reaction is measured in 
"real-time", allowing data to be collected throughout the PCR process, rather than at the 
end of the PCR. In real-time PCR, reactions are characterised by the point-in-time during 
cycling when amplification of a target is first detected rather than the amount of target 
accumulated after a fixed number of cycles. The higher the starting copy number of the 
nucleic acid target, the sooner a significant increase in fluorescence is observed. In contrast, 
an endpoint assay measures the amount of accumulated PCR product at the end of the PCR 
cycle which can differ purely through the reaction kinetics alone. 
1.11 Hypothesis 
Specific ErbB receptor tyrosine kinases are involved with airway mucin synthesis and 
selective ErbB RTKIs attenuate this mucin synthesis (particularly MUC5AC) in human 
respiratory epithelial cells. 
1.12 Specific aims 
The purpose of the studies herein was to investigate the above overall hypothesis using 
expression of MUC5AC mRNA as a marker of mucin synthesis and the A549 and NCI- 
H292 human respiratory epithelial cell lines as models of human airway mucus-secreting 
cells. 
The specific aims were: 
1. Assess EtB1 receptor cell surface expression during cell culture and optimize 
culture conditions for optimal receptor expression 
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2. Confine that EGF and PMA induce MUC5AC mRNA expression in A549 and 
H292 cells and determine whether or not the response is via direct (e. g. EGF) or 
indirect (e. g. PMA) activation of ErbB receptor tyrosine kinase(s). 
3. Confirm EGF- and PMA-induced MUC5AC mRNA expression can be inhibited by 
the glucocorticosteroid dexamethasone as an assessment of assay `robustness'. 
4. Ascertain the effects of ErbB RTKIs on EGF- and PMA-induced MUC5AC mRNA 
expression. 
5. Confirm the pharmacological activity of ErbB RTKIs in an ErbB receptor mediated, 
non-mucin related, pathway - cell proliferation. 
6. Determine the effect of ErbB RTKs on EGF-induced ErbBl and ErbB2 
autophosphorylation. 
7. Determine the effect of ErbB RTKs on EGF-induced phosphorylation of 
downstream kinases - ERKI/2. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
MATERIAL 
162 cm2 sterile culture flask 
30 mm six-well sterile culture plates 
SUPPLIER 
Corning, Fisher Scientific, Loughborough, 
Leicestershire 
Corning Fisher Scientific, Loughborough, 
Leicestershire 
96-well optical reaction plate Applied Biosystems, Warrington, Cheshire 
ß-mercaptoethanol Sigma-Aldrich Chemical Company, Poole, 
Dorset 
All ErbB receptor tyrosine kinase inhibitors G1axoSmithKline, King of Prussia, U. S. A. 
(single and dual) 
Anti-EGFR (Rabbit, polyclonal) Catalogue New England Biolabs (UK) Ltd., Hitchin, 
number: #2232 Hertforshire 
Anti-EGFR (phospho Y1068) (Rabbit, 
polyclonal) Catalogue number: ab5644 
Anti-EGFR (phospho Y1148) (Rabbit, 
polyclonal) Catalogue number: #4404 
Anti-EGFR (phospho Y1173) (Rabbit, 
monoclonal) Catalogue number: #4027 
Abcam PLC, Cambridge, U. K. 
New England Biolabs (UK) Ltd., Hitchin, 
Hertforshire 
New England Biolabs (UK) Ltd., Hitchin, 
Hertforshire 
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Anti-ERKI/2 (Rabbit, polyclonal) Catalogue New England Biolabs (UK) Ltd., Hitchin, 
number: #4404 Hertforshire 
Anti-phospho-ERKI/2 (Rabbit, polyclonal) New England Biolabs (UK) Ltd., Hitchin, 
Catalogue number: #4404 Hertforshire 
Bovine Serum Albumin (BSA) 
Dexamethasone 
Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Dimethyl sulphoxide (DMSO), Hybri-Max, Sigma-Aldrich Chemical Company, Poole, 
sterile filtered Dorset 
dNTP master mix Bioline Ltd. London 
Dulbecco's Modified Eagles Media (DMEM) Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Ethanol BDH, Poole, Dorset 
FACE TM EGFR chemiluninescence assay Active Motif Rixendart, Belgium 
Foetal calf serum (FCS) Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Full-Range RainbowTM Molecular Weight Amersham (GE), Buckinghamshire 
Markers 
GAPDH endogenous control gene expression Applied Biosystems, Warrington, Cheshire 
assay (Assay ID number Hs99999905_ml) 
Glycine Sigma-Aldrich Chemical Company, Poole, 
Dorset 
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Hanks' Balanced Salt Solution (HBSS) 
Hexanucleotides 
L-Glutamine 
Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Promega, Southampton, Hampshire 
Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Methylthiazolyldiphenyl-tetrazolium bromide Sigma-Aldrich Chemical Company, Poole, 
(MTT) Dorset 
20 x MOPS running buffer Invitrogen Ltd., Paisley, UK 
MUC5AC gene expression assay (Assay ID Applied Biosystems, Warrington, Cheshire 
number Hs01365601 ml) 
Non-enzymatic cell dissociation solution Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Nuclease-free water 
Phorbol 12-myristate 13-acetate (PMA) 
PD 98059 
QlAshredder 
Recombinant Human EGF 
RPMI 1690 medium 
RNase-free DNase I 
RNeasy Mini Kit 
Promega, Southampton, Hampshire 
Sigma-Aldrich Chemical Company, Poole, 
Dorset 
MERCK Chemicals Ltd., Nottingham, 
Nottinghamshire 
Qiagen, Crawley, Sussex 
R&D Systems, Abingdon, Oxfordshire 
Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Qiagen, Crawley, Sussex 
Qiagen, Crawley, Sussex 
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Trizma Base Sigma-Aldrich Chemical Company, Poole, 
Dorset 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Chemical Company, Poole, 
Dorset 
TagMan® Universal PCR Master Mix, No Applied Biosystems, Warrington, Cheshire 
AmpErase® UNG 
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2.2 SOLUTIONS 
2.2.1 Phosphate Buffered Saline (PBS) with Azide and BSA (PAB) 
0.1 M Potassium phosphate (1X) supplemented with 0.5% (w/v) BSA and 0.1% (w/v) 
sodium azide. 
2.2.2 GW459135, GW282974, GW808884, GW813334 and GSK916664 stock solutions 
GW459135, GW282974, GW808884, GW813334 and GSK916664 were all gifts from 
GlaxoSmithKline and were reconstituted in DMSO to a concentration of 20 mM and stored 
in 20 Al aliquots (foiled wrapped when light sensitive) at -20°C. 
2.2.3 EGF stock solution and vehicle 
EGF was reconstituted in filter-sterilised, 10 mM acetic acid containing 0.1% (w/v) bovine 
serum albumin, to a concentration of 40 µg/ml and stored in 12 µl aliquots at -20°C. 
2.2.4 PMA stock solution 
PMA was reconstituted in DMSO to a concentration of 2x10"3 M and stored in 20 z1 
aliquots in a foil sealed container to avoid contact with light at -20°C. 
2.2.5 Dexamethasone stock solutions 
Dexamethasone was reconstituted in Hank's balanced salt solution to a concentration of 
1x10-3M and stored at 4°C. 
69 
2.2.6 TAPI-2 
TAPI-2 was reconstituted in DMSO to a concentration of 60 mM and stored in 20 µl 
aliquots at -20°C. 
2.2.7 RNA lysis buffer 
Comprised RLT buffer (supplied with RNeasy kits) supplemented with 0.1% (v/v) /3- 
mercaptoethanol. 
2.2.8 Avian Myeloblastosis Virus (AMV) reverse transcriptase mastermix solution 
Consisted of (per reaction), 1 µl hexanucleotides (0.5 µg final concentration), 2 µl dNTP 
master mix (2.5 mM final concentration for dATP, dGTP, dCTP and dTTP), 4 µl AMV 
buffer (final concentrations of 50 mM Tris-HCI, 50 mM KCI, 25 mM MgC12,0.5 mM 
spermidine and 10 mM DTT), 2 µl RNase-fi-ee water, 1 µl (40 units) RNasin and 1 µl (10 
units) AMV-Reverse transcriptase. 
2.2.9 PCR mastermix solution 
Consisted of (per reaction), 1.25 µl either MUC5AC or GAPDH primer/probe solution 
(ABi), 12.5 11 TagMan® Universal PCR Master Mix, No AmpErase® UNG and 6.25 µl 
nuclease-free water (Promega). Both mastermix and primer/probe solutions were supplied 
in a concentrated format, the described volumes (per reaction) achieved a 1X working 
concentration. 
2.2.10 MTT solution 
Consisted of 0.1% (w/v) methylthiazolyldiphenyl-tetrazolium bromide (MTT) in HBSS. 
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2.2.11 Anti-BrdU-POD working solution 
Anti-BrdU-POD was supplied lyophilised and made up to as a stock solution according to 
manufacturers guidelines (dissolved in 1.1 ml double distilled water - supplied with kit). 
Anti-BrdU-POD stock solution was diluted 1: 100 with antibody dilution solution (supplied 
with kit) to give the final anti-BrdU-POD working solution. 
2.2.12 Protein lysis buffer 
Comprised CelLytic M solution (Sigma) containing 0.1% (v/v) protease and phosphatase 
inhibitor cocktail. 
2.2.13 Bradford assay solution 
Bradford assay solution from Biorad was diluted 1: 5 with distilled water. 
2.2.14 Sample buffer 
Made up in 10 ml containing 125 mM Tris-Cl (pH 6.8), 4% (v/v) SDS, 15% (v/v) glycerol, 
10% (v/v) ß-Mercaptoethanol and 0.05% (w/v) Bromophenol blue. 
2.2.15 SDS-PAGE running buffer 
Type of running buffer depended on the gel used. For Novex 8% Tris-Glycine gels, running 
buffer (made up to 1 L) containing 25 mM Tris, 192 mM glycine and 0.1 % (w/v) SDS was 
used. For NuPAGE 10% Bis-Tris gels, the NuPAGE® MOPS SDS running buffer from 
Invitrogen was purchased (as this running buffer is optimised for a better spread of lower 
molecular weight proteins). 
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2.2.16 Transfer buffer 
Made up to 1L and contained 50 mM Trisma, 39 mM Glycine and 20% (v/v) methanol. 
2.2.17 Tris Buffered Saline (TBS) - Tween Western blotting wash buffer 
Made up according to Cell Signal Technology (antibody supplier) guidelines contained 
(final concentrations); 20 mM Trisma, 137 mM NaCl, 0.1 % (v/v) Tween-20 and pH 
balanced with HCl to pH 7.6. 
2.2.18 Western blotting block buffer 
Consisted of TBS buffer supplemented with 5% (w/v) non-fat dry milk. 
2.2.19 Primary antibody dilution buffer 
All primary antibodies were made up in 10 ml TBS buffer supplemented with 5% bovine 
serum albumin. 
2.2.20 Secondary antibody dilution buffer 
Secondary antibody (mouse anti-rabbit unless otherwise stated) was made up in 10 ml (per 
membrane) TBS buffer supplemented with 5% non-fat dry milk with a dilution factor of 
1: 1000. An anti-biotin antibody (supplied with biotinylated molecular weight protein 
ladder) was also added to the secondary antibody dilution buffer, diluted 1: 10000, to allow 
visualisation of the protein ladder. 
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2.2.21 Membrane stripping buffer 
Consisted of 100 mM ß-mercaptoethanol, 2% SDS and 62.5 mM Tris-HC1 pH 6.7. 
2.2.22 Fixing buffer (for FACETM EGFR ELISA) 
Consisted of 4% (v/v) formaldehyde in PBS. 
2.2.23 Wash buffer (for FACETM EGFR ELISA) 
Contained 0.1% (v/v) Triton X-100 in PBS 
2.2.24 Quenching buffer (for FACETM EGFR ELISA) 
Consisted of 0.1% (v/v) Triton X-100,1% (v/v) H202, and 0.1 % (v/v) sodium azide in 
PBS. 
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2.3 METHODS 
2.3.1 Cell culture 
NCI-H292 (herein shortened to `H292') cells and A549 cells were both obtained from the 
American Type Culture Collection (LGC Promochem, Teddington Middlesex, U. K. ) and 
grown on 162 cm2 tissue culture flasks in RPMI 1640 medium for H292 cells and DMEM 
for A549 cells, both supplemented with 10% (v/v) foetal calf serum and 2 mM L-glutamine 
(in the absence of antibiotics). For both cell types, cells were cultured at 37°C in a 
humidified 5% CO2 atmosphere and grown to approximately 90% confluency before 
passaging. For passaging, media was removed by aspiration and replaced with 5 ml Hank's 
balanced salt solution containing 0.25% trypsin and 1 mM EDTA-Na then incubated at 
37°C until no longer adherent (approximately for 3-5 minutes). Trypsin was neutralised by 
the addition of 15 ml serum-containing media and cells were then centrifuged 
(approximately 500 x g, 4°C, for 5 minutes) and reconstituted in 10 ml serum containing 
media before seeding at appropriate density, on appropriate vessels. For both cell lines, the 
maximum amount ofpassage events was restricted to no more than 10. 
2.3.2 Flow-cytometry for ErbBl receptor expression 
Cells were removed from culture plates using 1.5 ml non-enzymatic cell dissociation 
solution (EDTA, glycerol and sodium citrate made up in Hank's buffered saline solution, 
Sigma) and left for 20 minutes at 37°C. Duplicate treatments were pooled together at this 
stage, transferred to FACS tubes and spun at approximately 500 xg at 4°C for 4 minutes. 
After spinning, supernatant was removed except for 100 - 150 µl which the cell pellet was 
re-suspended in, followed by the addition of either 20 yl anti-EGFR or 20 yl isotype control 
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(IgG2A), both diluted 1 in 1000 with PAB (section 2.2.1). After incubation with primary 
antibody for 45 - 60 minutes at room temperature, cells were washed by diluting with 1 ml 
PAB and centrifuged at approximately 500 xg at 4°C for 4 minutes. Supernatant was 
removed except for 100 - 150 µl which the cell pellet was re-suspended in followed by the 
addition of 20 µl rabbit, anti-mouse secondary antibody (diluted 1 in 1000 with PAB) 
conjugated to R-phycoerthrin (RPE). Cells were incubated with secondary antibody for 45 
- 60 minutes at room temperature (shielded from light) then washed twice by diluting the 
cells in 1 ml PAB followed by centrifugation at approximately 500 xg at 4°C for 4 minutes. 
After the final wash, supernatant was completely removed and cells resuspended in 300 µl 
FACS flow solution. 
Flow cytometry analysis was preformed using a Becton Dickinson FACScanTM machine 
using CellQuestTM software. All samples were run until 4000 gated events had passed. For 
detection of cell surface markers, compensations in voltage were performed for the RPE 
fluorochrome which was detected in the FL2 channel. All analyses were compared with 
isotype control and, for initial experiments, unstained cells were also analysed to determine 
comparative physical properties such as size and shape using changes in forward and side 
scatter (Fig. 2.1). This was to ensure cell debris and aggregated cells were not included in 
the analysis. Flow cytometric data was analysed using WinMDI software by Joe Trotter. 
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Figure 2.1: Sample dotplot scattergraphs of cell populations showing the distribution of cell 
size. Panel A shows an example dotplot of A549 cells and panel B shows 1-1292 cells, both grown at 
100%, confluency and without serum starvation. Both panels show side scatter (SSc) on the Y-axis 
and forward scatter (FSc) on the X-axis. The polygon shapes on both dotplots indicates the cell 
population selected - or gated - for analysis. Gates were drawn so as to exclude cell debris and 
delineate a homogenous cell population. 
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2.3.3 Reverse transcription and real-time, quantitative, polymerase 
chain reaction (RT-qPCR) for MUC5AC mRNA 
Following treatment, cells were lysed using 350 µl RNA lysis buffer (section 2.2.7) whilst 
total RNA was isolated from cells using the QIAshredder and RNeasy kits from Qiagen 
according to the manufacturer's protocols. Briefly, cell lysates were loaded onto 
QlAshredder columns and centrifuged according to a recommended protocol to 
homogenise the samples. An equal volume of ethanol (350 µl) was then added to the eluted 
sample and the total volume was transferred into an RNeasy column and the isolation steps 
followed accordingly. During the isolation procedure, columns were incubated with RNase- 
free DNase to digest any genomic DNA in the samples (as suggested by manufacturer). 
RNA was eluted in 30 µl nuclease free water and quantified using spectrophotometry 
(Spectromax Plus, Molecular Devices, CA, U. S. A) measuring absorbance at 280 and 260 
nm wavelengths. The ratio of between absorbance values at these wavelengths (A260/A280) 
provides an estimate of the purity of RNA with repesct to other UV absorbing contaminants 
(e. g. protein) and should be within the range of 1.9 - 2.1. RNA concentration was 
calculated for each sample (on the basis that an absorbance of 1 unit at 260 nm corresponds 
to 40 µg of RNA per ml) and RNA was reverse transcribed into cDNA using 0.5 gg RNA 
in a total volume of 9 gl RNase-free water and 11 µl reverse transcriptase reaction mixture 
(section 2.2.8). RNA samples were denatured by heating to 90°C for 5 minutes then, once 
cooled to 42°C, 11 µl reaction mixture was added to samples giving a total volume of 20 pl 
and incubated at 42°C for 1 hour. The reaction was terminated by incubating the mixture at 
70°C for 10 minutes. Samples were then diluted with 40 µl nuclease-free water and stored 
at 4 °C for later analysis. 
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Figure 2.2: Detection of gene expression using oligonucleotide TaqMan-Minor Groove 
Binding (MGB) probes. The TaqMan-MGB probe anneals specifically to a complementary 
sequence between the forward and reverse primer sites. When the probe is intact, the proximity of 
the reporter dye (R - 3' end) to the non-fluorescent quencher (NFQ - 5' end) results in suppression 
of the reporter fluorescence. Taq DNA polymerase (Taq Pol) only cleaves probes that are 
hybridized to the target gene sequence. Cleavage separates the reporter dye from the NFQ, which 
results in increased fluorescence by the reporter. The increase in fluorescence signal occurs only if 
the amplified target sequence is complementary to the probe, hence target gene expression can me 
measured relative to this increase in fluorescence. The MGB moiety positioned at the 3' end after 
the NFQ binds to the minor grove in the DNA strand and increases the melting temperature of the 
probes, allowing for the use of shorter probes. 
RT-qPCR was performed using the AppliedBiosystems (ABI, Warrington, Cheshire), 96- 
well-plate-based, 7500 Real-Time PCR sequence detection system and the accompanying 
TagMan® Gene Expression Assays and TaqMan master-mix. AppliedBiosystems gene 
expression assays contain forward and reverse oligonucleotide primers which allow for the 
selective amplification of the gene of interest during the PCR reaction, and an MGB (Minor 
Grove Binding) probe which provides the detection mechanism (Fig. 2.2). During PCR, the 
probe anneals specifically to complementary sequence between the forward and reverse 
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NFQ 
4* 1- Detection 
primer site allowing Taq DNA polymerase to cleave the reporter dye at the 3' end of the 
probe. Once cleaved, the reporter dye emits a fluorescent signal (Fig. 2.2) which is detected 
by the 7500 Real-Time PCR sequence detection system, and used to generate a CT (cross- 
over threshold) value. The Cr value denotes the cycle number at which the fluorescent 
signal becomes detectable, and can be used as a reference to calculate relative gene 
expression (based on the principle that if large amounts of target gene are present in the 
cDNA sample, a detectable fluorescent signal will be generated earlier in the PCR cycle 
and therefore give a lower CT value). MUC5AC mRNA expression was measured using the 
primers and probe supplied with the AppliedBiosystems MUC5AC gene expression assay 
and compared with a GAPDH endogenous control (see section 2.1 for assay ID numbers), 
using the OOCt method of analysis (section 2.3.4). Samples were run in triplicate to monitor 
sample variability (Fig 2.3) using 5 µl cDNA per well and 20 µl of PCR master-mix 
solution (section 2.2.9). Samples were analysed using the software supplied with the 
thermal cycling machine (Sequence Detection System - SDS 1.1). 
79 
7.00 
6.00 
5.00 
4.00 
NC 
300 
2.00 
1.00 
OR 
Figure 2.3: Example of a PCR profile expressed as Rn vs cycle number for a non-treated, 
control sample run in triplicate using GAPDH primers/probe. mRNA harvested from untreated 
H292 cells was converted to cDNA by reverse transcriptase PCR then subjected to RT-qPCR 
(section 2.3.3). Rn (normalised reporter signal: the fluorescence emission intensity of the reporter 
dye of the probe divided by the fluorescence emission intensity of the passive reference dye present 
in the PCR mastermix) is on the Y-axis and cycle number is on the X-axis. The green-dotted line 
marks the point of "cycle threshold" or CT value - i. e. the cycle number at which PCR product starts 
to become detectable. These values were ultimately used to calculate AAC1 and RQ values (section 
2.3.4). Note how the three triplicates share the same CT values (around 22) but terminate with 
different amounts of PCR product - emphasising the advantages of RT-qPCR. 
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2.3.4 Comparative CT method (OACT) for relative quantification of gene 
expression 
The comparative CT (cross-over threshold), or AL CT, method of analysis was used to 
calculate the relative quantity of MUCSAC gene expression. For this method to be valid, 
the efficiency of the target amplification and the efficiency of the reference (house keeping 
gene) amplification must be approximately equal. The target and reference primer sets must 
have similar PCR efficiencies, denoted by a regression gradient of between -3.2 and -3.7 
when calculated from CT vs Log concentration, or <0.1 when calculated from ACT (see 
equation below) vs Log concentration. Both of these gradient values can be calculated from 
the amplification of serially-diluted template cDNA. Figure 2.4 shows the standard curves 
generated using a pooled sample of cDNA, plotting CT against Log arbitrary concentration 
(panel A) and ACT vs Log concentration (panel B) using the MUC5AC and GAPDH 
primers obtained from Applied Biosystems. The gradient values obtained from both graphs 
in figure 2.4 (-3.48 and -3.46 respectively) indicate that both primer sets have very similar 
PCR efficiencies and, thus, it is valid to use the comparative Cr method to quantify the 
relative amounts of gene expression. 
Whilst it is possible to simply compare ACT values to look at variations in gene expression, 
it is also possible to analyse the data further by normalising Cr values generated from 
treated samples (e. g. EGF stimulated samples) against those generated from non-treated 
control samples to obtain the LL&CT value. The non-treated sample CT value which is used 
as a comparator for all the treated sample CT values is referred to as the "calibrator". The 
final "relative quantity" (RQ) is calculated using the simple transformation: 2'°°CT. 
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Data obtained using Taqman RT-QPCR was analysed using the MCI method of analysis. 
Briefly, CT values were taken (determined automatically by the SDS 1.1 software 
accompanying the 7500 thermal cycle unit) for endogenous control gene (GAPDH) and 
target gene (MUC5AC) for each, individual sample. The following calculation (as 
described above) was then used to quantify the relative quantity of each sample: 
ACT = CT(gene of interest) - CT(reference gene) 
AOCT = ACT(treated sample) - zCT(calibrator) 
Relative quantity (RQ) =2 -°°CT 
For most experiments, the calibrator sample used to calculate the OOCT value was the 
stimulus vehicle or the stimulus vehicle and compound vehicle combined (if the experiment 
involved drugs). 
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Figure 2.4: Target and reference gene PCR efficiency: validation of comparative CT method 
(OOCT) for relative quantification of gene expression. Panel A shows CT values plotted against 
Log concentration (arbitrary units) of serial diluted template cDNA amplified with MUC5AC and 
GAPDH primer sets. MUC5AC and GAPDH slope values were -3.475 and -3.457 respectively. 
Panel B shows ACT values from the same serial dilutions as panel A, plotted against Log 
concentration (arbitrary units) and confirms the slope is within the < 0.1 constraint. 
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2.3.5 Cell proliferation assay 
Cell proliferation (and its inhibition by ErbB RTKIs) was measured using the Cell 
Proliferation ELISA, BrdU (chemiluminescent) system from Roche, based on measuring 
BrdU incorporation during DNA synthesis in proliferating cells. The protocols provided by 
the supplier were followed accordingly. Throughout the cell culture and treatment steps, 
media supplemented with 1% (v/v) foetal calf serum and 2 mM L-glutamine was used 
(apart from certain control conditions were media supplemented with only 2 mM L- 
glutamine was used). H292 cells were plated out onto 96-well, Costar (3603) black, clear 
bottom plates at a density of approximately 80,000 cells per well (in 200 µl media) and left 
to equilibrate overnight. The following morning, cells were treated accordingly with all 
conditions performed in quadruplicate. After 2 hours of the 24 hour incubation time had 
past, BrdU labelling reagent made up in the appropriate cell culture media was added to 
each well to give a final concentration of 10 µM. Cells were then once again transferred to 
an incubator and left for the remaining 22 hours. 
After treatment for 24 hours, BrdU incorporation into synthesised DNA was measured. 
Culture media was gently removed by suction and cells were fixed with 200 µl fixation 
solution (supplied with kit) for 30 minutes at room temperature. Fixation solution was then 
removed by flicking/tapping and 100 µl anti-BrdU-POD working solution (section 2.2.11) 
was added to each well followed by 90 minutes incubation at room temperature. Antibody 
conjugate was then removed by flicking off and washing three times with 200 µl washing 
buffer (supplied with kit) for 5 minutes each wash. After the final wash, plates were tapped 
to remove excess wash buffer before addition of 100 µl substrate (supplied with kit) and 
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incubation at room temperature for 5 minutes. Light emission was measured using a 
luminometer (Fluostar Optima, BMG Labtech, Durham U. S. A. ). 
2.3.6 Cell viability assay 
Cell viability was measured using the MTT (3-[4,5-dimethylthiazol-2-yl)]-2.5- 
diphenyltetrazolium bromide) assay (Mosmann, 1983). The assay is based on the ability of 
mitochondrial dehydrogenase from viable cells to cleave the tetrazolium rings of pale 
yellow MTT and form dark blue formazan crystals. These are largely impermeable to cell 
membranes, thus resulting in their accumulation within healthy cells. Lysis of the cells by 
the addition of DMSO results in the liberation and solubilisation of the crystals with the 
number of viable cells being directly proportional to the concentration of formazan product. 
After completion of an experiment, media supernatant was removed and replaced with 1 ml 
(for experiments carried out on 6-well plates) MTT solution (section 2.2.10) and left for 10- 
15 minutes at room temperature. MTT solution was then removed and the assay terminated 
by applying 1 ml DMSO to each well. Absorbance was measured at 550 nm. 
2.3.7 Western blotting 
Western blotting was used to detect the extent of autophosphorylation (compared with 
whole receptor) of Y1068, Y1148 and Y1173 on the ErbBl receptor and Y1221/2 on the 
ErbB2 receptor. The phosphorylation (and thus activation) of ERK1/2 was also measured 
using Western blotting (see section 2.1 for origin of all antibodies). 
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2.3.7.1 Protein isolation and quantification 
After appropriate treatment, cells were washed twice in ice-cold PBS, then scraped using a 
cell scraper in 10 ml ice-cold PBS, then transferred to an ice-cold centrifuge tube. The cell 
suspension was spun at 4°C for 5 minutes at approximately 450 x g, followed by removal 
of the supernatant and lysis of the cell pellet, on ice, in 225 µl protein lysis buffer (section 
2.2.12). Lysates were either stored at -80°C or processed immediately. Processing the 
lysates involved spinning at approximately 15,000 xg at 4°C for 20 minutes then 
transferring the supernatant to a pre-chilled Eppendorf tube (pellet was discarded). The 
protein concentration of each sample was measured using a Bradford assay against a bovine 
serum albumin (BSA) standard. The BSA standard curve was generated starting at 5 µg/µl 
BSA, working down in increments of 0.5, to a final concentration of 0.5 yg/µl BSA (Fig 
2.5), with a working volume of 200 µl. Protein samples were diluted 1: 100 with Bradford 
assay solution (section 2.2.13) to give a working volume of 200 µl. Optical density was 
measured at 600 nm and sample protein concentration was calculated from regression data 
generated from the BSA standard curve (Fig 2.5). 
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Figure 25: Example of protein concentration standard curve generated using bovine serum 
albumin (BSA). Sample protein concentrations were extrapolated from the regression data. Protein 
concentration was calculated from the following equation: [Protein] (µg/µ1) = (a x O. D. of sample)- 
b. 
2.3.7.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using the Invitrogen XCell Sure LockTM system, in conjunction 
with Invitrogen pre-cast gels. After protein had been extracted and quantified from cell 
lysates, samples were diluted 1: 4 with sample buffer (section section 2.2.14) and denatured 
by boiling for 5 minutes and approximately 70 µg protein was then loaded onto either 
NuPAGE® Novex 10% Bis-Tris gels or Novex 8% Tris-Glycine gels (depending on the 
protein being probed for). The running buffer used during electrophoresis also varied 
depending on the gel. For 8% Tris-Glycine gels, SDS running buffer (section 2.2.15) was 
used whereas NuPAGES MOPS SDS running buffer, obtained from Invitrogen, was used 
for NuPAGE® 10% Bis-Tris gels (as this buffer is optimized to give better separation of 
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lower molecular weight proteins). In all gels, two lanes were used for molecular weight 
determination where one lane was loaded with 10 µl Full-Range RainbowTM Molecular 
weight markers and the other with 2µl Biotinylated Protein Ladder. 500 /Al WAGE 
Antioxidant was added to the upper buffer chamber to stop protein tertiary structure 
reforming. Running conditions were; 200 V/ 80 mA for 1.5 hours for NuPAGES 10% Bis- 
Tris gels and 125 V/ 40 mA for 2 hours for 8% Tris-Glycine gels. 
2.3.7.3 Western blotting of gels 
Following SDS-PAGE, protein bands were transferred onto a Hybond-ECLTM 
nitrocellulose membrane using the Invitrogen, XCell IITM Blot Module system (according 
to manufacturer's protocols) and transfer buffer (section 2.2.14). Transfer conditions varied 
depending on the gel used during electrophoresis; 25 V/ 100 mA for 1.75 hours for 8% 
Tris-Glycine gels or 30 V/ 170 mA for 1.5 hours for NuPAGE® 10% Bis-Tris gels. 
2.3.7.4 Immunodetection of EGFR, phospho-EGFR, ERK1/2 and 
phospho-ERK1/2 
Following Western blot transfer, membranes were allowed to equilibrate in wash buffer 
(section 2.2.17) for 5 minutes before blocking on a rocking platform for 1.5-2 hours at 
room temperature, with 25 ml block buffer (section 2.2.18). After blocking, membranes 
were washed three times for 5 minutes in 15 ml wash buffer, followed by the application of 
10 ml primary antibody solution (section 2.2.19). Primary antibody dilution factors varied 
according to the antibody; all three phospho-EGFR antibodies were made up using a 
dilution factor of 1: 200, whereas anti-EGFR, anti-ERKI/2 and anti-phospho-ERK1/2 were 
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diluted 1: 500. Primary antibody blotting occurred overnight at 4°C on a rocking platform. 
Following overnight incubation with primary antibody, membranes were washed three 
times in 15 ml wash buffer before the addition of 10 ml secondary antibody buffer (section 
2.2.20) for 1 hour, on a rocking platform at room temperature. The membranes were then 
washed again three times for 5 minutes with 15 ml wash buffer and proteins detected using 
enhanced chemiluminescence (ECLTM) followed by exposure to HyperfilmTM ECL. 
Exposure times varied depending on the primary antibody used but were generally between 
0.5-5 minutes. Autoradiographs were quantitated using densitometry software (using the 
GelDoc-It system and Labworks Image Acquisition and Analysis Software, Version 
4.6.00.0, Ultra-Violet Products Ltd., Cambridgeshire, UK). 
2.3.7.5 Membrane stripping 
Nitrocellulose membranes were stripped by immersing the membrane in membrane 
stripping buffer (section 2.2.21) and incubating at 50°C for 15 minutes with occasional 
agitation. Membranes were then washed extensively (for 10 minutes at least three times) 
with 15 ml TBS-Tween wash buffer (section 2.2.17 prior to blocking with 25 ml block 
buffer (section 2.2.18) on a rocking platform for 1.5-2 hours at room temperature. 
Membranes were then re-probed according to section 2.3.7.4. 
2.3.8 Cell-based ELISA for measurement of Y992 autophosphorylation 
The autophosphorylation of Y992 was measured using a commercially available 
chemiluminescent assay from Active Motif called the Fast Activated Cell-Based (FACETM) 
EGFR ELISA. In the FACE method, cells are cultured in 96-well plates and stimulated 
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accordingly. Following stimulation, the cells are fixed, which preserves protein 
modifications, including phosphorylation. Each well is then incubated with a primary 
antibody specific for the activated protein and a secondary HRP-conjugated antibody. 
Addition of developing solution provides an easily quantified, chemiluminescent readout. 
Signals are then normalised for cell number using Crystal Violet dye. This approach was 
taken to measure autophosphorylation of Y992 since a higher output was achieved and 
measurements were more quantitative than traditional Western blotting. However, at the 
time of experimentation, the only antibody available with the FACETM EGFR assay was 
anti-phospho-Y992. It would have been beneficial to measure phosphorylation of other 
tyrosine residues with this method had they been available at the time. 
The manufacturer's protocol was followed accordingly. Briefly, cells were seeded onto 
white, Greiner (655098), 96-well plates at 75% confluency, left overnight, and then 
incubated for 24 hours in serum-free media prior to treatment. After treatment, media was 
removed and cells fixed by the addition of 100 ul fixing buffer (section 2.2.22) for 20 
minutes at room temperature. Fixing buffer was then removed and the cells were washed 
three times for 5 minutes each with 200 ul wash buffer (section 2.2.23). Endogenous 
peroxidase activity was inactivated by incubating the cells at room temperature with 100 µl 
quenching buffer (section 2.2.24) for 20 minutes. After washing twice (as previously 
described), cells were then blocked for an hour at room temperature with 100 µl antibody 
blocking buffer supplied with the ELISA kit. Blocking buffer was then removed and cells 
washed three times (as previously described) before the addition of 40 ul primary antibody 
(anti phospho-ErbB 1 Y992 - diluted 1 in 400 with supplied antibody dilution buffer) and 
overnight incubation at 4°C. 
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Following overnight primary antibody incubation, cells were washed three times (as 
previously described) before incubation for one hour at room temperature with 100 µl 
secondary antibody (HRP-conjugated, IgG anti-rabbit - supplied with the assay kit and 
diluted 1 in 1000 with supplied antibody dilution buffer). After washing three times (as 
previously described), 50 ul chemiluminescent working solution (supplied with kit) was 
added to the cells and luminescence was measured using a luminometer (Fluostar Optima, 
BMG Labtech, Durham U. S. A. ). Once luminescence was measured, cell number per well 
was assessed. Cells were washed 3 times to remove chemiluminescence solution and 
incubated for 30 minutes with crystal violet stain (provided with assay kit) then solubilized 
with 1% (w/v) SDS solution (provided with assay kit) and absorbance was read using a 
spectrophotometer (Spectromax Plus) at 595 nm (wavelength proportional to cell number). 
Luminescence values were then normalised to cell number. 
Confirmation that the experiment protocol did not affect total EGFR expression was 
ascertained by measuring its expression using the EGFR antibody provided with the assay. 
Measurement of EGFR expression followed the same procedure described for that of 
phospho-EGFR (see above), with the only difference being the substitution of EGFR 
antibody for the phospho-EGFR (Y992) antibody. The experiment showed that there was 
no change in the expression of EGFR (at the time points examined) in H292 cells treated 
with EGF compared with untreated cells (Fig. 2.6). 
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Figure 2.6: Effect of stimulation with EGF on EGFR expression in H292 cells. After 24-hour 
serum starvation, cells were incubated with EGF (20 ng/ml) for 5 minutes followed by assessment 
of EGFR expression by cell-based ELISA (section 2.8). Data are expressed as Arbitrary 
Luminescence Units (ALU - 106) for 5 independent experiments. No significant differences were 
observed. 
2.3.9 Data analysis 
2.3.9.1 Statistics 
Statistical analysis was performed using the statistical package GraphPad Prism (GraphPad 
Software Inc., San Diego, California). All data was subjected to the D'Agostino and 
Pearson omnibus normality test to determine whether or not the distribution was Gaussian. 
No data-sets were found to be normally distributed, however, since all data looked 
essentially the same when plotted in means or medians (see Fig. 2.7 for examples), data 
was subsequently plotted as mean and standard error of the mean (S. E. M. ) for familiarity of 
presentation. In accordance with the fact that the distribution of all data was non-Gaussian, 
statistical significance was analysed using the non-parametric Kruskal-Wallis test with 
Dunn's post-test correction for multiple group comparisons to compare treated data-sets 
against non-treated, control data-sets. Results were considered significant when p<0.05 
(*p<0.05, **p<0.01, ***p<0.001). 
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Figure 2.8: Comparison between plotting data from the same data-sets as mean values (and 
standard error of the mean - S. E. M. - error bars) with the median values (and interquartile 
range error bars). Two separate data-sets are shown expressed as means or medians. Panels A and 
B show data taken from Fig. 3.5 (Effect of PMA on MUC5AC mRNA expression in H292 cells) 
plotted as means and S. E. M. (A) and medians and interquartile range error bars (B). Panels C and D 
show data taken from Fig. 5.13 (Effect of PD 98059 on EGF-induced MUC5AC mRNA expression) 
plotted as means and S. E. M. (C) and medians and interquartile range error bars (D). 
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CHAPTER 3 
CHARACTERISATION OF STIMULATED 
MUC5AC mRNA EXPRESSION IN HUMAN 
RESPIRATORY EPITHELIAL CELLS 
3.1 INTRODUCTION 
One of the primary objectives of the work described in this thesis was to examine the effect 
of ErbB tyrosine kinase inhibitors on stimulated MUC5AC gene expression (as a marker of 
mucin synthesis). In order to do this, appropriate experimental systems for induction of 
MUC5AC mRNA expression needed to be characterised in terms of cell type and stimuli to 
be used. The stimuli needed to be characterised not only for their effect on MUC5AC 
mRNA expression, but also for their effect on cell viability, whether or not any effect on 
MUC5AC mRNA expression could be inhibited by a `standard' inhibitor (in this case the 
glucocorticosteroid dexamethasone), and whether or not the stimuli worked via direct or 
indirect mechanisms, as outlined below. 
The two human respiratory epithelial A549 and H292 cell lines were selected herein to 
study mucin gene expression, as they are both established as models of human airway 
mucus-secreting cells (section 1.9). 
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Cell density alters ErbB 1 receptor cell surface expression whereby the receptors are down- 
regulated in cells that are compactly populated (Rizzino et al., 1990; Kuszynski et al., 
1993). This negative feedback system provides an essential "off-switch" since signalling of 
ErbB receptors is responsible for driving cell proliferation. However, because cell density 
effects ErbB1 receptor expression, and, hence, the magnitude of stimulated, EGF receptor- 
mediated responses, characterising receptor expression as a function of cell density in the 
A549 and H292 cell lines was important for experimental design. Consequently, ErbB 1 
receptor expression was analysed in the present chapter by measuring cell surface receptor 
expression at three different cell densities. 
In experimental in vitro systems, ErbB receptor signalling can be triggered directly by 
applying soluble ligand (e. g. EGF) or indirectly by stimulating TACE (e. g. with PMA) to 
release soluble ligand (sections 1.6.2 and 1.6.2.1). EGF and PMA were used in the present 
chapter as direct and indirect activators respectively of ErbB receptors. Whilst it is possible 
to stimulate TACE and increase the release of soluble ligand with compounds such as 
PMA, it is also possible to inhibit its activity with inhibitor compounds such as TAPI-2 
(section 1.6.2.1). TAPI-2 was used to determine whether or not activation of TACE 
impacted on PMA-induced MUC5AC mRNA expression in the cell lines used. 
Finally, glucocorticosteroids suppress the transcription of pro -inflammatory genes, 
including MUC5AC mRNA expression (section 1.4). To ensure the in vitro model used 
herein was steroid-inhibitable (and therefore potentially inhibitable by other drugs), the 
effect ofdexamethasone on induced MUC5AC mRNA expression was assessed. 
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3.2 METHODS 
3.2.1 Protocol to determine the effect of cell density and serum on 
ErbB1 receptor expression in respiratory epithelial cell lines 
A549 and H292 cells were passaged and seeded onto 30 mm, 6-well culture plates (section 
2.3.1) at approximately 50,75 or 100% confluency (in duplicate) and incubated overnight 
in media containing foetal calf serum (FCS). Cells were then cultured for a further 24 hours 
in culture media with or without serum (depending on the experimental conditions), prior to 
antibody staining and measurement of ErbB 1 receptor expression by flow-cytometry 
(section 2.3.2). Duplicate cell populations were pooled together prior to antibody staining. 
The spontaneous fluoresence of unlabelled cell populations was set within the first decade 
of the fluorescence scale (section 2.3.2). Cells incubated with isotype control showed no 
difference in fluorescence to the unlabelled cells. Analysis markers (M1 and M2) were set 
so that the M1 marker included all cellular events and M2 marker included only the upper 
2% of these events. The percentage of gated cells expressing ErbBI receptors was assessed 
by determining the percentage of the population within the M2 marker (denoted `percent 
positive'). This gave an indication of the proportion of cells expressing ErbBI receptors. 
The median fluorescence intensity (MFI) was also measured for each sample to give an 
indication of receptor expression per cell (median was used instead of mean as a normal 
distribution cannot be assumed). 
Culturing cells at 75% confluency was found to be optimal for ErbBl receptor expression 
(section 3.3) and was used in all protocols below. 
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3.2.2 Protocol to determine the PMA and EGF time-course for 
MUC5AC mRNA expression and cell viability 
A549 or H292 cells were passaged and seeded onto 30 mm, 6-well culture plates at 
approximately 75% confluency and left overnight (section 2.3.1). Cells were then serum- 
starved for 24 hours by incubating in serum-free medium prior to treatment with 1 ml 
serum free media containing either PMA 0.1 µM, EGF 20 ng/ml, or appropriate vehicle 
(0.05% DMSO for PMA or 0.05 % EGF vehicle - see section 2.2.4) for 2- 24 hours. After 
treatment, cells were either subjected to the MTT assay to measure cell viability (section 
2.3.6) or were lysed and subjected to real-time PCR to measure MUC5AC mRNA 
expression (sections 2.3.3 and 2.3.4). 
Stimulated MUC5AC mRNA expression in A549 cells differed from H292 cells whereby 
the levels of expression were lower in response to both PMA and EGF (sections 3.9 and 
3.11) - in particular EGF. For this reason, the A549 cell line was not used for subsequent 
studies (with the inhibitor compounds). 
3.2.3 Protocol to determine the PMA concentration-response for 
MUC5AC mRNA expression 
H292 cells were passaged and seeded onto 30 mm, 6-well culture plates at approximately 
75% confluency and left overnight (section 2.3.1). Cells were then serum-starved for 24 
hours by incubating them in serum-free medium prior to treatment with 1 ml serum free 
media containing either PMA 1 nM - 1µM or PMA vehicle (0.05% DMSO) for 4 hours. 
PMA stock solutions (section 2.2.5) were serially diluted in DMSO to maintain equal 
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amounts of vehicle throughout the concentration range. After treatment, cells were lysed 
and subjected to real-time PCR to measure MUC5AC mRNA expression (sections 2.3.3 
and 2.3.4) 
3.2.4 Protocol to determine the effect of TAPI-2 on stimulated 
MUC5AC mRNA expression and cell viability 
H292 cells were seeded onto 30 mm 6-well plates at approximately 75% confluency and 
left for 24 hours. Cells were then serum-starved for 24 hours by incubating them in serum- 
free medium prior to exposure to TAPI-2 (see below). Stock solutions of TAPI-2 (section 
2.2. ) were serially diluted in DMSO to maintain equal amounts of vehicle throughout the 
concentration range, and dissolved in serum-free media to give a final vehicle concentration 
of 0.05%. 
Serum-starved cells were pre-exposed to 1 ml serum-free media containing TAPI-2 (3 - 30 
µM) or vehicle (0.05% DMSO) for 45 minutes, after which TAPI-2 was removed and re- 
applied along with the appropriate stimulus (EGF 20 ng/ml or PMA 0.1 µM). The effect of 
TAPI-2 alone on MUC5AC mRNA baseline expression was examined by incubating cells 
with the highest concentration of TAPI-2 (30 µM), but in the absence of the stimulus. After 
treatment, cells were subjected either to the MTT assay to measure cell viability (section 
2.3.6) or lysed and subjected to real-time PCR to measure MUCSAC mRNA expression 
(sections 2.3.3 and 2.3.4). 
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3.2.5 Protocol to determine the effect of dexamethasone on stimulated 
MUC5AC mRNA expression 
H292 cells were seeded onto 30 mm 6-well culture plates at approximately 75% confluency 
and left overnight. Cells were then serum-starved for 24 hours by incubating them in 
serum-free medium prior to exposure to dexamethasone. Stock solutions of dexamethasone 
(section 2.2.3) were serially diluted in DMSO to maintain equal amounts of vehicle 
throughout the concentration range, and dissolved in serum-free media to give a final 
vehicle concentration of 0.05%. 
Serum-starved cells were pre-exposed to 1 ml serum-free media containing dexamethasone 
(1 pM - 0.1 µM) or vehicle (0.05% DMSO) for 45 minutes, after which dexamethasone 
was removed and re-applied along with the appropriate stimulus (EGF 20 ng/ml or PMA 
0.1 MM). The effect of dexamethasone on MUC5AC mRNA baseline expression was 
examined by incubating cells with the highest concentration of dexamethasone (0.1 µM), 
but in the absence of the stimulus. After treatment, cells were subjected either to the MTT 
assay to measure cell viability (section 2.3.9) or lysed and subjected to real-time PCR to 
measure MUC5AC mRNA expression (sections 2.3.3 and 2.3.4). 
3.3 Effect of cell density and serum on ErbB1 cell surface expression in 
respiratory epithelial cells 
Since ErbB 1 receptors are integrally involved in cell growth, adhesion and survival, flow- 
cytometry was used to determine the effects of the cell culture conditions used in 
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experiments herein (i. e. cell seeding density and presence/absence of serum) on cell surface 
expression of ErbB 1 receptors in A549 and H292 cells. 
ErbB 1 receptor expression in A549 cells cultured in media containing FCS decreased 
proportionally as cell density increased (Fig 3.1A). Approximately 98% of cells cultured at 
50% confluency showed positive staining for ErbBI receptors (i. e. 98% of events were in 
the M2 marker region) (Fig. 3.1B). Cells cultured at 75% confluency showed 90% positive 
staining for ErbBI receptors, not significantly different to 100% confluency whereas only 
75% of cells cultured at 100% confluency were positively stained which was significantly 
lower than cells grown at 50% confluency (Fig 3.1B). The MFI (i. e. the relative expression 
per cell) also decreased with increasing cell density, where the MFI values for cells 
cultured at 50% confluency was 45 (arbitrary units), 30 for cells cultured at 75% 
confluency, and 25 for cells cultured at 100% (Fig 3.1C). However, neither the MFI values 
for 75% confluent cells or 50% confluent cells were significantly different from that of the 
100% confluency MFI value. 
The level of ErbB 1 receptor expression by A549 cells cultured in serum-free media and 
increasing cell density was similar to that exhibited by cells grown in media containing 
FCS (3.2A). Approximately 85% of cells cultured at 50% confluency expressed ErbBI 
receptor, 75% in cells cultured at 75% confluency, and 61% in cells cultured at 100% 
confluency (Fig. 3.2B). MFI also decreased with increasing confluency, with median values 
of 38 (AU) for cells cultured at 50%, 30 for cells cultured at 75% and 21 for cells cultured 
at 100% (Fig. 3.2C). Neither the amount of ErbBI receptor expression nor the MFI values 
for cells cultured at 50 and 75% confluency where significantly different from those 
measured from cells cultured at 100% confluency. 
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Figure 3.1: Effect of cell density on EGFR expression on A549 cells cultured in the presence of 
FCS. Cells were seeded at 50%, 75% and 100% confluency and cultured overnight before analysis 
of ErbBl receptor expression by flow-cytometry. Panel A is a representative histogram (Y-axis: 
number of events, X-axis: fluorescence) of ErbBl cell surface expression on gated cell population 
cultured at densities of 100% (-), 75% (-) and 50% (-) compared with isotype control (grey - 
solid). M1 marker indicates total cell population; M2 marker indicates positively stained population. 
Panel B represents the percent of gated cell population present in M2 region (i. e. the amount of 
positively stained cells) for each cell density; panel C represents the median intensity (arbitrary 
units - AU) of the positively stained population for each cell density. Data in panels B and C are 
expressed as mean and S. E. M. for 6 individual experiments. For panel B, ** p<0.01 compared with 
50%. No significant differences were observed for panel C. 
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Figure 3.2: Effect of cell density on EGFR expression on A549 cells cultured in serum free 
conditions. Cells were seeded at 50%, 75% and 100% confluency and cultured overnight then 
serum-starved for 24 hours before analysis of ErbBl receptor expression by flow-cytometry. Panel 
A is a representative histogram (Y-axis: number of events, X-axis: fluorescence) of ErbBl cell 
surface expression on gated cell population cultured at densities of 100% (-), 75% (-) and 50% 
(-) compared with isotype control (grey - solid). M1 marker indicates total cell population; M2 
marker indicates positively stained population. Panel B represents the percent of gated cell 
population present in M2 region (i. e. the amount of positively stained cells) for each cell density; 
panel C represents the median intensity (arbitrary units - AU) of the positively stained population 
for each density. Data in panels B and C are expressed as mean and S. E. M. for 6 individual 
experiments. No significant differences were observed. 
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ErbB 1 receptor expression in H292 cells was very similar to that observed in A549 cells 
where increasing confluency reduced receptor expression, irrespective of the presence of 
FCS (Figs. 3.3 and 3.4). 
H292 cells cultured with FCS at a confluency of 50% showed 70% positive staining for 
ErbB 1 receptor whereas cells cultured at 75% and 100% confluency showed 39% and 24% 
positive staining respectively - both significantly lower than the expression of cells 
cultured at 50% confluency (Fig. 3.3B). MFI was noticeably lower in H292 cells compared 
with A549 cells, with values of 28 (AU), 20 and 18 respectively for cells grown at 50,75 
and 100% confluency (Fig. 3.3C). Only the MFI of cells cultured at 100% confluency was 
significantly lower than cells cultured at 50%. 
H292 cells subjected to serum-starvation also exhibited decreased receptor expression with 
increasing cell density. Around 80% of cells grown at 50% confluency showed positive 
staining for ErbB 1 receptor, 60% for cells grown at 75% confluency and 30% for cells 
cultured at 100% confluency - both significantly lower than the expression demonstrated 
by cells grown at 50% confluency (Fig. 3.4B). MFI values were 26,22 and 19 respectively 
for cells grown at 50%, 75% and 100% confluency, although no significant differences 
were observed (Fig. 3.4C). 
The above data indicate that ErbB 1 receptor expression was higher in both A549 and H292 
cell populations seeded at low densities. In order to maintain a high level of ErbB 1 receptor 
expression during experiments involving stimulants (and inhibitory drugs), cells were 
cultured at 75 - 80% confluency prior to experimentation. Although cells grown at 50% 
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confluency exhibited the highest level of ErbBl receptor expression, RNA yields from 
these cell populations were low, hence this density was not used. 
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Figure 3.3: Effect of cell density on EGFR expression on H292 cells cultured in the presence of 
FCS. Cells were seeded at 50%, 75% and 100% confluency and cultured overnight before analysis 
of ErbB 1 receptor expression by flow-cytometry. Panel A is a representative histogram (Y-axis: 
number of events, X-axis: fluorescence) of ErbBl cell surface expression on gated cell population 
cultured at densities of 100% (-), 75% (-) and 50% (-) compared with isotype control (grey - 
solid). M1 marker indicates total cell population; M2 marker indicates positively stained population. 
Panel B represents the percent of gated cell population present in M2 region (i. e. the amount of 
positively stained cells) for each cell density; panel C represents the median intensity (arbitrary 
units - AU) of the positively stained population for each density. Data in panels B and C are 
expressed as mean and S. E. M. for 6 individual experiments. * p<0.05, ** p<0.01 and *** p<0.001 
compared with 50% confluency. 
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Figure 3.4: Effect of cell density on EGFR expression on H292 cells cultured in serum free 
conditions. Cells were seeded at 50%, 75% and 100% confluency and cultured overnight 
then serum-starved for 24 hours before analysis of ErbB 1 receptor expression by flow- 
cytometry. Panel A is a representative histogram (Y-axis: number of events, X-axis: 
fluorescence) of ErbB 1 cell surface expression on gated cell population cultured at densities 
of 100% (-), 75% (-) and 50% (-) compared with isotype control (grey - solid). M1 
marker indicates total cell population; M2 marker indicates positively stained population. 
Panel B represents the percent of gated cell population present in M2 region (i. e. the 
amount of positively stained cells) for each cell density; panel C represents the median 
intensity (arbitrary units - AU) of the positively stained population for each density. Data 
in panels B and C are expressed as mean and S. E. M. for 6 individual experiments. For 
panel B, ** p<0.01 and *** p<0.001 compared with 50% confluency. No significant 
differences were observed for panel C. 
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3.4 Effect of PMA on MUC5AC mRNA expression in H292 cells: time 
course 
In order to establish the time course effect of PMA on MUCSAC mRNA expression, H292 
cells were incubated with a fixed concentration of PMA (0.1 µM) for 2- 24 hours (section 
3.2.2). PMA significantly increased MUC5AC mRNA relative quantity (RQ) in a time- 
dependent manner, with 10-12-fold increases in MUC5AC mRNA RQ above vehicle 
control at 4 and 6 hours (not significant for latter time point), 30-40-fold increases at 8 and 
16 hours and 150-fold increase at 24 hours (Fig. 3.5). A4 hour incubation time point was 
used for experiments involving inhibitor compounds (unless otherwise stated - Chapters 3 
and 4), as MUC5AC mRNA was significanctly elevated at this time point, and was also 
synonymous with that of the exposure time selected for EGF stimulation of MUC5AC 
mRNA expression (section 3.8). 
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Figure 3.5: Effect of PMA on MUC5AC mRNA expression in H292 cells: time course. Cells 
were incubated with PMA (0.1 µM) for 2- 24 hours before RNA was harvested. Cells were also 
treated with PMA vehicle (0.1 % DMSO) in conjunction with PMA treated cells for every time 
point in order to obtain an accurate ACT value per time point. Expression of MUC5AC mRNA is 
represented as relative quantity (RQ, arbitrary units - AU), calculated using the OOCt method of 
analysis (using the ACT value for vehicle control, VC, as the calibrator). Data are expressed as mean 
fold increase in expression of MUC5AC relative to GAPDH and S. E. M. for 3-6 independent 
experiments. * p<0.05 and *** p<0.001 compared with VC. 
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3.5 Effect of PMA on MUC5AC mRNA expression in H292 cells: 
concentration-response 
In order to establish the concentration-response relationship for the effect of PMA on 
MUC5AC mRNA expression, H292 cells were incubated for 4 hours (section 3.4) with 
increasing concentrations of PMA (1 nM to 1 µM - section 3.2.3). PMA increased 
MUC5AC mRNA expression in a concentration-dependent manner, with a maximal 
increase in RQ above vehicle control of 27-fold at 1µM and an EC50 of 12 nM (Fig 3.6). A 
sub-maximal concentration of 0.1 µM PMA was used in experiments involving inhibitor 
compounds (Chapter 4). 
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Figure 3.6: Effect of PMA on MUC5AC mRNA expression in H292 cells: concentration- 
response. Cells were treated with PMA in increasing concentrations for 4 hours before RNA was 
harvested. Expression of MUC5AC mRNA is represented as relative quantity (RQ, arbitrary units - 
AU), calculated using the MCT method of analysis (using the ACT value for vehicle control, VC, as 
the calibrator). Data are expressed as mean fold increase in expression of MUC5AC relative to 
GAPDH and S. E. M. for 4 independent experiments. * p<0.05 and *** p<0.001 compared with VC. 
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3.6 Effect of EGF on MUC5AC mRNA expression in H292 cells: time 
course 
In order to establish the time course effect of EGF on MUC5AC mRNA expression, H292 
cells were incubated with a fixed concentration of EGF (20 ng/ml) for 2-24 hours (section 
3.2.2). EGF-induced MUC5AC mRNA expression was time-dependent (Fig. 3.7), with 
significant 200% and 250% increases in MUC5AC mRNA RQ above vehicle control at 4 
and 6 hours respectively. At 8,16 and 24 hours, MUC5AC mRNA RQ increased by 7-, 14- 
and 19-fold above vehicle control respectively. A4 hour EGF incubation time was used for 
subsequent experiments examining the effect of EGF and inhibitors on MUC5AC synthesis 
(Chapters 3 and 4), as MUC5AC mRNA expression was significantly elevated at this time 
point, but cell viability remained unaffected (section 3.8). 
3.7 Effect of EGF on MUC5AC mRNA expression in H292 cells: 
concentration-response 
EGF concentration-response data was not collated in the present thesis as the majority of 
studies examining the effects of epidermal growth factor receptor (EGFR) activation by 
EGF (in a variety of experimental systems) use a concentration of 25 ng/ml (Perrais et al., 
2002; Takeyama et al., 1999; Mata et al., 2005). For all the studies examining the role of 
EGF on MUC5AC synthesis in this thesis, a concentration of 20 ng/ml was used. 
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3.8 Effect of EGF on H292 cell viability: time course 
The effect of EGF incubation on H292 cell viability was assessed by incubating cells with 
EGF 20 ng/ml, vehicle control, or serum free media for 4- 24 hours, followed by analysis 
using the MTT assay (section 3.2.2). Incubating cells with EGF for 4 or 6 hours had no 
significant effect on cell viability (although there was a modest increase at 6 hours), but 
after 8,16 and 24 hours incubation, viability was significantly increased above vehicle 
control by 30%, 23% and 42% respectively (Fig. 3.8). EGF vehicle had no significant effect 
on cell viability (measured and compared individually for each time point), indicating that 
the increase in viability was due to EGF rather than a non-selective effect of its vehicle. 
The MTT assay specifically measures mitochondrial respiration (the yellow MTT 
compound is reduced to purple formazan in the mitochondria of living cells) and for this 
reason, can be used to assess cell viability (as well as providing a crude method of 
evaluating of cell number). Data in this chapter indicated that H292 cell viability (or total 
mitochondrial activity) was significantly elevated after incubation with EGF for 8,16 and 
24 hours (Fig. 3.8), suggesting that EGF may have a positive role in increasing 
mitochondrial respiration. Because of this observation, and to avoid any possible effects 
long-term exposure to EGF may have on cellular metabolic activity, experiments involving 
induction of MUC5AC mRNA expression by EGF were restricted to an EGF incubation 
time of 4 hours. At this incubation time point, EGF still caused significant increases in 
MUC5AC mRNA' expression (Fig 3.7), but did not effect cell viability/mitochondrial 
respiration. 
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Figure 3.7: Effect of EGF on MUC5AC mRNA expression in 11292 cells: time course. Cells 
were incubated with EGF (20 rig/ml) for 2- 24 hours before RNA was harvested. Cells were also 
treated with EGF vehicle (10 µM acetic acid) in conjunction with EGF treated cells for every time 
point in order to obtain an accurate ACT value per time point. Expression of MUC5AC mRNA is 
represented as relative quantity (RQ, arbitrary units - AU), calculated using the AACt method of 
analysis (using the AC, value for vehicle control, VC, as the calibrator). Data are expressed as mean 
fold increase in expression of MUC5AC relative to GAPDH and S. E. M. for 3-5 independent 
experiments. ** p<0.01 and *** p<0.001 compared with VC. 
** 
p 
z 
O 
0 
5 
Figure 3.8: Effect of EGF 
on viability of 11292 cells: 
time course. Cells were 
incubated with EGF (20 
ng/ml), vehicle control 
(VC) or serum free media 
only (non-treated - NT) 
for the appropriate time 
point followed by 
assessment of cell viability 
using the MTT assay. Data 
are expressed as percent of 
NT incubated at the 
corresponding time point 
(mean and S. E. M) for 4 
independent experiments. 
**p<0.01 compared with 
NT. 
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3.9 Effect of PMA on MUC5AC mRNA expression in A459 cells: time 
course 
In order to establish the time course effect of PMA on MUC5AC mRNA expression, A549 
cells were incubated with a fixed concentration of PMA (0.1 µM) for 2-24 hours (sections 
3.2.2). Between 2,4,6 and 8 hours, PMA increased MUC5AC mRNA RQ in a time- 
dependent manner, with increases of 130% above vehicle control at 2 hours, 240% at both 
4 and 6 hours and 450% at 8 hours (Fig. 3.9). After a peak in MUC5AC mRNA expression 
at 8 hours, MUC5AC mRNA RQ decreased time-dependently at 16 and 24 hours with 
increases compared with vehicle control of 120% and 55% respectively. 
3.10 Effect of PMA on A459 cell viability: time course 
To determine whether the decrease in MUC5AC mRNA RQ at 16 and 24 hour incubation 
time points (section 3.9) was a result of toxicity of PMA, cell viability was measured using 
the MTT assay. Cells were incubated with either PMA 0.1 µM, vehicle control or serum 
free media for 8,16 or 24 hours, then subjected to the MTT assay. No significant difference 
in cell viability was seen with PMA at any of the time points examined (Fig. 3.10). 
Similarly, PMA vehicle had no significant effect on cell viability (measured and compared 
individually for each time point). Thus, the reduction in MUC5AC mRNA RQ seen after 
16 - 24 hours incubation with either PMA or its vehicle (section 3.8) does not appear to be 
due to loss of viability. 
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Figure 3.9: Effect of PMA on MUCSAC mRNA expression in A549 cells: time course. Cells 
were incubated with PMA (0.1 µM) for 2- 24 hours before RNA was harvested. Cells treated with 
PMA vehicle (0.1 `%o DMSO) were also cultured in conjunction with PMA treated cells for every 
time point in order to obtain an accurate , HOC i value. Expression of MUC5AC mRNA 
is 
represented as relative quantity (RQ, arbitrary units - AU), calculated using the AACt method of 
analysis (using the AC 1 value for vehicle control, VC, as the calibrator). Data are expressed as mean 
fold increase in expression of MUC5AC relative to GAPDH and S. C. M. for 3 independent 
experiments. *** p<0.001 compared with VC. 
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Figure 3.10: Effect of PMA 
on viability of A549 cells: 
time course. Cells were 
incubated with PMA (0.1 
µM), vehicle control (VC) or 
serum free media only (non- 
treated - NT) for the 
appropriate time point 
followed by assessment of 
cell viability using the MTT 
assay. Data are expressed as 
a percent of NT incubated at 
the corresponding time point 
(mean and S. E. M) for 4 
independent experiments. No 
significant differences were 
found. 
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3.11 Effect of EGF on MUC5AC mRNA expression in A549 cells: time 
course 
The relationship between EGF incubation time and MUC5AC mRNA expression was 
examined by incubating A549 cells with a fixed concentration of EGF (20 ng/ml) for 2- 24 
hours (section 3.2.2). EGF increased MUC5AC mRNA RQ in a time-dependent manner 
(Fig. 3.11), with 20-25% increases in MUC5AC mRNA RQ above vehicle control at 2 and 
4 hours, 38% at 6 hours and plateauing at 8- 24 hours (90 - 120% increases above vehicle 
control). Only the increases seen at 8,16 and 24 hours were significantly elevated above 
vehicle controls. An 8 hour incubation time point was used for experiments involving 
inhibitor compounds, except where stated otherwise (Chapter 4). 
3.12 Effect of EGF on A549 cell viability: time course 
In order to determine whether incubation with EGF had any effect on cell viability, A549 
cells were incubated with EGF 20 ng/ml, vehicle control or serum free media for 8,16 or 
24 hours, then subjected to the MTT assay. In contrast to its effect on viability of H292 
cells (increased viability: section 3.12), EGF had no significant effect on cell viability of 
A549 cells at any time point examined (Fig. 3.12). EGF vehicle had no significant effect on 
cell viability (measured and compared individually for each time point). 
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Figure 3.11: Effect of EGF on MUC5AC mRNA expression in A549 cells: time course. Cells 
were incubated with EGF (20 rig/ml) for 2- 24 hours before RNA was harvested. Cells treated with 
EGF vehicle (10 µM acetic acid) were also cultured in conjunction with PMA treated cells for every 
time point in order to obtain an accurate AAC1 value. Expression of MUC5AC mRNA is 
represented as relative quantity (RQ, arbitrary units), calculated using the AAC 1 method of analysis 
(using the AC, value for vehicle control, VC, as the calibrator). Data are mean fold increase in 
expression of MUC5AC relative to GAPDH (vertical bars = S. E. M) for 3 independent experiments. 
** p<0.01 and *** p<0.001 compared with VC. 
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Figure 3.12: Effect of EGF 
on viability of A549 cells: 
time course. Cells were 
incubated with EGF 20 
ng/ml, vehicle control (VC) 
or serum free media only 
(non-treated - NT) for the 
appropriate time point 
followed by assessment of 
cell viability using the MTT 
assay. Data are expressed as 
a percent of NT incubated at 
the corresponding time point 
(mean and S. E. M) for 4 
independent experiments. 
No significant differences 
were found. 
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3.13 Effect of TAPI-2 on EGF- or PMA-induced MUC5AC mRNA 
expression in H292 cells 
In order to assess the contribution of TACE activity to EGF- or PMA-induced MUC5AC 
mRNA expression, H292 cells were pre-treated with the TACE inhibitor TAPI-2 (3 - 30 
µM) for 45 minutes before stimulation with EGF (20 ng/ml) or PMA (0.1 µM) for 4 hours 
in the continued presence of TAPI-2 (section 3.2.5). EGF increased MUC5AC mRNA RQ 
approximately 5-fold above vehicle control (Fig. 3.13A) and PMA increased RQ around 
15-fold (Fig. 3.13B). TAPI-2 had no significant effect on baseline MUC5AC mRNA 
expression (Fig. 3.13A and B), but concentration-dependently inhibited PMA-induced 
MUC5AC mRNA RQ by 5% at 3µM, 25% at 10 µM and 40% at 30 µM (Fig. 3.14). In 
contrast, TAPI-2 had no significant effect on EGF-induced MUC5AC mRNA RQ at 3 and 
10µM, but significantly increased expression above stimulus by 38% at 30 µM (Fig. 3.14). 
The vehicle for TAPI-2 had no significant effect on either EGF- or PMA-induced 
MUC5AC mRNA RQ (Fig. 3.13A and B). 
3.14 Effect of TAPI-2 on H292 cell viability 
In order to determine whether the effect of TAPI-2 on EGF- or PMA-induced MUC5AC 
mRNA expression was associated with change in cell viability (section 3.13), cells were 
pre-incubated with TAPI-2 for 45 minutes prior to stimulation with either EGF (20ng/ml) 
or PMA (0.1 µM) for 4 hours in the continued presence of TAPI-2, followed by assessment 
of cell viability using the MTT assay (section 3.2.5). TAPI-2 had no significant effect on 
cell viability compared with vehicle controls, either in the absence or presence of EGF or 
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PMA (Fig. 3.15). Consequently, the changes in MUC5AC mRNA expression seen with 
EGF or PMA and TAPI-2 (section 3.13) were not due to effects of TAPI-2 on cell viability. 
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Figure 3.13: Effect of TAPI-2 on EGF-induced or PMA-induced MUCSAC mRNA expression. 
H292 cells were pre-incubated with TAPI-2 for 45 minutes prior to stimulation with either (A) EGF 
(20 ng/ml) or (B) PMA (0.1 µM) for 4 hours in the continued presence of TAPI-2, after which RNA 
was harvested. Data in both panels show the RQ values (arbitrary values, AU) calculated using 
AACI- (using vehicle control, VC, as the calibrator), values are expressed as mean and S. E. M. for 4 
independent experiments. V= vehicle for TAPI-2. ** p<0.01 compared with VC, # p<0.05 and ## 
p<0.01 compared with V+ EGF or PMA. 
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Figure 3.14: Effect of TAPI-2 on EGF- or PMA-induced MUCSAC mRNA expression. Data 
are represented as mean percent of PMA or EGF stimulus control (calculated for each individual 
experiment) and S. E. M. for 5 independent experiments. * p<0.05 and ** p <0.01 compared with 
either PMA or EGF stimulus (STIM). 
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Figure 3.15: Effect of TAPI-2 in conjunction with EGF or PMA on viability in H292 cells. 
Cells were pre-incubated with TAPI-2 (3-30 LM) for 45 minutes prior to stimulation with either (A) 
EGF (20 ng/ml) or (B) PMA (0.1 uM) for 4 hours in the continued presence of TAPI-2, followed by 
assessment of cell viability using the MTT assay. V= TAPI-2 vehicle control. Data are expressed as 
mean percent of VC and S. E. M for 4 independent experiments. No significant differences were 
found. 
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3.15 Effect of dexamethasone on PMA-induced MUC5AC mRNA 
expression in H292 cells 
In order to assess the effect of the glucocorticosteroid dexamethansone on PMA-induced 
MUC5AC mRNA expression, H292 cells were pre-incubated with dexamethasone (1 pM - 
0.1 µM) for 45 minutes before stimulation for 4 hours by PMA (0.1 µM), in the continued 
presence of dexamethasone (section 3.2.4). PMA increased MUC5AC mRNA expression 
approximately 20-fold above vehicle control (Fig. 3.16). Dexamethasone had no significant 
effect on baseline MUC5AC mRNA expression, but inhibited PMA-induced MUC5AC 
mRNA RQ in a concentration-dependent manner with an IC50 of 0.2 nM and approximately 
95% inhibition at 0.1 µM (Fig. 3.16): complete inhibition was not achieved over this 
concentration range. Inhibition of PMA-induced MUC5AC mRNA expression by 
dexamethasone was statistically significant at 0.1 nM and higher. The vehicle for 
dexamethasone had no significant effect on PMA-induced MUC5AC mRNA RQ. 
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Figure 3.16: Effect of dexamethasone on PMA-induced MUC5AC mRNA expression. H292 
cells were pre-incubated with appropriate concentration of dexamethasone (Dex) for 45 minutes 
before addition of PMA (0.1 µM), followed by incubation for 4 hours then RNA harvesting. Panel 
A shows the RQ values (arbitrary units AU) calculated using AAC (using the AC 1, value for vehicle 
control, VC, as the calibrator). V= vehicle for dexamethasone. Panel B represents the effect of Dex 
treatment as percent of PMA with V (calculated using the individual stimulus RQ values per 
experiment). All data are expressed as mean and S. E. M. for 4 independent experiments. For panel 
A, ** p<0.01 compared with VC, # p<0.05 and ## p<0.01 compared with PMA with V. For panel 
B, * p<0.05 and ** p<0.01 compared with stimulus (STIM). 
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3.16 Effect of dexamethasone on EGF-induced MUC5AC gene 
expression in H292 cells 
In order to assess the effect of dexamethansone on EGF-induced MUC5AC mRNA 
expression, H292 cells were pre-incubated with dexamethasone (1 pM - 0.1 µM) for 45 
minutes before stimulation for 4 hours by EGF (20 ng/ml), in the continued presence of 
dexamethasone (section 3.2.4). EGF increased MUC5AC mRNA expression approximately 
5-fold above vehicle control (Fig. 3.17). Dexamethasone had no significant effect on 
baseline MUC5AC mRNA expression, but inhibited EGF-induced MUC5AC mRNA RQ in 
a concentration-dependent manner with an IC50 of 0.3 nM and complete inhibition at 10 nM 
(Fig. 3.17). Inhibition of EGF-induced MUC5AC mRNA expression by dexamethasone 
was statistically significant at 1 nM and higher. The vehicle for dexamethasone had no 
significant effect on PMA-induced MUC5AC mRNA RQ. 
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Figure 3.17: Effect of dexamethasone on EGF-induced MUCSAC mRNA expression. H292 
cells were pre-incubated with appropriate concentration of dexamethasone (Dex) for 45 minutes 
before addition of EGF (20 ng/ml), incubation for 4 hours then RNA harvesting. Panel A shows the 
RQ values (arbitrary units, AU) calculated using AAC 1 (using the AC 1 value for VC as the 
calibrator). V= vehicle for dexamethasone. Panel B represents the effect of Dex treatment as 
percent of PMA with V (calculated separately from the individual stimulus RQ values per 
experiment). All data are expressed as mean and S. E. M. for 4 independent experiments. For panel 
A, ** p<0.01 compared with VC, # p<0.05 and ## p<0.01 compared with PMA with V. For panel 
B, * p<0.05 and ** p<0.01 compared with stimulus (STIM). 
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3.17 DISCUSSION 
The data shown in the present chapter outline the characteristics of ErbB receptor-mediated 
induction of MUC5AC synthesis within respiratory epithelial cell-based in vitro systems, 
and are discussed below. 
3.17.1 Effect of cell density and serum on ErbB1 receptor expression in 
A459 and H292 cells 
Cell density and the presence of serum in culture media are two important variables of any 
in vitro system which are likely to impact on various cellular pathways, particularly those 
involved in cell proliferation and adhesion. ErbB receptor signalling is integral to cell 
proliferation and adhesion. Consequently, the effect of cell density and the presence of 
foetal calf serum (FCS) on ErbB receptor expression (specifically ErbB1 expression) was 
investigated. 
Whilst the physical properties of the A549 and H292 cell types (i. e. size and shape) differed 
slightly (section 2.3.2, Fig. 2.1), the general pattern of cell surface expression of ErbBl 
receptors in these two cell types during different culture conditions was analogous. In both 
cell lines, expression of ErbB 1 receptors decreased with increasing cell density, regardless 
of the presence or absence of FCS (section 3.3). Down-regulation of ErbBl receptor 
expression has been reported previously in cell lines including A549 cells (Rizzino et al., 
1988; Rizzino et al., 1988; Rizzino et al., 1990; Kuszynski et al., 1993), and data obtained 
from the in vitro systems used in the present thesis corroborate these findings. 
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The presence or absence of FCS had little influence on the cell surface expression of ErbB 1 
receptors since both the amount of cells expressing ErbB 1 receptor (% positive) and the 
relative amount of ErbBI receptor per cell (median fluorescence intensity - MFI) 
diminished with increasing cell density (section 3.3) - an observation which applied to both 
cell lines. This indicates that cell density is more important than the presence of serum for 
cell surface ErbB 1 receptor down-regulation in respiratory epithelial cells. 
Although both the A549 and H292 cell lines were susceptible to cell density-dependent 
ErbB 1 receptor down-regulation, the H292 cells expressed less ErbB 1 receptor than A549 
cells when comparing both percent positive and MFI (Table 3.1). 
Table 3.1 ErbB1 receptor expression in A549 and H292 cells cultured at varying cell densities, 
with/without serum. 
Cell density - A549 H292 
Confluency Percent positive cells (°/a) Percent positive cells (%) 
(%) + FCS - FCS + FCS -FCS 
100 71 61 30 24 
75 89 75 60 39 
50 96 85 80` 70 
Cell density - 
Confluency 
A549 
MFI (AU) 
H292 
MFI (AU) 
(%) + FCS - FCS + FCS - FCS 
100 24 22 18 19 
75 31 30 20* 22 
50 45 38 - 
t-28 
27 
The top table compares the percent positive data (the percentage of cell population positively 
expressing ErbBl) between the two cell lines and the bottom table compares the difference in 
median intensity (the relative amount of ErbBI receptor per cell: arbitrary units - AU). H292 cells 
expressed significantly less ErbBI receptor compared with levels measured in A549 cells for a 
number of conditions: * p<0.05 and ** p<0.01 both compared with the value from the equivalent 
condition using A549 cells. FCS - foetal calf serum. MFI - median fluorescence intensity. 
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The number of H292 cells expressing ErbB l receptors at any given cell density (regardless 
of the presence of FCS) was significantly lower than that for A549 cells. Only H292 cells 
cultured at 75% and 50% showed significantly lower MFI to the A549 equivalent values. 
Both these observations suggest that A549 cells express more ErbBI receptor than H292 
cells, even at high cell densities and regardless of the presence of serum (FCS). However, 
this did not correlate with an increase in ErbBI receptor-induced MUC5AC mRNA 
expression in A549 cells, as discussed below (section 3.17.2). 
3.17.2 Effect of EGF and PMA on MUC5AC mRNA expression in A549 
cells 
EGF and PMA both induced MUC5AC mRNA expression in A549 cells to a certain extent, 
but this induction differed in a number of ways from that of the H292 cell line (section 
3.17.3). 
After 8 hours incubation with PMA, MUC5AC mRNA expression in A549 cells was 
maximal with a 4.5-fold increase in relative quantity (RQ), compared with a 30-fold 
increase observed in the H292 cells at the same time point, indicating the efficacy of PMA 
was much lower in A549 cells compared with H292 cells. Also, increases in MUC5AC 
mRNA relative quantity (RQ) induced by PMA diminished over time beyond 8 hours to as 
little as 50% after 24 hours in A549 cells. This did not occur in the H292 cell line, where 
MUC5AC mRNA RQ continued to increase time-dependently to a maximal 150-fold 
increase in MUC5AC mRNA RQ after 24 hours. In contrast, treatment with PMA for 24 
hours caused a 3-fold induction of MUC5AC mRNA expression in A549 cells (Yuan-Chen 
et al., 2007). Although findings from this study differ to that obtained in the present thesis, 
126 
the former data were collated from cells cultured for 21 days at air-liquid interface which 
may have altered cell phenotype (and thus cellular responses). 
The effect of EGF on MUC5AC mRNA expression in A549 cells was very different to that 
seen in H292 cells. A maximal and significant 2-fold increase in MUC5AC mRNA 
expression occurred after 8 hours incubation with EGF - parallel to the maximal increase 
observed in PMA-treated A549 cells (although the extent of increase in MUC5AC RQ was 
higher in PMA-treated cells). Increasing EGF incubation times beyond 8 hours did not alter 
this maximal MUC5AC expression which remained at around 2-fold that of control for 
both 16 and 24 hours incubation. Other studies examining EGF-induced MUC5AC mRNA 
expression have also demonstrated around a2-2.5-fold increase in RQ after 24-hours 
incubation (although with a Blighty higher concentration of EGF - 25 ng/ml) (Mata et al., 
2005). The effect of EGF on MUC5AC mRNA expression observed in A549 cells was in 
stark contrast to that observed in H292 cells where MUC5AC RQ increased time- 
dependently and was significantly elevated above control after 4 hours incubation rather 
than 8 hours. 
Although PMA and EGF induced MUC5AC mRNA expression to some extent in A549 
cells (suggesting the ErbB receptor signalling pathway responsible for induction of 
MUC5AC synthesis is functional), the precise reasons for the disparity in response by the 
two cell lines to these stimuli are unclear. Both cell lines are associated with expression of 
MUC5AC mRNA (Berger et al., 1999) and expression of the ErbBl receptor (section 
3.17.1), but evidently the signalling processes are different. In the case of PMA, it is 
unlikely to be due to TACE not being either expressed or non-functional since TACE is 
expressed in A459 cells and cleaves TNF-a (Burvall et al., 2005; Song et al., 2005b). 
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3.17.3 Induction of MUC5AC mRNA expression in H292 cells by PMA 
and EGF and the role of TACE 
PMA and EGF increased MUC5AC mRNA expression in H292 cells but with varied 
potency and through different mechanisms. 
PMA activates ErbB receptor signalling indirectly through stimulating TACE (Doedens et 
al., 2003) (see sections 1.6.3,1.6.4 and 1.6.4.1), and triggers downstream signal pathways 
which, in the case of MUC5AC gene transcription, involves the MAPK/ERK1/2 pathway 
and Spl (Perrais et al., 2002). As a phorbol ester, PMA can also activate protein kinase C 
(PKC), an enzyme responsible for a host of intracellular events (Carter, 2000). Previous 
studies showed induction of MUC5AC expression by PMA was due to a combination of 
PKC and TACE activation (Hewson et al., 2004). Hence, PMA can induce MUC5AC 
mRNA expression via EGFR-dependent and independent mechanisms. Data in the present 
thesis indicated that PMA (0.1 µM) increased MUC5AC mRNA expression in H292 cells 
both concentration- and time-dependently (Figs 3.5 and 3.6). MUC5AC expression was 
significantly elevated above control (10-fold) after exposure to PMA for 4 hours, and 
continued to increase during the time range with induction as high as 150-fold that of 
control after 24 hours exposure. These data are comparative to other studies examing PMA- 
induced MUC5AC mRNA expression using the H292 cell line. In separate studies, PMA 
induced expression of MUC5AC by 4-fold at 4 hours (PMA 10 nM) (Borchers et al., 1999) 
and 12-fold at 6 hours with maximal expression at 24 hours (PMA 10 ng/ml) (Shao et al., 
2003). Hewson et al. observed 150-fold increases in MUC5AC mRNA expression in H292 
cells exposed to PMA (20 nM) for 24 hours, an effect which was abolished in the presence 
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of the RNA synthesis inhibitor, actinomycin D, confirming the increase in MUC5AC 
expression was a result of de novo gene transcription. 
PMA was approximately four times more effective than EGF at inducing MUC5AC 
expression in H292 cells after four hours incubation (Figs. 3.5 and 3.7). The fact that PMA 
can induce MUC5AC mRNA expression by EGFR-dependent and independent 
mechanisms is consistent with the observations made in the present thesis that PMA 
induced higher expression of MUC5AC mRNA expression than EGF (at the same time 
points - Figs 3.5 and 3.7), and that TAPI-2, an inhibitor of TACE (Black et al., 1997; 
Maskos et al., 1998), only partially inhibited PMA-induced MUC5AC expression (Fig. 
3.13). Using the Chinese hamster ovarian cell line, Arribas et al. showed that PMA-induced 
TGF-a release was reduced by 80% when 20 µM TAPI-2 was present, and by 90% at 50 
µM (Arribas et al., 1996a). Other studies using the H292 cell line demonstrated complete 
inhibition of TNF-receptor shedding by TAPI-2 at 50 µM (Levine et al., 2005), and near- 
complete inhibition of neutrophil elastase-induced MUC5AC mRNA expression by the 
related compound, TAPI-1, at 20 µM (Shao and Nadel, 2005). However, data from figure 
3.13 indicates that the highest concentration of TAPI-2 tested (30 µM) attenuated only 40% 
of PMA-induced MUC5AC mRNA expression. It is accepted that in order to confirm 
whether this 40% inhibition was maximal (thus linking the other "60% portion" of the 
PMA-induced increase in MUC5AC mRNA expression with non-ErbB receptor-mediated 
mechanisms) requires further experiments. The specific activity of TACE, and therefore the 
extent of ectodomain shedding of ErbB I receptor ligands such as TGF-a, was not measured 
after 4 hours incubation with PMA. The amount of released soluble ligand should have 
been measured to confirm ectodomain was taking place and also to what extent. Whilst the 
partial inhibition of PMA-induced MUC5AC mRNA expression observed in the presence 
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of TAPI-2 suggests TACE does play a role in PMA activation of MUC5AC expression, it 
would be beneficial to measure the amount of soluble TGF-a throughout the time course 
examined in figure 3.5. This would provide a better understanding of the relationship 
between the activation of TACE by PMA, and the expression of MUC5AC in the current in 
vitro model. 
EGF, which directly activates ErbB receptor signalling, induced MUC5AC mRNA 
expression in H292 cells in a time-dependent manner, with a 3.5-fold increase at 4 hours. 
The time-dependent increase in MUC5AC RQ observed in EGF treated H292 cells is, to 
the knowledge of the author, the first time the effect has been reported. MUC5AC mRNA 
expression was induced by EGF, but this was not quantitative and without time-course data 
(Perrais et al., 2002). Northern blot analysis of EGF-induced MUC5AC gene expression 
corroborated this finding and suggested expression was only detectable at 24 hour 
incubation and not 12 hour (Takeyama et al., 1999). However, acrolein (a component of 
cigarette smoke) in conjunction with ErbB receptor-mediated MUC5AC expression in 
H292 cells, increased MUC5AC RQ by 2.5-fold with EGF for four hours (Deshmukh et al., 
2005) - consistent with the findings herein. 
Contrary to its inhibition of PMA-induced MUC5AC mRNA expression, TAPI-2 increased 
EGF-induced MUC5AC mRNA expression. This unanticipated result shows that EGF- 
induced MUC5AC mRNA expression was not due to indirect effects on TACE activity. 
However, whilst the mechanism(s) of the TAPI-2-mediated increase in EGF-induced 
MUC5AC mRNA expression are unclear, they are not associated with effects on cell 
viability. TACE does not exclusively cleave EGF-like peptides (Black, 2002), and TAPI-2 
is a broad-spectrum zinc metalloprotease inhibitor which inhibits other proteases such as 
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angiotensin-converting enzyme (ACE) secretase (an enzyme which cleaves membrane- 
bound ACE) (Parvathy et al., 1997). Hence, either of these factors may represent a negative 
feedback loop that regulates EGF-induced MUC5AC mRNA expression. 
3.17.4 Effect of EGF and PMA on cell viability 
EGF and PMA had different effects on cell viability, with EGF increasing viability and 
PMA having no effect. 
The MTT assay for cell viability (section 2.3.6) analyses the activity of mitochondrial 
dehydrogenase (and thus cell mitochondrial respiration) as an index of `healthy' cells 
However, the MTT assay is also used as a rudimentary measure of cell proliferation since 
increasing cell number results in an increase in mitochondria and thus an increase in 
mitochondrial dehydrogenase activity. 
The doubling time of H292 cells is 48 hours (http//www. lgcpromochem-atcc. com). Cells 
herein underwent a 24 hour serum-starvation period prior to exposure to treatments, which 
stagnates growth. It is possible that subsequent, EGF exposure induced cells to become 
metabolically active in preparation for proliferation, especially considering ErbB 1 receptors 
have been associated with translocation to the mitochondria (upon autophosphorylation of 
Tyr845) (Boerner et al., 2004) - the precise functions of which are unknown. One function 
may be to increase mitochondrial activity, as observed in the MTT viability experiments. 
The consequence of this increase in `cell viability' (or more specifically - mitochondrial 
activity) caused by EGF was that EGF stimulation of H292 cells was limited to four hours, 
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despite the fact that longer incubation times resulted in higher expression of MUC5AC 
mRNA. This was in order to rule out the effect of increased metabolism on any changes in 
MUC5AC mRNA. For continuity, a four hour incubation time point was also used for 
experiments involving PMA. 
3.17.5 Effect of dexamethasone on EGF- and PMA-induced MUC5AC 
mRNA expression in H292 cells 
The EGF- and PMA-induced MUC5AC mRNA responses were near-completely inhibited 
(95%) by the glucocorticoid (GC), dexamethasone (0.1 µM). These data are consistent with 
previous observations using dexamethasone and the H292 cell line (Kai et al., 1996) and 
other airway epithelial cell lines (Lu et al., 2005; Ishinaga et al., 2002), indicating the 
present cell system was functioning normally. 
The exact mechanisms by which dexamethasone represses MUC5AC gene expression 
remains to be clarified. GCs inhibit MUC5AC gene expression indirectly by silencing the 
transcription of pro-inflammatory cytokines that stimulate its synthesis (Dabbagh et al., 
1999; Louahed et al., 2000; Kim et al., 2002; Pelaia et al., 2003; Song et al., 2003; Chen et 
al., 2003). However, dexamethasone (and possibly other GCs) can directly decrease steady 
state mRNA abundance of secretory mucins (Lu et al., 2005). This may be a result of 
glucocorticoid response elements (GREs) in the MUC5AC promoter sequence (Li et al., 
1998) and binding of glucocorticoid receptor dimers to these elements can repress 
MUC5AC gene transcription (Chen et al., 2005). 
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Dexamethasone inhibited EGF-induced MUC5AC mRNA expression and therefore directly 
inhibited MUC5AC gene transcription induced by ErbB receptor signalling (section 3.16). 
The binding of Grb2 and Ras to ErbB phosphorylated receptor complexes is inhibited by 
dexamethasone (Croxtall et al., 2000), and Grb2 and Ras are involved in ErbB receptor 
mediated ERKI/2 signal transduction. Since ErbB receptor-mediated MUCSAC gene 
transcription is ERKI/2 dependent (Perrais et al., 2002), the inability of Grb2 and Ras to 
complex with phosphorylated ErbB receptor dimers in the presence of dexamethasone may 
explain the mechanism by which dexamethasone inhibited EGF-induced MUC5AC 
expression in the present thesis. 
PMA-induced MUC5AC mRNA expression was due to a combination of ErbB and non- 
ErbB receptor mediated pathways (section 3.17.3). Dexamethasone almost entirely 
inhibited PMA-induced MUC5AC expression (approximately 95%), suggesting either the 
two independent pathways are both inhibited by dexamethasone (although there is little 
evidence to suggest glucocorticoids have any effect on PKC), or dexamethasone reduces 
MUC5AC expression by direct repression of MUC5AC gene transcription (Li et al., 1998; 
Chen et al., 2005). The latter mechanism may also explain the inhibition of EGF-induced 
MUC5AC mRNA expression by dexamethasone observed herein. 
The observed effects of dexamethasone on the induction of MUC5AC mRNA expression in 
H292 cells with PMA or EGF indicate this in vitro model is steroid sensitive (Figs. 3.16 
and 3.17). However, COPD appears to be refractory to treatment with corticosteroids 
(Barnes, 2000; Suissa et al., 2007) and some inflammatory cells associated with COPD 
pathophysiology such as macrophages and neutrophils can exhibit lower sensitivities to 
glucocorticoids (Belvisi, 2004). It is possible that such a scenario may apply to epithelial 
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cells, and since the current in vitro mucus hypersecretion model was steroid sensitive, the 
model may be limited in terms of its relevance to mucus hypersecretion in COPD. 
Recent studies examining the mechanisms behind steroid insensitivity in COPD have 
highlighted the importance of a group of proteins involved in gene repression called histone 
deactylases (HDACs), particularly HDAC2 (Adcock et al., 2005). Decreases in HDAC2 
activity correlate with COPD severity (Ito et al., 2005). For this reason, examining the 
effects of HDAC2 knockdown on steroid sensitivity in the current in vitro model using 
siRNA would be beneficial, and perhaps provide a more accurate model of mucus 
hypersecretion in COPD. 
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3.18 Chapter Summary 
In this chapter, the A549 and H292 human respiratory epithelial cell lines were investigated 
as possible in vitro models of airway mucin synthesis. This was required in order to study 
subsequently the effects of ErbB receptor signalling on MUC5AC mRNA expression 
(Chapter 4). 
Cell density (confluency) altered ErbB 1 receptor expression in both A549 and H292 cells 
whereby expression increased proportionally with decreasing cell density. The presence or 
absence of FCS in the culture media did not significantly alter this effect. 
A549 and H292 cells differed in their ErbB receptor-induced MUC5AC mRNA expression 
levels. Although both cell lines expressed the ErbB 1 receptor, MUC5AC mRNA 
expression in the H292 cell line was far more sensitive to ErbB I receptor stimulation than 
the A549 cell line. Both direct ErbB receptor stimulation with EGF and indirect stimulation 
with PMA induced much higher levels of MUC5AC mRNA expression in H292 cells 
compared with A549. For this reason, only H292 cells were used in experiments beyond 
this stage. 
H292 cells were sensitive to pharmacological intervention, with both EGF- and PMA- 
induced MUC5AC mRNA increases inhibited by dexamethasone. Use of the TACE 
inhibitor TAPI-2 showed that PMA activates ErbB and non-ErbB receptor-mediated 
pathways. Conversely, EGF-induced MUC5AC mRNA expression appeared to be 
enhanced by TACE inhibition. 
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CHAPTER 4 
EFFECT OF ErbB RECEPTOR TYROSINE 
KINASE INHIBITORS ON MUC5AC GENE 
EXPRESSION AND PROLIFERATION IN H292 
CELLS 
4.1 INTRODUCTION 
In the previous chapter (Chapter 3), the induction of MUC5AC mRNA expression by 
activation of ErbB receptor signaling was examined. The optimal conditions for stimulation 
of MUCSAC mRNA expression by EGF and PMA in H292 cells were characterised and 
will be applied to protocols in this chapter to study the effects of ErbB receptor tyrosine 
kinase (RTK) inhibitors on ErbB receptor signaling-induced MUCSAC mRNA expression. 
The development of ErbB RTKIs was spurred on largely from the knowledge that ErbB 
receptor signaling promotes cell proliferation and the expression of proto-oncogenes 
(section 1.8). Most research examining the influence of ErbB receptors on the mucus 
hypersecretory phenotype of diseases such as asthma and COPD centres on the importance 
of EGFR (ErbB I). However, ErbB receptors can only signal by dimerising (sections 1.6.3 
and 1.6.4) and whilst the ErbB 1-ErbB 1 homo-dimer composition occurs upon EGF 
binding, so too can the ErbBl-ErbB2 hetero-dimer. In this chapter, five small-molecule 
ErbB RTKIs were used to dissect the relevant dimer composition regards ErbB receptor 
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activation of mucin MUC5AC mRNA expression. The ErbB3 and ErbB4 receptors were 
not examined as the ligands which instigate the signalling of these receptors are not 
currently perceived as being involved in the pathogenesis of airway inflammatory diseases 
(section 1.7). 
Although the main aim of this thesis was to examine the effect of ErbB RTKIs on mucin 
synthesis, it was important to confirm that the compounds tested were indeed 
pharmacologically active in another biological system. Hence, in this chapter, the effect of 
the ErbB RTKIs on cell proliferation was also examined. 
4.2 METHODS 
4.2.1 Protocol to determine the effect of ErbB receptor tyrosine kinase 
inhibitors on MOC5AC mRNA expression in H292 cells 
Cells were seeded onto 30 mm, 6-well plates at approximately 75% confluency (Chapter 3) 
and incubated overnight (section 2.3.1). Cells were then serum-starved for 24 hours by 
incubating in serum-free medium prior to exposure to ErbB receptor tyrosine kinase (RTK) 
inhibitor (see table below). Stock solutions of the required drug (section 2.2.3) were diluted 
in DMSO to maintain equal amounts of vehicle throughout the concentration range, and 
dissolved in serum-free media to give a final vehicle concentration of 0.05%. Serum- 
starved cells were pre-exposed to inhibitor compounds or vehicle control (the same for all 
inhibitors - DMSO) for 45 minutes, after which period drug solutions were removed then 
re-applied along with the appropriate stimulus (EGF 20 ng/ml or PMA 0.1 µM) and further 
incubation for 4 hours (Chapter 3). The effect of the inhibitors on MUC5AC mRNA 
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baseline expression was examined by incubating cells with the highest concentration of 
inhibitor, but in the presence of the stimulus vehicle. After treatment, cells were either 
subjected to the MTT assay to measure cell viability (see section 2.3.9) or lysed and 
subjected to real-time PCR to measure MUC5AC mRNA expression (see sections 2.3. and 
2.3). 
Table 4.1 ErbB receptor tyrosine kinase inhibitors: identification numbers and putative type 
of inhibitor 
INHBITOR NUMBER TYPE OF ErbB INHIBITOR 
GW459135 ErbB1 
GSK916441 ErbB2 
GW808884 Dual ErbB1 +2 
GW813324 Dual ErbB1 +2 
GW282974 Dual ErbB1 +2 
4.2.2 Protocol to determine the effect of ErbB receptor tyrosine kinase 
inhibitors on H292 cell proliferation (and viability) 
Cells were seeded (approximately 80,000 cells per well) onto black, clear bottomed, 96- 
well culture plates for cell proliferation assessment or onto clear 96-well culture plates for 
viability assessment and left overnight (section 2.3.5). Cells on both plates were then 
treated in quadruplicate for 2 hours with ErbB RTKIs (1 or 10 µM, made up in 1% FCS 
containing cell culture media) either in the absence or presence of EGF (20 ng/ml), 
followed by co-incubation for a further 22 hours with bromodeoxyuridine (BrdU). A 
number of control conditions were also used to validate the proliferation assay. Cells were 
treated (in quadruplicate) with either 0.05% EGF vehicle (section 2.2.4), EGF 20 ng/ml, 
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ErbB RTK vehicle (0.05% DMSO) or EGF 20ng/ml + ErbB RTK vehicle - all made up in 
1% FCS culture media and subjected to the same incubation steps as described previously. 
Cells were also cultured in quadruplicate in serum free culture media to measure the effect 
of serum on proliferation. BrdU incorporation into synthesised DNA was measured by 
chemiluminescent ELISA (section 2.3.5) and cell viability was measured by MTT assay 
(see section 2.3.6). 
4.3 Effect of an ErbBl receptor tyrosine kinase inhibitor on EGF- or 
PMA-induced MUC5AC mRNA expression 
The effect of the ErbBl RTK inhibitor GW459135 on EGF- or PMA-induced MUC5AC 
mRNA expression was examined by pre-treating H292 cells for 45 minutes with 
GW459135 (0.3 - 10 AM) before stimulation with EGF (20 ng/ml) or PMA (0.1 AM) for 4 
hours in the continued presence of GW459135 (section 4.2.1). EGF increased MUC5AC 
mRNA RQ approximately 3-fold above vehicle control (Fig. 4.1A) and PMA increased RQ 
by around 15-fold (Fig. 4.1B). GW459135 had no significant effect on baseline MUC5AC 
mRNA expression (Fig. 43A and B), but concentration-dependently inhibited EGF- 
induced MUC5AC mRNA expression with an IC50 of 1.2 µM and complete inhibition at 3 
µM (Figs. 4.1A and 4.2). PMA-induced MUC5AC mRNA RQ was only partially inhibited 
by GW459135 with a decrease compared with stimulus of 30% at 0.1 µM and plateauing 
out at 0.3 - 10 µM (with a maximal inhibitory response of around 60% at 0.3 uM) and an 
IC50 of 0.2 µM (Figs. 4.1A and 4.2). GW459135 shared the same vehicle as that for 
dexamethasone (0.1% DMSO) which was previously established as having no significant 
effect on EGF- or PMA-induced MUC5AC mRNA expression (sections 3.13 and 3.14, 
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Figs. 3.9 and 3.10). Because increases in MUC5AC mRNA in response to PMA are due to 
ErbB-mediated and ErbB-independent pathways (Chapter 3), and also because inhibition 
by GW459135 was only partial (despite complete inhibition of EGF-induced MUC5AC 
mRNA), PMA was not used subsequently as a stimulus. 
140 
A 
B 
a ýý 
Z 
c1 
E 
U 
LU 
U 
Z) 
2 
PMA (0.1 µM) 
Figure 4.1: Effect of (he H: rbnl R'1'K inhibitor, GW459135, on EGF-induced or PMA-induced 
MU('5A(' mRNA expression. 11292 cells were pre-incubated with GW459135 for 45 minutes 
prior to stimulation with either (A) EGF (20 ng/ml) or (B) PMA (0.1 µM) for 4 hours, in the 
continued presence of inhibitor, after which RNA was harvested. Data in both panels show the RQ 
values (arbitrary units, AU) calculated using AAC1 (using vehicle control, VC, as the calibrator) and 
expressed as mean and S. F. M. tier 5 independent experiments. V= GW459135 vehicle. For both 
panels, ** p<0.0 I compared with VC, ## p<0.0I compared with V (for EGF or PMA). 
141 
NO [GW459135] (ECM) 
EGF (20 ng/ml ) 
No 
de 
[GW459135] (µM) 
4.4 Effect of an ErbB1 receptor tyrosine kinase inhibitor on cell viability 
In order to determine whether or not the effect of GW459135 on EGF- or PMA-induced 
MUC5AC mRNA expression was associated with changes in cell viability, H292 cells were 
pre-incubated with GW459135 (0.3 - 10 µM) for 45 minutes prior to stimulation with 
either EGF (20 ng/ml) or PMA (0.1 µM) for 4 hours in the continued presence of 
GW459135, followed by assessment of cell viability using the MTT assay. GW459135 had 
no significant effect on cell viability compared with vehicle control, either in the absence or 
presence of EGF or PMA (Fig. 4.3). Consequently, the inhibitory effect of GW459135 on 
EGF- or PMA-induced MUC5AC mRNA expression was not a result of loss of cell 
viability. 
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Figure 4.2: Effect of the ErbBl RTK inhibitor, GW459135, on EGF- or PMA-induced 
MUCSAC mRNA expression. Data are represented as percent of PMA or EGF stimulus, STIM, 
(calculated for each individual experiment) and expressed as mean and S. E. M. for 5 independent 
experiments. ** p<0.01 compared with EGF stimulus and ## p<0.0I compared with PMA stimulus. 
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Figure 43: Effect of EGF or PMA and the ErbB1 RTK inhibitor, GW459135, on cell viability. 
H292 cells were pre-incubated with GW459135 (0.3-10 µM) for 45 minutes prior to stimulation 
with either (A) EGF (20 ng/ml) or (B) PMA (0.1 µM) for 4 hours in the continued presence of 
GW459135, followed by assessment of cell viability by MTT assay. V= vehicle for GW459135. 
Data are expressed as mean percent of vehicle control (VC) and S. E. M for 3 independent 
experiments. No significant differences were found. 
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4.5 Effect of an ErbB2 tyrosine receptor kinase inhibitor on EGF- 
induced MUC5AC mRNA expression 
The effect of the ErbB2 tyrosine kinase inhibitor, GSK916441, on EGF-induced MUC5AC 
mRNA expression was examined by pre-treating H292 cells for 45 minutes with 
GW459135 (1 - 10 AM) before stimulation with EGF (20 ng/ml) for 4 hours in the 
continued presence of GSK916441. EGF increased MUC5AC mRNA RQ approximately 
3.5-fold above vehicle control (Fig. 4.4). GSK916441 had no effect on baseline MUC5AC 
mRNA expression (Fig. 4.4) and had no inhibitory effect on EGF-induced increases in 
MUC5AC mRNA RQ (Fig. 4.4). GSK916441 shared the same vehicle as that for 
dexamethasone (0.1% DMSO) which was previously established as having no significant 
effect on EGF-induced MUC5AC mRNA expression (section 3.14, Fig. 3.10). 
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Figure 4.4: Effect of the ErbB2 RTK inhibitor, GSK916441, on EGF-induced MUCSAC 
mRNA expression. 11292 cells were pre-incubated with GSK916441 (1-10 UM) for 45 minutes 
prior to stimulation with EGF (20 ng/rnl) in the continued presence of inhibitor, after which RNA 
was harvested. MUC5AC mRNA expression is expressed as mean relative quantity (RQ, arbitrary 
units -- AU), calculated using the AACt method of analysis (using the AC1 value for vehicle control, 
VC, as the calibrator) and S. E. M. for 4 independent experiments. V= vehicle for GSK916441. 
p<0.05 and ** p<0.01 compared with VC. 
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4.6 Effect of a dual ErbB1+2 receptor tyrosine kinase inhibitor on EGF- 
induced MUC5AC mRNA expression 
The effect of the dual ErbB1+2 RTK inhibitor, GW813324, on EGF-induced MUC5AC 
mRNA expression was examined by pre-treating H292 cells for 45 minutes with 
GW813324 (0.3 - 10 µM) before stimulation with EGF (20 ng/ml) for 4 hours in the 
continued presence of GW813324. EGF increased MUC5AC mRNA RQ approximately 3- 
fold above vehicle control (Fig. 4.5A). GW813324 had no significant effect on baseline 
MUC5AC mRNA expression (Fig. 4.5A), but concentration-dependently inhibited EGF- 
induced MUC5AC mRNA expression by 40% at 3 µM and 80% at 10 µM (Fig. 4.5B). 
GW813324 shared the same vehicle as that for dexamethasone (0.1% DMSO) which was 
previously established as having no significant effect on EGF-induced MUC5AC mRNA 
expression (section 3.14, Fig. 3.10). 
4.7 Effect of a dual ErbB1+2 receptor tyrosine kinase inhibitor on cell 
viability 
In order to determine whether or not the inhibitory effect of GW813324 on EGF-induced 
MUC5AC mRNA expression was a result of toxicity, H292 cells were pre-incubated with 
GW813324 (1 - 10 µM) for 45 minutes prior to stimulation with EGF (20 ng/ml) for 4 
hours in the continued presence of GW813324, followed by assessment of cell viability 
using the MTT assay. GW813324 had no significant effect on cell viability compared with 
vehicle control, either in the absence or presence of EGF (Fig. 4.6). Consequently, the 
inhibitory effect of GW813324 on EGF-induced MUC5AC mRNA expression was not a 
result of loss of cell viability. 
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Figure 4.5: Effect of the dual ErbB1+2 RTK inhibitor, GW813324, on EGF-induced 
MUC5AC mRNA expression. H292 cells were pre-incubated with GW813324 (1-10 µM) for 45 
minutes prior to stimulation with EGF (20 ng/ml) in the continued presence of inhibitor, after which 
RNA was harvested. Panel A shows the RQ values (arbitrary units, AU) calculated using AACT 
(using the ACT value for vehicle control, VC, as the calibrator). V= vehicle for GW813324. Panel 
B represents the effect of GW813324 as percent of EGF with V (calculated separately from the 
individual stimulus RQ values per experiment). All data are expressed as mean and S. E. M. for 4 
independent experiments. For panel A, ** p<0.01 compared with VC and # p<0.05 compared with 
EGF stimulus control. For panel B, ** p<0.01 compared with EGF stimulus (STIM). 
147 
p %10 
`'ýo [GV'i813324] (tM) 
t 
0 
Figure 4.6: Effect of the dual ErbBl+2 RTK inhibitor, GW813324, on cell viability. H292 
cells were pre-incubated with GW813324 for 45 minutes prior to stimulation with or EGF (20 
ng/ml) for 4 hours in the continued presence of inhibitor, after which viability was assessed by 
MTl assay. V= vehicle for GW813324. Data are expressed as mean percent of vehicle control 
(VC) and S. E. M for 3 independent experiments. No significant differences were found. 
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4.8 Lack of effect of the dual ErbB1+2 tyrosine kinase inhibitors, 
GW808884 and GW282974, on EGF-induced MUC5AC mRNA 
expression 
The effect of the dual ErbB1+2 RTK inhibitors, GW808884 and GW282974 on EGF- 
induced MUC5AC mRNA expression was examined by pre-treating H292 cells for 45 
minutes with GW459135 (1 - 10 µM) before stimulation with EGF (20 ng/ml) for 4 hours 
in the continued presence of GSK916441. For both GW808884 and GW282974 
experiments, EGF increased MUC5AC mRNA RQ approximately 3.5-fold above vehicle 
control and neither inhibitor had any significant effect on baseline expression of MUC5AC 
mRNA (Fig. 4.7). Furthermore, neither GW808884 norGW282974 had any significant 
effects on EGF-increased MUCSAC mRNA expression (Fig. 4.7A and B). GW808884 and 
GW282974 shared the same vehicle as that for dexamethasone (0.1% DMSO) which was 
previously established as having no significant effect on EGF-induced MUC5AC mRNA 
expression (sections 3.14, Fig. 3.10). 
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Figure 4.7: Effect of the dual Erbt3l+2 RT'K inhibitors, GW808884 and GW282974, on EGF- 
induced MUC5AC mRNA expression. 11292 cells were pre-incubated with (A) GW813324 (1 - 
10, uM) or (13) GW282974 (3 - 30 jtM) for 45 minutes prior to stimulation with EGF (20 ng/ml) in 
the continued presence of inhibitor. Both panels show the RQ values (arbitrary units, AU) 
calculated using MC 1 (using the AC 1 value for vehicle control, VC, as the calibrator). For both 
panels, V= vehicle for GW inhibitor. All data are expressed as mean and S. E. M. for 4 independent 
experiments. For both panels, ** p<0.01 compared with VC. 
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4.9 Effect of single and dual ErbB1+2 RTK inhibitors on cell 
proliferation and viability 
In order to determine whether or not the lack of inhibition of MUC5AC mRNA expression 
by the ErbB2 RTK inhibitor and the two dual ErbB 1+2 RTK inhibitors (GW282974 and 
GW808884) was due to use of inactive compounds, as well as investigating further the 
activity of ErbB RTKs, the effect of these drugs, as well as the ErbBl RTK inhibitor and 
the dual ErbBl+2 RTK inhibitor (GW813324) that suppressed MUC5AC mRNA 
expression, on another biological system, cell proliferation, was analysed. DNA synthesis 
was used as a marker of cell proliferation and was examined by measuring BrdU 
incorporation into synthesised DNA (section 2.3.5). Cell viability experiments were run in 
parallel to establish whether or not changes in cell proliferation caused by inhibitor 
treatment were associated with changes in viability. 
4.9.1 Effect of serum on cell proliferation (DNA synthesis) 
Proliferation (DNA synthesis measured by BrdU incorporation) of H292 cells grown in 
serum free (SF) media was examined and compared with the proliferation of cells grown in 
1% FCS containing media (both in the absence or presence of EGF). 
The proliferation of cells grown in SF cell culture media achieved approximately 1x106 
arbitrary luminescence units (ALU) (Fig. 4.8A). Incubating cells in 1% FCS media in the 
presence of EGF vehicle achieved around 1.35x106 ALU, approximately 30% higher than 
that of cells grown in SF media (Fig. 4.8A). Cells grown in 1% FCS media and treated with 
EGF (20 ng/ml) achieved around 1.5x106 ALU, approximately 50% higher and 
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significantly so, than that of cells grown in SF media alone (Fig. 4.8A). However, there was 
no significant difference in BrdU incorporation between cells grown in 1% FCS and treated 
with EGF vehicle and those grown in I% FCS and treated with EGF (Fig. 4.8A). The effect 
of' the ErbB RTKI vehicle was also examined and achieved similar relative amounts of 
proliferation (I. 32x106 ALU) as that of cells treated with EGF vehicle (data not shown). 
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Figure 4.8: Effect of serum free media (in the absence or presence of EGF) on BrdU 
incorporation and viability. 11292 cells were seeded onto 96-well plates at a specified density in 
serum free (SIF) culture media or I'%O ITS-containing media and left overnight before treatment with 
EGF vehicle (vehicle control, VC) or EGF (20 rig/ml) for 24 hours. For proliferation studies, cells 
were also incubated with BrdU-peroxidase conjugate for 22 hours out of the 24 hour treatment time. 
BrdU incorporation into newly synthesised DNA was measured using an ELISA, and viability 
measured by M"F°1' assay. Panel A shows cell proliferation in Arbitrary Luminescence Units (ALU - 
105) and panel B represents viability expressed as optical density at 550 nm. Both panels are 
expressed as mean and S. E. M. for 6 independent experiments. For panels A and B, ** p<0.01 
compared with SF. 
4.9.2 Effect of serum on cell viability 
The type of culture media also effected cell viability in a similar way to its effect on 
proliferation. The mean optical density (OD) of cells cultured in SF media was around 0.43 
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whereas for cells cultured in 1% FCS and treated with EGF vehicle, mean OD was around 
0.57 (significantly higher by approximately 30% - Fig. 4.8B). Cells grown in 1% FCS 
media and treated with EGF (20 ng/ml) achieved an OD of 0.59, significantly higher than 
that of cells grown in SF media by approximately 50% higher (although not significantly 
different from cells grown in 1% FCS media, minus EGF - Fig. 4.8B). 
4.9.3 Effect of ErbB RTKIs on cell proliferation (DNA synthesis) and 
viability 
At 1 uM and in the absence of EGF, none of the five ErbB RTKIs had any significant effect 
on DNA synthesis (measured by BrdU incorporation) in H292 cells (Fig 4.9A). Conversely, 
at this same concentration, the effective ErbBl RTK inhibitor (GW459135) and the 
effective dual ErbBl+2 RTK inhibitor (GW813324), significantly reduced cell viability 
compared with vehicle control, by 30% and 25% respectively (Fig 4.9B). 
At a concentration of 10 µM and in the absence of EGF, only GW813324 and GSK916441 
(ErbB2 RTK inhibitor) significantly attenuated BrdU incorporation by approximately 35% 
and 40% respectively (Fig. 4.10A). The two, ineffective dual ErbBl+2 RTK inhibitors 
GW808884 and GW282974 both reduced BrdU incorporation by approximately 20%, 
although these values were not significant (Fig 4.10A). However, GW459135, GW808884 
and GW813324 all significantly reduced viability by 40% that of vehicle control (Fig 
4.10B). Conversely, GW282974 and GSK916441 had no significant effects on cell viability 
(Fig 4.1 OB). 
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Figure 4.9: Effect of ErbB RTKIs (1 µM) in the absence of EGF on cell proliferation and 
viability. H292 cells were seeded onto 96-well plates at a specified density in culture media 
containing I% FCS and left overnight before treatment with ErbB RTKIs (1 AM) for 24 hour. For 
proliferation studies, cells were also incubated with BrdU-peroxidase conjugate for 22 hours out of 
the 24 hours treatment time. Cell proliferation (BrdU incorporation into DNA) was measured using 
an ELISA, and viability measured by MTT assay. Panel A represents cell proliferation expressed as 
percent of inhibitor vehicle control (VC) and panel B represents viability, also expressed as percent 
of VC. All data are mean and S. E. M. for 6 independent experiments. For panel B, * p<0.05 and ** 
p<0.01 compared with VC. For legend, RTKI: Receptor Tyrsoine Kinase Inhibitor. 
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Figure 4.10: Effect of ErbB RTKIs (10 µM) in the absence of EGF on cell proliferation and 
viability. H292 cells were seeded onto 96-well plates at a specified density in culture media 
containing 1% FCS and left overnight before treatment with ErbB RTKIs (10 uM) for 24 hour. For 
proliferation studies, cells were also incubated with BrdU-peroxidase conjugate for 22 hours out of 
the 24 hours treatment time. Cell proliferation (BrdU incorporation into DNA) was measured using 
an ELISA, and viability measured by MTT assay. Panel A represents cell proliferation expressed as 
percent of inhibitor vehicle control (VC) and panel B represents viability, also expressed as percent 
of VC. All data are mean and S. E. M. for 6 independent experiments. * p<0.05 and ** p<0.01 
compared with VC. For legend, RTKI: Receptor Tyrsoine Kinase Inhibitor. 
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Although EGF (20 ng/ml) did not significantly increase BrdU incorporation (cell 
proliferation) compared with vehicle controls (Fig 4.8A), its presence did increase the 
inhibitory effect of the five ErbB RTKIs (Figs. 4.11 and 4.12). All five inhibitors 
(GW459135, GW808884, GW813324, GW282974 and GSK916441) at 1 µM significantly 
inhibited BrdU incorporation compared with vehicle control (and EGF + inhibitor vehicle) 
by approximately 35%, 45%, 60%, 45%, and 50% respectively (Fig. 4.11A). None of the 
inhibitors at 1 µM caused any significant loss in cell viability compared with vehicle 
control (Fig 4.11 B). 
At a concentration of 10 µM, and in the presence of EGF (20 ng/ml), all five inhibitors 
significantly attenuated BrdU incorporation compared with vehicle control (and EGF + 
inhibitor vehicle) by approximately 65%, 65%, 70%, 50%, and 75% respectively (Fig. 
4.12A). Only the effective ErbB 1 RTK inhibitor GW459135 and the effective dual 
ErbB1+2 RTK inhibitor GW813324 significantly reduced cell viability compared with 
vehicle control at a concentration of 10 µM (35% and 25% respectively) (Fig. 4.12B). 
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Figure 4.11: Effect of ErbB RTKIs (1 uM) in the presence of EGF on cell proliferation and 
viability. H292 cells were seeded onto 96-well plates at a specified density in culture media 
containing 1% FCS and left overnight before treatment with ErbB RTKIs (1 µM) and EGF (20 
ng/ml) for 24 hours. For proliferation studies, cells were also incubated with BrdU-peroxidase 
conjugate for 22 hours out of the 24 hours treatment time. Cell proliferation (BrdU incorporation 
into DNA) was measured using an ELISA, and viability measured by MTT assay. Panel A 
represents cell proliferation expressed as percent of inhibitor vehicle control (VC) and panel B 
represents viability, also expressed as percent of VC. V= vehicle for inhibitors. Both panels are 
mean and S. E. M. for 6 independent experiments. For panel A, * p<0.05, ** p<0.01 compared with 
VC and ## p<0.01 compared with V (for EGF). For panel B, no significant differences were found. 
For legend, RTKI: Receptor Tyrsoine Kinase Inhibitor. 
157 
I rti bitor (1 IA NA) 
I rtii bitor (1 A) 
A 
5 
_o 
Irtiibitor (10 p M) 
B 
EGF (20 r g/ml) 
rhbitor Type: 
ErbBl FZT}4 
ErbBl +2 FRTI4 
ErbBl +2 FZTI4 
ErbBl +2 RT}4 
- ErbB2 RTF4 
rti bitor (1 0 W) 
EGF (20 r fn1) 
Figure 4.12: Effect of ErbB RTKIs (10 µM) in the presence of EGF on cell proliferation and 
viability. H292 cells were seeded onto 96-well plates at a specified density in culture media 
containing 1% FCS and left overnight before treatment with ErbB RTKIs (10 µM) and EGF (20 
ng/ml) for 24 hours. For proliferation studies, cells were also incubated with BrdU-peroxidase 
conjugate for 22 hours out of the 24 hours treatment time. Cell proliferation (BrdU incorporation 
into DNA) was measured using an ELISA, and viability measured by MTT assay. Panel A 
represents cell proliferation expressed as percent of inhibitor vehicle control (VC) and panel B 
represents viability, also expressed as percent of VC. V= vehicle for inhibitors. Both panels are 
mean and S. E. M. for 6 independent experiments. For panel A, ** p<0.01 compared with VC and ## 
p<0.01 compared with V (for EGF). For panel B, * p<0.05 compared with VC. For legend, RTKI: 
Receptor Tyrsoine Kinase Inhibitor. 
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4.10 DISCUSSION 
Attenuation of ErbB receptor-induced MUC5AC synthesis by certain ErbB RTKIs has 
already been established both in vitro and in vivo (Takeyama et al., 1999; Takeyama et al., 
2001b). The focus of the present thesis was to investigate the ErbB receptor signalling 
mechanisms involved in inducing MUC5AC synthesis and, by using a selection of ErbB 
RTKIs (single ErbBl, single ErbB2 and dual ErbB1+2) as pharmacological tools, further 
dissect the pathway. ErbB receptors dimerise prior to signalling (section 1.6.3) making 
pharmacological interference of this system complex, since transduction is generated from 
any two out of a possible four receptor subtypes (the composition of which varies 
depending on cell type and functional output), thus providing two targets for any one 
chemotherapeutic agent. For this reason, a variety of ErbB RTKIs selective for ErbBl, 
ErbB2 and ErbB 1+2 were used in the present thesis to isolate the most probable ErbB 
receptor signalling mechanisms involved in induced MUC5AC mRNA expression. 
4.10.1 The effect of ErbB RTKIs on induced MUC5AC mRNA 
expression 
Of the five small molecule ErbB RTKIs examined in this thesis, only the single, ErbB 1 
RTK inhibitor, GW459135, completely inhibited EGF-induced MUC5AC mRNA 
expression (sections 4.3,4.5 and 4.6), which was not attributed to a loss in cell viability 
(section 4.4). These data corroborate other findings indicating the in vitro and in vivo 
potential of small molecule ErbB1 RTK inhibitors to attenuate ErbB-receptor induced 
MUCSAC synthesis (Takeyama et al., 1999; Takeyama et al., 2001b; Shao et al., 2003). Of 
interesting note is that all the compounds used in these published studies were selective for 
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the ErbB 1 receptor, as is GW459135 (unlike the other compounds tested herein which had 
little or no effect on MUCSAC mRNA expression and were selective for both ErbB 1+2 or 
ErbB2 alone). However, the lack of inhibition shown by three of the five ErbB RTKls does 
not necessarily indicate the compounds were pharmacologically inactive as exemplified by 
the inhibitory effects on cell proliferation (discussed later in this chapter- section 4.10.3). 
The effect of GW459135 on PMA-induced MUC5AC mRNA expression (i. e. indirect 
stimulation of ErbB receptor signalling by activation of TACE) was also measured. The 
partial inhibition of PMA-induced MUC5AC mRNA expression observed with the TACE 
inhibitor TAPI-2 (Chapter 3) was mirrored by GW459135, although GW459135 was more 
potent since maximal reduction in MUC5AC expression was 60% compared with TAPI-2 
which was 40%. This contrasts data by Shao et al. (Shao et al., 2003) where complete 
inhibition of PMA-induced MUC5AC mRNA expression in A549 cells by the ErbBl 
selective inhibitor AG1478 (and an EGFR blocking antibody) was observed. However, 
complete inhibition with TAPI-1 was also observed by this group, suggesting a possible 
difference in TACE activity between A549 and H292 respiratory epithelial cell lines. 
Although GW459135 was the only compound tested in the present thesis to completely 
inhibit EGF-induced MUC5AC mRNA expression, expression was also significantly 
reduced by the dual ErbB1+2 RTK inhibitor, GW813324. However, since the significance 
of this attenuation altered depending on the mode by which data were expressed (section 
4.6 and Fig. 45), it is hard to clarify whether there was true inhibition of EGF-induced 
MUC5AC expression by GW813324 or whether this was a result of off-target effects (the 
"raw-data" - Fig 4.5, panel A- suggests significant inhibition was only achieved at the 
highest concentration of 10 µM). Selectivity data provided by GSK regarding GW813324 
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(summarised in table 4.2) indicates the compound is highly selective (and was in fact, of all 
five inhibitors, the compound with the least cross-reactivity with other kinases). In light of 
this, and coupled with the fact that no negative effects on cell viability were observed for 
GW813324 (section 4.7), GW813324 may well have genuinely inhibited EGF-induced 
MUC5AC mRNA, but with a lower efficacy compared with GW459135. 
Table 4.2 Summary of GSK ErbB RTK inhibitor compound selectivity data 
ErbB1 ErbB2 ErbB4 Other kinases with IC50values : 50.1 pM 
GW459135 GSK-3, B (0.1 NM) 
(ErbB1) 10 nM 
1 NM 1 NM ZAP70 (0.1, pM) 
F nT 0.1 pM) 
GW808884 0.1 NM 10 nM 1 NM - (ErbB1+2) 
GW813324 10 nM 10 nM 1 NM - (ErbB1+2) 
GW282974 10 nM 10 nM 1 NM - (ErbB1+2) 
GSK916441 1 NM 10 nM 1 NM - (ErbB2) 
The selectivity of the five ErbB RTKIs tested in the present thesis were screened in-house by GSK 
through measuring IC50 values for around 60 other kinases including major enzymes such as IKKs, 
Akts, P13s and MAPKs. Screening was based on assessment using enzymatic assays, and was not 
cell-based. IC50 values are given for each compound for ErbB 1, ErbB2 and ErbB4 receptor tyrosine 
kinase activity (no data was available for ErbB3 since there is no kinase activity for this specific 
receptor). Compounds which produced IC50 values of 50.1 µM for off-target kinases are also 
indentified. GSK-3ß - Glycogen Synthase Kinase 3ß, ZAP70 - Zeta Associated Protein 70 (kDa), 
FynT - Fyn Tyrosine Kinase. 
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It must be noted that the single most effective compound at inhibiting EGF- (and PMA-) 
induced MUC5AC expression was also the least specific. Data from GSK indicated that 
GW459135 inhibited three other non-ErbB receptor proteins; GSK-3ß, ZAP70 and FynT, 
with IC50 values in the nanomolar region (table 4.2). It is therefore pertinent to discuss the 
specific functions of these proteins in relation to the current in vitro system, and to discuss 
what future experiments can be employed in order to determine whether these proteins 
impact on the pathway involved in EGF-induced MUC5AC synthesis. 
ZAP70 (Zeta-chain-Associated Protein kinase 70) is a protein tyrosine kinase primarily 
expressed in T cells (Latour et al., 1997), and has a critical role in the initiation of T-cell 
signalling (Chan et at., 1992; Chan et al., 1994). FynT is a Src-family tyrosine kinase 
upstream of ZAP70 and therefore, like ZAP70, is important in the development and 
function of T-lymphocytes (Picard et al., 2002). Considering both ZAP70 and FynT are 
expressed in T-cells and are involved in their development and function, any off-target 
inhibition of these kinases by GW459135 is unlikely to impact on the respiratory epithelial 
cell in vitro system used in the current thesis (since the two systems are unrelated). 
However, it would be beneficial to measure the mRNA and protein expression of ZAP70 
and FynT in H292 cells (by PCR and Western blotting respectively) to confirm that these 
proteins are not present in the current in vitro model. 
GSK-3 (Glucogen Synthase Kinase-3) is a multi-functional serine-threonine protein kinase 
with two isoforms, GSK-3a and GSK-30. GSK-3 is widely expressed in a vartiety of tissue, 
including lung (Woodgett, 1990), and is important in several signalling pathways involved 
in regulation of cell fate including; Wnt and Hedgehog signal transduction, protein 
synthesis, glycogen metabolism, mitosis and apoptosis (Forde and Dale, 2007). It has 
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already been reported that TDZD-8, a selective GSK-3ß inhibitor, inhibits ovalbumin- 
induced aiway mucus production in BALB/c mice, which was associated with decreased 
IL-5 and IL-13 expression and decreased NFKB activity (Bao et al., 2007). The fact that 
GW459135 inhibits the GSK-3ß isoform of GSK-3 (with an IC50 value of 100 nM) is 
therefore particularly significant and poses the question: does GW459135 attenuate EGF- 
induced MUC5AC synthesis through inhibition of EGFR signalling or inhibition of GSK- 
30 activity? To address this question, future experiments must be undertaken to determine 
both the effect of GSK-30 on EGF-induced MUC5AC synthesis, and the effect of 
GW459135 of GSK-3ß signalling. 
Firstly, it is important to establish whether or not GSK-30 mediates any effects on the 
signalling pathway involved in EGF-induced MUC5AC synthesis. Since activation of 
GSK-3ß is dependent upon the phosphorylation of Tyr216 (Bax et al., 2001), the amount of 
Tyr216-phosphorylated GSK-3ß should be measured in H292 cells after treatment with 
EGF (20 ng/ml) for four hours (in accordance with the experimental protocols of this 
chapter) - e. g. by Western blotting. This will determine whether or not stimulation with 
EGF induces the activation of GSK-3ß in H292 cells. Next, it must be determined whether 
or not there is a role for GSK-3ß in the EGF-induced MUC5AC synthesis pathway. This 
can be addressed by knocking down the expression of GSK-3ß using targeted small 
interference RNA (siRNA), then measuring MUC5AC mRNA expression upon stimulation 
with EGF. If EGF-induced phosphorylation of GSK-3ß Tyr216 does not occur, and 
removing the expression of GSK-3ß has no effect on EGF-induced MUC5AC mRNA 
expression, then it can be assumed that the attenuation of EGF-induced MUC5AC synthesis 
observed in this chapter for GW459135 is not associated with its capability to inhibit GSK- 
3ß. 
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However, if it transpires that GSK-3ß does have a functional role in the process of EGF- 
induced MUC5AC mRNA expression, another set of experiments is required to determine 
whether GW459135 attenuated EGF-induced MUC5AC mRNA expression through 
inhibition of EGFR signalling, or through inhibition of GSK-3ß activity (or indeed a 
combination of both). H292 cells should be exposed to a selective GSK-3ß inhibitor (e. g. 
TDZD-8) prior and during treatment with EGF, to determine whether or not EGF-induced 
MUC5AC mRNA expression can be attenuated by pharmacological inhibition of GSK-3ß. 
Also, experiments measuring the effect of GW459135 on GSK-3ß activity in the current in 
vitro model should be carried out. An innovative method of measuring GSK-3ß substrate 
phosphorylation using mass spectrometry has been developed which can be used to assess 
activity of GSK-3ß purified from cell extracts (Bowley et al., 2005). Using this method, the 
effect of GW459135 on the activity of GSK-30 purified from H292 cells could be assessed. 
Together, these key experiments would confirm whether or not GSK-3ß is involved in 
EGF-induced MUC5AC synthesis in the current in vitro system, and whether or not the 
inhibitory activity of GW459135 on GSK-3ß is a necessary component for the compound's 
capacity to attenuate EGF-induced MUC5AC synthesis. 
4.10.2 The effect of serum and EGF on cell proliferation 
Data herein confirmed that both DNA synthesis (BrdU incorporation) and cell respiration 
was significantly higher in cells cultured in media containing 1% FCS compared with cells 
cultured in media lacking serum (sections 4.9.1 and 4.92). However, supplementing 1% 
FCS-containing media with EGF did not significantly induce further DNA synthesis. 
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During the cell cycle, DNA synthesis can only occur after cells have passed through the 
Gl/S checkpoint and into S-phase (Scholey et al., 2003). In the protocols used to measure 
DNA synthesis in the current chapter, cells were plated out overnight in 1% FCS- 
containing media, then exposed (or not) to EGF for 24 hours prior to measurement of BrdU 
incorporation (Fig. 4.8). Although it has been reported that the doubling time for H292 cells 
is approximately 24 hours when cultured in FCS containing media (Liu et al., 1998; Mul et 
al., 2000), the percentage of cells in S-phase after the 24 hour incubation period in the 
current protocols was not established. Future experiments should address this issue by 
analysing cell cycle progression using flow-cytometry coupled with propidium iodide 
staining (Deitch et al., 1982; Nunez, 2001). Using this method, cell cycle progression is 
measured by staining cellular DNA content with propidium iodide (a DNA binding, 
fluorescent compound), and subsequently analysing by flow-cytometry. Analysing cell 
cycle progression of H292 cells cultured under the three conditions examined in figure 4.8 
would confirm whether or not S-phase had been entered at the point where BrdU 
incorporation was measured. This would clarify whether or not significant cell proliferation 
had been induced under the conditions used in figure 4.8. 
Although cell cycle analysis was not performed, data in figure 4.8 does suggest that cells 
cultured in 1% FCS-containing media, and cells cultured in 1% FCS-containing media plus 
EGF (20 ng/ml), had probably begun to enter S-phase, since BrdU incorporation was 
significantly higher than that of cells cultured in serum-free media (approximately 35% and 
40% higher respectively). However, it would be beneficial to analyse the percentage of 
H292 cells in S-phase over a time course, in order to determine the time point where DNA 
synthesis is at its peak. 
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It was also evident that the addition of EGF (20 ng/ml) to 1% FCS-containing media did 
not significantly induce any further DNA synthesis compared with 1% FCS-containing 
media alone (Fig. 4.8). Assuming cells cultured in I% FCS-containing media probably had 
begun to enter S-phase (since DNA content had significantly increased compared with cells 
cultured in serum-free media), this would indicate that the presence of 1% FCS alone was 
sufficient to induce DNA synthesis (although this could only be confirmed by analysing 
cell cycle progression. It also indicates that EGF-induced cell proliferation was not 
achieved using the current protocols. FCS is harvested from bovine foetuses and consists of 
a wide variety of macromolecular proteins, low molecular weight nutrients, carrier proteins 
for water-insoluble components, and other compounds necessary for in vitro cell growth, 
such as hormones and attachment factors (Tracqui et al., 2005). It is also likely to contain 
EGF itself. Hence, the presence of 1% FCS in the media may have interfered with 
measuring EGF-induced cell proliferation by inducing "background" proliferation. The 
implications of this in terms of measuring the effect of ErbB RTKIs on EGF-induced cell 
proliferation (using the current protocols) are discussed in the next section. 
4.10.3 The effect of ErbB RTKIs on cell proliferation 
The data obtained from experiments examining the effect of ErbB RTKIs on cell 
proliferation was conflicting and consequently somewhat inconclusive. Whilst it was 
evident that supplementing 1% FCS-containing culture medium with EGF resulted in no 
additional DNA synthesis (compared with 1% FCS-containing media alone - section 
4.9.2), it was also evident that the reduction in DNA synthesis (BrdU incorporation) 
induced by all five ErbB RTKIs required the presence of EGF (section 4.9.3). These points 
are discussed below. 
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At 1 µM, none of the five ErbB RTKIs examined attenuated DNA synthesis in the absence 
of EGF, although significant reductions were observed at 10 µM for both GW813324 
(ErbBl+2 RTKI) and GSK916441 (ErbB2 RTKI) (approximately 40% - section 4.9.3). 
Conversely, cell respiration (measured by MTT assay) in the absence of EGF was 
significantly lower for cells treated with 1 µM of GW459135 (ErbBl RTK inhibitor) or 
GW813324 by 30% and 25% respectively, which increased to 40% at 10 µM (section 
4.9.3). GW808884 (ErbB1+2 RTK inhibitor) also significantly reduced cell respiration by 
40% at 10 µM (but not at 1 µM). 
The effect of the ErbB RTKIs in the presence of EGF on DNA synthesis and cell 
respiration was quite opposite to that seen in experiments where EGF was omitted. All five 
ErbB RTKIs significantly reduced DNA synthesis (ranging from 40-60% inhibition) at 1 
pM whilst in the presence of EGF. Increasing the concentration to 10 µM resulted in all 
five ErbB RTKIs significantly blocking DNA synthesis by approximately 60% (section 
4.9.3). These data correspond to reported anti-proliferative effects of small molecule ErbB 
RTKIs measured both in vitro and in vivo (Partik et al., 1999; Faust et al., 1999; Rusnak et 
al., 2001; Gonzales and Fry, 2005; Yan et al., 2006; Lee et al., 2007), and equates to them 
being targeted as anti-cancer agents (section 1.8). In contrast, cell respiration in the 
presence of EGF remained unaltered by all compounds at 1 µM (although GW459135 
exhibited a non-significant 20% reduction - section 4.9.3). However, GW459135 and 
GW813324 at the higher concentration of 10 µM significantly lowered cell respiration by 
30% and 25% respectively, similar to that observed for these two drugs at a concentration 
of 1 µM and in the absence of EGF (Figs. 4.9 and 4.12) 
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The effectiveness with which the ErbB RTKIs attenuated DNA synthesis was dependent on 
the presence of EGF in the culture media. Despite this, it can not be concluded that the 
ErbB RTKIs inhibited EGF-induced proliferation specifically, since no significant increases 
in DNA synthesis or cell respiration were seen in cells cultured in media supplemented with 
EGF, compared with those cultured without (sections 4.9.1,4.9.2 and 4.10.2). 
As previously mentioned, the presence of 1% FCS in the media interfered with measuring 
cell proliferation induced specifically by EGF (section 4.10.2). To measure the effect of the 
ErbB RTKIs specifically on EGF-induced cell proliferation, the protocols used herein need 
to be redesigned whereby DNA synthesis is induced by EGF alone. To achieve this, H292 
cells must first be serum-starved until synchronised in Go arrest (the stage in the cell cycle 
where proliferation ceases), then exposed to EGF to induce DNA synthesis (or cell 
proliferation). The period of serum-starvation required for H292 cells to enter to Go arrest 
can be assessed using flow-cytometry coupled with propidium iodide staining (Deitch et al., 
1982; Nunez, 2001). Having established Go arrest, EGF-induced DNA synthesis in H292 
cells can then be measured by assessing BrdU incorporation over a time course (e. g. 6,12, 
24,48,72 hours), in order to determine at what point significant DNA synthesis occurs. 
Again, this can be confirmed by measuring the proportion of cells in S-phase using flow- 
cytometry and propidium iodide staining. Finally, having established the optimal conditions 
required to obtain EGF-induced DNA synthesis, the effect of the ErbB RTKis on this 
process can be measured. 
168 
4.11 Chapter summary 
In this chapter, the pharmacological activity of five ErbB RTKIs was investigated in two 
distinct, ErbB receptor-mediated biological processes: induced MUC5AC mRNA 
expression and cell proliferation. Only the ErbBl selective inhibitor effectively attenuated 
EGF-induced (and PMA-induced) MUC5AC mRNA expression, with inconclusive 
inhibition by the dual ErbBl+2 RTKI, GW813324. However, data concerning the effect of 
the ErbB RTKIs on cell proliferation (DNA synthesis) was inconclusive. Despite the fact 
that attenuation of DNA synthesis (BrdU incorporation) observed for all ErbB RTKIs was 
dependent on the presence of EGF in the culture media, the conditions required to 
specifically measure EGF-induced cell proliferation were not achieved. Further 
experiments are needed to clarify whether or not the compounds inhibit EGF-induced cell 
proliferation. 
The differential capacity of one ErbB RTKI to block ErbB receptor-driven processes over 
another underlines the complexity of ErbB receptor signalling, and the mechanisms by 
which these events occur are explored in the next chapter. 
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CHAPTER 5 
EFFECT OF ErbB RECEPTOR TYROSINE 
KINASE INHIBITORS ON ErbBl AND ErbB2 
RECEPTOR AUTOPHOSPHORYLATION AND 
DOWNSTREAM ERK1/2 PHOSPHORYLATION 
5.1 INTRODUCTION 
The two previous chapters (Chapters 3 and 4) investigated the expression of MUC5AC 
mRNA in an in vitro system and examined the effects of ErbB RTKIs within this system. 
Chapter 4 outlined a disparity between the five ErbB RTKIs investigated whereby only the 
single ErbB 1 RTKI convincingly attenuated EGF-induced MUC5AC mRNA expression, 
despite the observation that all compounds exhibited pharmacological activity by inhibiting 
DNA synthesis. In order to explain this discrepancy, and based on evidence that ErbB 
receptor-mediated induction of MUC5AC synthesis is ERK1/2 dependent (Perrais et al., 
2002; Hewson et al., 2004), the effect of the ErbB RTKIs on autophosphorylation of ErbB 1 
and ErbB2 receptor tyrosine residues involved in ERKI/2 activation was assessed in the 
present chapter. The effect of the ErbB RTKIs on downstream phosphorylation (and thus 
activation) ofERKI/2 was also examined. 
Whilst ErbBl and ErbB2 receptors have a number of tyrosine autophosphorylation sites 
(section 1.6.4.1 and Fig. 1.8), only Y992, Y1068, Y1148 and Y1173 on the ErbBl receptor, 
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and predominantly Y1221/2 on the ErbB2 receptor, induce ERKI/2 phosphorylation. 
Consequently, autophosphorylation of the latter five ErbB tyrosine residues was 
investigated in this chapter. 
5.2 METHODS 
5.2.1 Protocol to determine the time-course of EGF-induced ErbB1 
receptor autophosphorylation and ERK1/2 phosphorylation 
H292 cells were grown in 162 cm2 flasks until 75% confluent (Chapter 3) then serum 
starved for 24 hours. Following serum starvation, cells were treated with EGF (100 ng/ml) 
for 1- 40 minutes (section 5.3), in a volume of 15 ml serum-free media. After treatment, 
supernatants were removed and cells subjected to Western blotting (section 2.3.7), probing 
for any of the three phospho-ErbBl tyrosine residues Y1068, Y1148, Y1173 or phospho- 
ERKI/2 (samples were run on separate gels for each protein of interest). After probing for 
phospho-protein, nitrocellulose membranes were stripped and re-probed for the 
corresponding whole protein (ErbB 1 or ERKI/2) (section 2.3.7.5). 
In the current thesis, stimulating H292 cells with 20 ng/ml EGF induced a 4-fold increase 
in MUC5AC mRNA expression (Chapter 4), hence EGF (20 ng/ml) was used in subsequent 
experiments to examine the effects of ErbB RTKIs on EGF-induced MUCSAC mRNA 
expression (Chapter 4). However, receptor autophosphorylation was undetectable after 
treating H292 cells with 20 ng/ml EGF, despite the detection of positive control (A431 cells 
treated with EGF 100 ng/ml) using the same antibodies and Western blotting conditions 
(Fig. 5.1). In order to obtain a detectable signal, the concentration of EGF was increased to 
171 
100 ng/rnl for experiments involving the analysis of EGF-induced ErbB receptor 
autophosphotylation by Western blotting. This was based on recommendations from the 
antibody suppliers to increase the concentration of EGF and also on the tact that a wide 
range of EGF concentrations have been used in previous studies examining ErbB receptor 
activation and/or (unction (in a various in vitro systems) (Boomer et al., 2004; Honegger et 
at., 1990; Harper et al., 2002; Fan et at., 2004, Fan et al., 2005; Hunter and Cooper, 1981; 
Sturani et al., 1988), with the majority of studies opting for a concentration of 100 ng/ml 
(King et at., 1988; Chattopadhyay et al., 1999; Moriki et at., 2001; Keely and Barrett, 
1999). 
A431 H292 
EGF -+-+ 
175 kDa 00- _* P-Y1068 
175 kDa º on" an* r some EGFR 
Figure 5.1: Comparison of ErbBI Y1068 autophosphorylation in A431 cells treated with EGF 
(100 ng/ml) with that of ErbBl Y1068 autophosphorylation in 11292 cells treated with EGF 
(20 ng/ml). EGF (100 rig/ml) treated and non-treated A431 cell lysates were obtained from the 
antibody supplier (Cell Signal Technology) whilst H292 cells were incubated with EGF (20 ng/ml) 
for 2.5 minutes then lysed. Samples from both cell lines were analysed by SDS-PAGE and Western 
Blotting probing for phospho(P)-Y 1068 and EGFR, under the same conditions (see sections 2.3.7.2, 
2.3.7.3, and 2.3.7.4). 175 kDa marker indicates ErbBl receptor molecular weight (identified by 
protein ladder not shown). Blots representative of 3 independent experiments. 
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5.2.2 Protocol to determine the effect of ErbB RTKIs on ErbB1 Y1068, 
Y1148, Y1173 and ErbB2 Y1221/1222 autophosphorylation 
H292 cells were grown in 162 cm2 flasks until 75% confluent (Chapter 3) then serum 
starved for 24 hours. Following serum starvation, cells were pre-treated with ErbB RTKI (1 
or 10 µM) for 45 minutes before stimulation with EGF (100 ng/ml) for 2.5 minutes, which 
was found to be optimal for ErbB autophosphorylation (section 5.3), in the continued 
presence of inhibitor, in a volume of 15 ml serum-fi-ee media. Stock solutions of the 
required drug (section 2.2.3) were diluted in DMSO to maintain equal amounts of vehicle 
throughout the concentration range, and dissolved in serum-free media to give a final 
vehicle concentration of 0.05%. Cells were also treated with EGF (100 ng/ml) alone to 
measure the extent of tyrosine residue autophosphorylation induced by EGF. After 
treatment, supernatants were removed and cells were subjected to Western blotting (section 
2.3.7), probing for the three phospho-ErbBl residues Y1068, Y1148, Y1173 and the ErbB2 
residue Y1221/1222. After probing for phospho-protein, nitrocellulose membranes were 
stripped and re-probed for the corresponding whole protein (ErbB 1 or ErbB2) (section 
2.3.7.5). 
5.2.3 Protocol to determine the effect of ErbB RTKIs on EGF-induced 
ErbB1 Y992 autophosphorylation 
H292 cells were plated onto a 96-well plate at 75% confluency (Chapter 3), serum-starved 
for 24 hours, then pre-treated with ErbB RTKI (0.3 - 30 µM for GW282974,0.1 - 10 µM 
for all other inhibitors) for 45 minutes before stimulation with EGF (20 ng/ml) for 5 
minutes in the continued presence of inhibitor. All treatments were performed, in triplicate. 
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Extent of EGF-induced ErbBI Y992 autophosphorylation was then measured by 
chemiluminescent ELISA and normalised to cell number (section 2.3.8). 
5.2.4 Protocol to determine the effect of ErbB RTKIs on ERK1/2 
(p42/p44) phosphorylation 
H292 cells were grown in 162 cm2 flasks until 75% confluent (Chapter 3) then serum 
starved for 24 hours. Following serum starvation, cells were pre-treated with ErbB RTKI (1 
or 10 µM) for 45 minutes before stimulation with EGF (100 ng/ml) for 2.5 minutes (section 
5.7) in the continued presence of inhibitor, in a volume of 15 ml serum-free media. Stock 
solutions of the required drug (section 2.2.3) were diluted in DMSO to maintain equal 
amounts of vehicle throughout the concentration range, and dissolved in serum-free media 
to give a final vehicle concentration of 0.05%. Cells were also treated with EGF (100 
ng/ml) alone to measure the extent of tyrosine residue autophosphorylation induced by 
EGF. After treatment, supernatants were removed and cells were subjected to Western 
blotting (section 2.3.7), probing for phospho-ERK1/2. After probing for phospho-protein, 
nitrocellulose membranes were stripped and re-probed for whole ERK1/2 (section 2.3.7.5). 
5.2.5 Protocol to determine the effect of PD 98059 (MEK1/2 inhibitor) 
on EGF-induced MUC5AC mRNA expression 
In order to investigate the involvement of the ERK1/2 pathway in EGF-induced MUC5AC 
mRNA expression, an inhibitor of upstream MEK1/2, PD 98059 (section 1.6.4.3) was used. 
H292 cells were seeded onto 30 mm 6-well culture plates at approximately 75% confluency 
(Chapter 3) and incubated overnight (section 2.3.1). Cells were then serum-starved for 24 
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hours by incubating them in serum-free medium prior to exposure to PD 98059. Stock 
solutions of PD 98059 (section 2.2.3) were serially diluted in DMSO to maintain equal 
amounts of vehicle throughout the concentration range, and dissolved in serum-free media 
to give a final vehicle concentration of 0.05%. 
Serum-starved cells were pre-exposed to 1 ml serum-free media containing PD 98059 (1 
pM - 0.1 µM) or vehicle (DMSO) for 45 minutes, after which PD 98059 was removed and 
re-applied along with EGF (20 ng/ml). The effect of PD 98059 on MUC5AC mRNA 
baseline expression was examined by incubating cells with the highest concentration of PD 
98059 (0.1 µM), but in the absence of the stimulus. After treatment, cells were lysed and 
subjected to real-time PCR to measure MUC5AC mRNA expression (sections 2.3.3 and 
2.3.4). 
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5.3 Effect of time of incubation on EGF-induced ErbBl 
autophosphorylation of tyrosine residues 1068,1148 and 1173 
To determine the effect of time of incubation on EGF-induced ErbBl receptor tyrosine 
autophosphorylation, H292 cells were stimulated with EGF (100 ng/ml) for 1- 40 minutes, 
lysed, then analysed by Western blotting probing for ErbB 1 and phosphorylated ErbB 1 
tyrosine (Y) residues Y1068, Y1148 and Y1173. 
Cells not incubated with EGF (non-treated - NT) exhibited no autophosphorylation of 
Y1068, Y1148 or Y1173 (Fig. 52). Incubation with EGF caused time-dependent 
autophosphorylation of Y1068 with maximal phosphorylation of 230 - 245-fold above that 
of NT control at 2.5 and 5 minutes (Fig. 5.2 and 5.3A). After this peak, EGF-induced 
autophosphorylation of Y1068 decreased time-dependently with significant increases from 
that of NT control of 150-fold at 10 minutes, 120-fold at 20 minutes and 85-fold (not 
significant) at 40 minutes (Fig. 5.2A). 
EGF-induced autophosphorylation of Y1148 followed a similar pattern to that of Y1068 
with time-dependent, significant increases in phosphorylation reaching a maximum of 90 - 
100-fold above that of NT at 2.5 and 5 minutes, followed by a time-dependent decrease in 
maximal phosphorylation with elevations above NT control of 75-fold at 10 minutes, 50- 
fold at 20 minutes and 8-fold (not significant) at 40 minutes (Fig. 5.2 and 5.3B). 
EGF-induced autophosphorylation of Y1173 increased time-dependently up until 5 minutes 
where phosphorylation peaked at 150-fold above that of NT control (Fig. 5.2 and Fig. 
5.3C). EGF-induced autophosphorylation of Y1173 subsequently decreased from the 
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maximum response at 5 minutes with elevations above NT control of 80-fold at 10 minutes, 
50-Ibid at 20 minutes and 15-fold at 40 minutes (Fig. 5.2 and 5.3C). 
An incubation time of 2.5 minutes was thus used subsequently for experiments using 
inhibitor compounds on F. GF-induced autophosphorylation of ErbB receptor tyrosine 
residues. 
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Figure 5.2: Effect of time of incubation on EGF-induced autophosphorylation of ErbBl 
Y1068, Y1148 and Y1173 - representative blots. 11292 cells were incubated with F, 61' (100 
ng/ml) for 1 40 minutes, lysed, then analysed by SDS-PAGE and Western Blotting probing for 
phospho(P)-YIO68, P-Y1148 or P-Y1173. Blots were then stripped and re-probed for ErhBl 
(EGFR). 175 kla marker indicates ErbBI receptor molecular weight (identified by protein ladder - 
not shown). Ni' = non-treated. Blots representative of 3 independent experiments (see Fig. 5.3). 
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Figure 53: Effect of EGF on autophosphorylation of ErbB1 Y1068, Y1148 and Y1173 - 
mean data for time course. Band intensity of phospho(P)-Y1068, P-Y1148, P-Y1173 and ErbBl 
Western blots (Fig. 5.2) was measured per blot using image analysis and extent of phosphorylation 
calculated as a ratio of phospho-Y residue band intensity over ErbBl band intensity. Panel A shows 
data for P-Y1068, panel B data for P-Y1148 and panel C data for P-Y1173. All data are expressed 
as mean fold increase from non-treated (NT) ratio, and S. E. M. for 3 independent experiments. For 
all panels, * p<0.05 and ** p<0.01 compared with NT. 
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5.4 Effect of ErbB RTKIs on EGF-induced autophosphorylation of 
ErbBl tyrosine residues 1068,1148 and 1173 
To investigate the effects of ErbB RTKIs on EGF-induced autophosphorylation of ErbBI, 
H292 cells were pre-incubated with ErbB RTKIs (1 or 10 µM) prior to stimulation for 2.5 
minutes (see section 5.3) with EGF (100 ng/ml) in the continued presence of inhibitor. 
Cells were then lysed and phosphorylation analysed using Western blotting, probing for 
phospho(P)-Y1068, P-Y1148, P-Y1173 and ErbBl. EGF induced the autophosphorylation 
of all three tyrosine residues compared with non-treated controls (Fig. 5.4). 
The ErbB 1 RTKI GW459135 completely inhibited the EGF-induced autophosphorylation 
of Y1148 and Y1173 at both 1 µM and 10 µM (Fig. 5.4A and B, Fig. 5.5A and B), and 
virtually and completely inhibited autophosphorylation of Y1068 at 1 and 10 µM 
respectively. 
In contrast to GW459135, the dual ErbBl+2 RTKI GW808884 did not significantly inhibit 
the autophosphorylation of any of the three tyrosine residues at 1 LM, but at 10 µM, 
significantly inhibited autophosphorylation of all the residues, all by approximately 80% 
that of stimulus (Fig. 5.4A and B, Fig. 5.5A and B). 
At 1 µM, the dual ErbBl+2 RTK inhibitor GW813324 inhibited EGF-induced 
autophosphorylation of both Y1068 and Y1173 by approximately 50% (although not 
statistically significant), but had no such effect on the phosphorylation of Y1148 (Fig. 5.4A 
and Fig. 5.5A). At 10 µM, GW813324 significantly inhibited autophosphorylation of 
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Figure 5.4: Fffect of ErbR R'FKIs on EGF-induced ErbB1 autophosphorylation of tyrosine 
residues \'1068, YI 148 and Y1173. H292 cells were pre-incubated with either 1µM (A) or 10 µM 
(13) I: rbll R'I'K inhibitor tor 45 minutes prior to incubation for 2.5 minutes with EGF (100 ng/ml) in 
the continued presence of inhibitor. Cells were then lysed and analysed by SDS-PAGF and Western 
Blotting, probing for Frbß 1-phospho(P)-Y 1068, P-Y114S or P-Y 1173. Blots were then stripped and 
re-probed for ErbBl (F. GFR). Lane I. Inhibitor vehicle. Lane 2: EGF (100 ng/ml). Lane 3: 
GW459135 + EGF. Lane 4: GW808884 + EGF. Lane 5: GWS 13324 + EGF. Lane 6: GW282974 + 
EGF. Lanee7: GSK916441 + FGF. 175 kDa marker indicates ErbBl (EGFR) receptor molecular 
weight. Blots representative of 3 independent experiments (see Fig 5.5). 
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Y1068 and Y1148 by 90% and completely inhibited autophosphorylation of Y1173 (Fig. 
5.4B and Fig. 5.5B). 
The ErbB2 RTK inhibitor GSK916441 had no significant effect on EGF-induced 
autophosphorylation of any of the three tyrosine residues at 1 µM (although a 25% decrease 
in Y1173 autophosphorylation was observed) (Fig. 5.4A and Fig. 5.5A). However, at 10 
µM, GSK916441 significantly inhibited EGF-induced autophosphorylation of all three 
tyrosine residues by 70-75% that of stimulus (Fig. 5.4B and Fig. 5.5B). 
In contrast to all the other ErbB RTKIs, the dual ErbB 1+2 RTK inhibitor GW282974 (at 
either 1 or 10µM) had no significant effect on EGF-induced autophosphorylation of any of 
the three tyrosine residues analysed (Fig. 5.4A and B and Fig. 5.5A and B). 
All five ErbB RTKIs exhibited a degree of concentration-dependent inhibition of EGF- 
induced ErbB 1 autophosphorylation (summarised in Fig. 5.6). 
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Figure 5.5: Effect of ErbB RTKIs on EGF-induced ErbBl autophosphorylation of tyrosine 
residues Y1068, Y1148 and Y1173 - mean data. Band intensity of phospho(P)-Y1068, P-Y1148, 
P-Y 1173 and ErbB 1 Western blots (Fig. 5.4) was measured per blot using image analysis and extent 
of phosphorylation was calculated as a ratio of phospho-Y residue band intensity over ErbBI band 
intensity. Panel A shows data for I µM treatment, panel B shows data for 10 µM treatment. Data are 
mean percent of EGF stimulus (calculated per blot) and S. E. M. for 3 independent experiments. For 
both panels, * p<0.05, ** p<0.01 compared with EGF stimulus. 
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Figure 5.6: Concentration-dependent effect of ErbB RTKIs (1 and 10 UM) on EGF-induced 
autophosphorylation of ErbBI tyrosine residues Y1068, Y1148 and Y1173. Panel A shows 
Y 1068 phosphorylation, panel BY 1148 phosphorylation and panel CY 1173 phosphorylation, all 
expressed as mean percent of EGF stimulus and S. E. M, for 3 independent experiments, from data in 
Fig. 5.4. For all panels, * p<0.05, ** p<0.01 compared with EGF stimulus. 
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5.5 Effect of ErbB RTKIs on EGF-induced autophosphorylation of 
ErbB1 tyrosine 992 
Continuing the investigation of the effect of single ErbB and dual ErbB 1+2 RTK inhibitors 
on EGF-induced ErbB1 tyrosine autophosphorylation, phosphorylation of Y992 was 
measured by chemiluminescent ELISA. Data were normalised to relative cell count 
(quantified per experiment after ELISA measurement of Y992 phosphorylation). 
For all five ErbB RTKIs, neither vehicle (0.1% DMSO for all inhibitors) nor the inhibitors 
themselves had any significant effect on baseline phosphorylation of Y992 compared with 
non-treated cells (Fig. 5.7A). EGF significantly increased autophosphorylation of Y992 by 
2.5-fold above non-treated control (Fig. 5.7A). 
The ErbB 1 RTK inhibitor GW459135 concentration-dependently inhibited EGF-induced 
autophosphorylation of Y992 with an IC50 value of 70 nM and 75% inhibition at 10 µM 
(Fig. 5.7B). The ErbB2 RTK inhibitor GSK916441 also concentration-dependently 
inhibited EGF-induced autophosphorylation of Y992 with an IC50 value of 0.2 µM and 
complete inhibition at 10 µM (Fig. 5.7C). 
Of the three dual ErbBl+2 RTK inhibitors, only GW282974 did not attenuate EGF-induced 
autophosphorylation of Y992 whereas the responses of GW808884 and GW813324 were 
very similar, both concentration-dependently inhibiting autophosphorylation with IC50 
values of 5 µM and 125 nM respectively and approximately 75% inhibition at 10 µM (Fig. 
5.8A, B and Q. 
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Figure 5.7: Effect of EGF on autophosphorylation of ErbBl Y992 and effect of the ErbBI 
RTK inhibitor, GW459135 and ErbB2 RTK inhibitor, GSK916441, on EGF-induced ErbBl 
Y992 autophosphorylation. H292 cells were pre-incubated with ErbB RTK inhibitor (0.1 - 10 
µM) for 45 minutes prior to stimulation (STIM) with EGF (20 ng/ml) for 5 minutes, in the 
continued presence of inhibitor, followed by assessment of Y992 autophosphorylation by ELISA. 
Panel A shows the effect of no treatment (NT), inhibitor vehicle (V), ErbB RTKIs alone and EGF 
on phosphorylation of Y992. Data are expressed as Arbitrary Luminescence Units (ALU - 106). 
Panel B represents the effect of GW459135 and panel C the effect of GSK916441 on EGF-induced 
Y992 autophosphorylation expressed as percent of EGF stimulus (STIM), minus background (0 
baseline - mean background phosphorylation measured from non-treated cells was removed from 
data obtained from all treated cells). Data in all three panels are mean and S. E. M. for 5 independent 
experiments. For panel A, ** p<0.01 compared with NT. For panels B and C, *p<0.05 and ** 
p<0.01 compared with STIM. 
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Figure 5.8: Effect of the dual ErbB1+2 RTK inhibitors GW808884, GW813324, and 
GW282974 on EGF-induced autophosphorylation of ErbB1 Y992. H292 cells were pre- 
incubated with ErbB RTK inhibitor (0.1 - 10 µM, 0.3 - 30, uM for GW282974) for 45 minutes prior 
to stimulation (STIM) with EGF (20 ng/ml) for 5 minutes, in the continued presence of inhibitor, 
followed by assessment of Y992 autophosphorylation by ELISA. Panel A represents the effect of 
GW808884, panel B the effect of GW813324 and panel C the effect of GW282974 on EGF-induced 
Y992 autophosphorylation expressed as percent of EGF stimulus (STIM), minus background (A 
baseline - mean background phosphorylation measured from non-treated cells was removed from 
data obtained from all treated cells). Data in all three panels are mean and S. E. M. for 5 independent 
experiments. For panels A and B, *p<0.05 and ** p<0.01 compared with STIM. No significant 
differences were found for panel C. 
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5.6 Effect of ErbB RTKIs on autophosphorylation of ErbB2 tyrosine 
1221/1222 
ErbB receptors homo- and hetero-dimerise upon ligand binding resulting in 
autophosphorylation of specific tyrosine residues and the subsequent triggering of signal 
transduction pathways. Having investigated the EGF-induced autophosphorylation of 
ErbB 1 tyrosine residues and the effect of ErbB RTKIs on this process (sections 5.3,5.4 and 
5.5), autophosphorylation of ErbB2 was examined in this section. 
H292 cells were pre-incubated with ErbB RTKIs (1 or 10 µM) prior to stimulation for 2.5 
minutes with EGF (100 ng/ml) in the continued presence of inhibitor. Cells were then lysed 
and phosphorylation analysed by Western blotting, probing for ErbB2 and the 
phosphorylated tyrosine residues Y1221/1222. 
EGF significantly induced the autophosphorylation of ErbB2 Y1221/1222 by 
approximately 120% above that of non-treated cells (Figs. 5.9 and 5.10A). This response 
was significantly attenuated by 40% by the dual ErbBl+2 RTK inhibitor GW282974 and 
by 65-75% for the other inhibitors at 1µM (Fig. 5.9A and Fig. 5.10B). Increasing the 
concentration to 10 µM did not increase the level of inhibition observed at 1µM (40% that 
of stimulus for GW282974 and 65-75% for the other inhibitors) (Figs. 5.9B and 5.10B). 
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Figure 5.9: Effect of Erbil RTKIs on EGF-induced ErbB2 autophosphorylation of tyrosine 
residue Y1221/1222.11292 cells were pre-incubated with either I AM (A) or 10 µM (B) I: rbB 1(1'K 
inhibitor for 45 minutes prior to incubation for 2.5 minutes with FGF (100 ng/ml), in the continued 
presence of' inhibitor. Cells were then lysed and analysed by SDS-PAGE and Western Blotting, 
probing for 1? rbB2 phospho(P)-Y1221/1222. Blots were then stripped and re-probed for FrbB2. 
Lane I. - Inhibitor vehicle. Lane 2: EGF (100 ng/ml). Lane 3: GW459135 + FGF. Lan(, 4: 
GW908884 + I: GF. Lane 5: GW813324 + EGF. Lane 6: GW282974 + EGF. Lane7: GSK916441 + 
FGF. 185 kl)a marker indicates ErbB2 receptor molecular weight. Blots representative of 3 
independent experiments (see Fig. 5.10). 
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Figure 5.10: Effect of EGF on autophosphorylation of ErbB2 tyrosine Y1221/1222 and effect 
of ErbB RTKIs on EGF-induced ErbB2 Y1221/1222 autophosphorylation - mean data. Band 
intensity of phospho(P)-Y 1221 /1222 and ErbB2 Western blots (Fig. 5.9) was measured per blot 
using image analysis and extent of phosphorylation was calculated as a ratio of phospho- 
Y1221/1222 band intensity over ErbB2 band intensity. Panel A shows the ratio values of non- 
treated (NT) cells compared with EGF (100 ng/ml) treated cells. Panel B shows phosphorylation of 
Y1221/1222 expressed as percent of EGF stimulus. Data in both panels are mean and S. E. M. for 3 
independent experiments. For panel A, ** p<0.01 compared with NT and for panel B, * p<0.05, ** 
p<0.01 compared with EGF stimulus. 
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5.7 Effect of time of incubation on EGF-induced phosphorylation of 
ERK1/2 (p42/44) 
ERK1/2 (p42/44) is a downstream kinase involved in the ErbB receptor signalling pathway 
that induces MUC5AC mRNA expression. To determine the effect of time of incubation on 
EGF-induced ERKI/2 phosphorylation, H292 cells were stimulated with EGF (100 ng/ml) 
for 0- 40 minutes before analysis of phosphorylation by Western blotting, probing for 
ERK1/2 and phosphorylated (P)-ERKI/2. 
EGF rapidly induced ERKI/2 phosphorylation, being significantly 4-fold for p42 and 5- 
fold for p44 higher than non-treated cells after one minute of incubation with EGF (Fig. 
5.11A and B). Increasing EGF incubation time to 2.5 minutes resulted in a maximal 
increase in p44 phosphorylation of 6-fold above that of non-treated control, which 
subsequently diminished over time to 4.5-fold that of non-treated control at 40 minutes 
(Fig. 5.11A and B). The EGF-induced phosphorylation of p42 followed an identical pattern 
with a maximal 5-fold increase above that of non-treated controls at 2.5 and 5 minutes 
which subsequently diminished over time to 3-fold that of non-treated control at 40 minutes 
(Fig. 5.11A and B). 
An EGF incubation time of 2.5 minutes was therefore used subsequently for experiments 
involving inhibitor treatments. 
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Figure 5.11: Effect of time of incubation on EGF-induced phosphorylation of ERKI/2. H292 
cells were incubated with EGF (100 ng/ml) for 1- 40 minutes, lysed, then analysed by SDS-PAGE 
and Western Blotting probing for ERKI/2 (p44/p42) and phospho(P)-ERKI/2. Panel A are 
representative blots of the effect of time of incubation on EGF-induced ERK1/2 phosphorylation. 
44 and 42 kDa markers indicate the two ERKI/2 molecular weights (identified by protein ladder - 
not shown). Blots representative of 3 independent experiments. For panel B, band intensity of 
phospho-p44/p42 and p44/p42 was measured per blot using image analysis and extent of 
phosphorylation was calculated and expressed as mean ratio of phospho-p44/p42 band intensity 
over p44/p42 band intensity and S. E. M. for 3 independent experiments. NT = non-treated. * p<0.05 
and ** p<0.01 compared with appropriate NT (p44 or p42). 
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5.8 Effect of ErbB receptor tyrosine kinase inhibitors on EGF-induced 
phosphorylation of ERK1/2 
ERKI/2 is a downstream kinase involved in the ErbB receptor signalling pathway that 
induces MUCSAC mRNA expression. In order to examine the differences in efficacy of 
ErbB RTKIs in inhibiting EGF-induced MUC5AC mRNA expression (Chapter 4), their 
ability to attenuate or otherwise ERKI/2 phosphorylation was measured. 
H292 cells were pre-incubated with ErbB RTKIs (1 or 10 µM) prior to stimulation for 2.5 
minutes with EGF (100 ng/ml) in the continued presence of inhibitor. Cells were then lysed 
and phosphorylation analysed by Western blotting, probing for ERK1/2 and the 
phosphorylated (P)-ERK1/2. 
The ErbBl RTKI GW459135 was the only one of the five inhibitors to inhibit EGF- 
induced ERK1/2 phosphorylation (Figs. 5.12 and 5.13). At 1 1M, GW459135 significantly 
inhibited EGF-induced p44 phosphorylation by 75% and p42 phosphorylation by 65% 
compared with stimulus (Fig. 5.12A and Fig. 5.13A). At 10 µM, GW459135 significantly 
inhibited EGF-induced p44 phosphorylation by 90% and p42 phosphorylation by 85% 
compared with stimulus (Fig. 5.12B and Fig. 5.13B). 
Neither GW808884, GW813324, GW282974 nor GSK916441 had any significant effect on 
EGF-induced ERK1/2 phosphorylation at concentrations of 1µM or 10 µM (Fig. 5.12A and 
B and Fig. 5.13A and B). 
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Figure 5.12: Effect of Erbil R'FKls on EGF-induced ERKI/2 phosphorylation. 11292 cells were 
pre-incubated with either I pM (A) or 10 µM (B) ErbB RTK inhibitor for 45 minutes prior to 
incubation for 2.5 minutes with EGF (100 ng/ml), in the continued presence of inhibitor. Cells were 
then lysed and analysed by SDS-PAGI and Western Blotting, probing forphospho(P)-ERK1/2 then 
stripped and re-probed for F. RKI/2. Lane 1: Inhibitor vehicle. Lane 2: EGF (100 ng/ml). Lane 3: 
GW459135 + FGF. Lane 4: GW808884 + EGF. Lane 5: GW813324 + EGF. Lane 6: GW282974 + 
EGF. Lanee7: GSK916441 + EGF. 44 and 42 kDa markers indicate the two ERKI/2 proteins, p44 
and p42 molecular weights. Blots representative of n=3 (see Fig. 5.12). 
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Figure 5.13: Effect of ErbB RTKIs on EGF-induced ErbB2 autophosphorylation of tyrosine 
residues Y1221/1222 - mean data. Band intensity of phospho(P)-Y1221/1222 and ErbB2 Western 
blots (Fig. 5.12) was measured using image analysis and extent of phosphorylation was calculated 
as a ratio of P-Y 1221/1222 band intensity over ErbB2 band intensity (per blot). Panel A shows data 
for I µM treatment panel B shows data for 10 1M Data are expressed as mean percent of EGF 
stimulus control (calculated per blot) and S. E. M. for 3 independent experiments. For both panels: 
** p<0.01 compared with EGF stimulus. 
194 
' 9 
4ý/ý ýrp 
>> 
5.9 Effect of the MEK/ERK inhibitor PD 98059 on EGF-induced 
MUC5AC mRNA expression 
To clarify the role of ERKI/2 in the signal transduction pathway involved in EGF-induced 
MUC5AC mRNA expression, ERKI/2 was inhibited using PD 98059 (an inhibitor of 
MEKI/2, a kinase immediately upstream of ERK1/2). H292 cells were pre-treated with PD 
98059 (0.3 - 30 µM) for 45 minutes prior to stimulation with EGF (20 ng/ml) for 4 hours, 
in the continued presence of PD 98059. 
PD 98059 had no significant effect on baseline expression of MUC5AC mRNA expression 
(Fig. 5.14A). EGF significantly increased MUC5AC mRNA by 5-fold above that of vehicle 
control. PD 98059 concentration-dependently inhibited EGF-induced MUC5AC mRNA 
expression with an IC50of 0.6 µM and complete inhibition at 30 µM (Fig. 5.14A and B). 
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Figure 5.14: Effect of PD 98059 (MEKI/2 inhibitor) on EGF-induced MUC5AC rnRNA 
expression. H292 cells were pre-incubated with PD 98059 (0.3-30 µM) fier 45 minutes prior to 
stimulation with I: GI (20 ng/ml) for 4 hours in the continued presence of inhibitor, after which 
RNA was harvested. Panel A shows the relative quantity (RQ) values (arbitrary units, AU) 
calculated using AAC i (using the AC value for vehicle control, VC, as the calibrator). V= vehicle 
for PI) 99059. Panel 13 represents the effect of PD 98059 as percent of I. GI" with V (calculated 
separately from the individual stimulus RQ values per experiment). All data are expressed as mean 
and S. E. M. for 5 independent experiments. For panel A, ** p<0.01 compared with VC and ## 
p<0.01 compared with FGF. For panel B, ** p<0.01 compared with EGF stimulus (S'L'IM). 
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5.10 DISCUSSION 
All five ErbB RTKIs examined in this thesis exhibited anti-proliferative capabilities 
(Chapter 4) whilst only the ErbB 1 receptor selective inhibitor attenuated EGF-induced 
MUC5AC mRNA (Chapter 4). Data collated in this chapter attempted to determine why the 
compounds differed and, at the same time, uncover the mechanisms involved in the signal 
transduction of ErbB receptor-mediated MUC5AC expression. 
5.10.1 Induction of ErbBl receptor autophosphorylation and 
downstream ERK1/2 phosphorylation by EGF 
Phosphorylation events involved in the signalling processes of receptor tyrosine kinases 
generally occur rapidly (Schlessinger, 2000), but the kinetics governing ErbB 1 receptor 
tyrosine autophosphorylation itself (initiated by EGF) depend on cell type (Sturani et al., 
1988; Sturani et al., 1990). Time course experiments indicated the rate of EGF-induced 
autophosphorylation of three ErbBl tyrosine residues implicated in the propagation of 
ERKI/2 signalling (Tyr 1068,1148 and 1173) occurred in two distinct phases. The first 
stage involved a rapid increase in autophosphorylation up to five minutes incubation with 
EGF. This stage was followed by a time-dependent decrease in autophosphorylation 
(section 5.3). 
During the initial stage of the EGF-induced, ErbBl receptor autophosphorylation kinetics, 
all three tyrosine residues were markedly detectable after one minute and maximal after 2.5 
-5 minutes (section 53). Thus H292 cells initially exhibit rapid reaction kinetics of EGF- 
induced ErbBl receptor autophosphorylation, similar to other epithelial cell lines (e. g. 
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A431 cells) where receptor autophosphorylation in response to ligand binding is also a 
speedy event (Sturani et al., 1988). 
The subsequent downstream phosphorylation of ERKI/2 was also measured over time, and 
displayed equally rapid kinetics as that of ErbBl receptor autophosphorylation (section 
5.7). Autophosphorylation of Y1068,1148 and 1173 was detectable after incubation with 
EGF for one minute, but the response was less than half the maximal increase in 
phosphorylation for each residue. Despite this, ERK1/2 phosphorylation was near-maximal 
at this same time point, and continued to remain significantly elevated above control even 
after 40 minutes, regardless of the corresponding relatively low levels of ErbB receptor 
tyrosine autophosphorylation observed (section 5.3). This suggests that extensive numbers 
of autophosphorylated ErbBI receptors are not necessary to evoke signal transduction, and 
low amounts of phosphorylated receptor can result in ERK1/2 phosphorylation. Evidently, 
ERK1/2 dephosphorylation occurs rapidly (within 2.5 minutes) upon loss of the upstream 
MEK1/2 signal (Zhande et al., 2006), meaning the ERK1/2 phosphorylation observed 
herein at longer time points (and thus low levels of ErbBl receptor autophosphorylation) 
could be due to the continuation of signal transduction induced by ErbBl receptor 
signalling, and not the aftermath of previous signal propagation. Alternatively, the 
continued ERK1/2 phosphorylation observed during low levels of ErbBI receptor 
autophosphorylation may be a result of signalling through the endocytic pathway 
(Miaczynska et al., 2004). Sequestration of EGF-bound ErbBl receptors into endosomes 
promotes the binding of Grb2, an initiator of Ras and MAPK signalling pathways (Sorkin 
et al., 2000), providing another possible activation mechanism for ERK1/2. 
198 
5.10.2 EGF-induced autophosphorylation of ErbB2 
EGF-induced ErbB2 autophosphorylation, like ErbBl autophosphorylation, occurs rapidly 
in the presence of EGF (King et al., 1988) and data obtained in the present thesis confirmed 
that Y1221/1222 on the ErbB2 receptor was autophosphorylated after 5 minutes incubation 
with EGF (Fig. 5.9, panels A and B, lanes 1 and 2). 
5.10.3 Effect of MEK1/2 inhibition on EGF-induced MUC5AC mRNA 
expression 
ErbB receptor-mediated induction of MUC5AC mRNA expression is an ERKI/2 
dependent process (Perrais et al., 2002) and this observation was confirmed using the 
upstream ERK1/2 inhibitor, PD 98059. PD 98059 concentration-dependently inhibited 
EGF-induced MUC5AC mRNA expression with an IC50 of 0.6 µM (section 5.9), 10-fold 
lower than the value determined using other cell types and protocols (Alessi et at., 1995; 
Dudley et al., 1995). This indicates that ERK1/2 signalling in H292 cells is particularly 
sensitive to the MEK1/2 inhibitor PD 98059, although complete inhibition was not 
observed within the concentration range used herein. 
5.10.4 Effect of ErbB RTKIs on ErbB1 and ErbB2 receptor 
autophosphorylation 
The effect of the five ErbB RTKIs on the autophosphorylation of five ErbB receptor 
tyrosine residues implicated in the propagation of ERK1/2 signalling was measured. These 
residues included Y992, Y1068, Y1148 and Y1173 on the ErbBI receptor and Y1221/1222 
on the ErbB2 receptor. 
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As outlined in section 5.2.1, a concentration of 20 ng/ml EGF was used to induce ErbB 
receptor-dependent MUC5AC expression in Chapter 4, but this concentration had to be 
increased to 100 ng/ml in order to effectively analyse ErbB receptor autophosphorylation 
by Western blotting. However, this only applied when measuring ErbB receptor 
autophosphorylation by Western blotting (i. e. phosphorylation of tyrosine residues 1068, 
1148 and 1173), since measurement of ErbB 1 Y992 phosphorylation involved an assay 
system sensitive enough to detect phosphorylation induced by EGF 20 ng/ml (Fig. 5.7A). 
It is accepted that the discrepancy between the concentration of EGF used in Chapters 3 
and 4 to measure EGF-induced MUC5AC mRNA expression (20 ng/ml EGF), with that of 
the concentration used in the current chapter to examine ErbB receptor autophosphorylation 
of Y1068, Y1148 and Y1173 (100 ng/ml EGF), presents limitations when interpreting data 
from the two data-sets (particularly when considering the effects of the ErbB RTKIs on 
receptor autophosphorylation and downstream ERK1/2 activity- sections 5.10.4 and 5.10.5 
respectively). For example, the extent of ErbB receptor autophosphorylation is likely to be 
higher following treatment with EGF (100 ng/ml) compared with EGF (20 ng/ml) and 
increasing the extent of receptor autophosphorylation may impair the ability of the ErbB 
RTKIs to inhibit the ErbB receptor signalling pathway. This may, in turn, result in the IC50 
values for the ErbB RTKIs obtained in Chapter 4 no longer being valid. However, although 
the concentration of EGF was increased to 100 ng/ml in this chapter, all five ErbB RTKI 
compounds - even those that did not inhibit EGF (20 ng/ml)-induced MUC5AC mRNA 
expression - demonstrated some degree of inhibition of EGF-induced EtB1 and ErbB2 
receptor autophosphorylation (Figs. 5.4 and 5.9, Table 5.1). This suggests that the drugs 
were still capable of inhibiting ErbB receptor kinase activity in the presence of EGF 100 
ng/ml. 
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Nonetheless, it would be necessary in future work to properly determine the submaximal 
concentration of EGF by performing an EGF concentration-response curve for the 
induction of MUC5AC mRNA. It would also be necessary to measure the effect of ErbB 
RTKIs on MUC5AC mRNA expression induced using EGF (100 ng/ml). This would 
provide data (including IC50 values) more relevant to this chapter, and therefore allow for a 
more accurate comparison between data in this chapter, and data in chapter 4. 
Evidently, the disparity between the pharmacological activities of each of the ErbB RTKIs 
investigated in the present thesis (Chapter 4) also applied to the inhibition of the ErbB 
receptor phosphoproteome. GW459135 (ErbBl RTKI), the only ErbB RTKI to 
convincingly inhibit EGF-induced MUC5AC mRNA, completely attenuated the 
autophosphorylation of the ErbBl residues measured by Western blot: Y1068, Y1148 and 
Y1173 (Fig. 5.4), a characteristic not attributed to any of the other five ErbB RTKIs. 
GW459135 also inhibited autophosphorylation of ErbBl Y992 (measured by ELISA) by 
50% and 75% at 1 and 10 µM respectively (Fig. 5.7B), and autophosphorylation of 
Y1221/1222 on the ErbB2 receptor back to baseline (Fig. 5.9). In contrast to GW459135, 
the other four ErbB RTKIs did not demonstrate comprehensive inhibition of the ErbB 
receptor phosphoproteome at 1 µM, and required an increased concentration to significantly 
attenuate tyrosine autophosphorylation (Figs. 5.4 and 5.5, summarised in table 5.1). These 
data relate to a previously-described discrepancy between different EIbB RTKIs in the 
extent of inhibition of ErbB receptor tyrosine autophosphorylation, a phenomenon which 
occurs at a number of time-points (Wood et al., 2004). 
It must be highlighted that the effect of the ErbB RTKIs on ErbB 1 and ErbB2 
autophosphorylation was examined using a higher concentration of EGF than that used to 
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induce MUC5AC mRNA expression. It is possible that the four ErbB RTKIs which did not 
attenuate EGF-induced MUC5AC mRNA expression induced after treating H292 cells with 
20 ng/ml (Chapter 4) may have significantly inhibited receptor autophosphorylation 
induced after treating cells with 20 ng/ml EGF. 
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Table 5.1 Summary of ErbB RTK inhibitor (1 and 10 AM) attenuation of EGF-induced ErbBl 
and ErbB2 receptor tyrosine autophosphorylation 
P-Y122111222 
I pM P-Y992 P-Y1068 P-Y1148 P-Y1173 (ErbB2) 
GW459135 
++ ++/+++ +++ +++ +++ 
ErbB1 
GW808884 
ErbB1+2 
GW813324 
ErbB1+2 
GW282974 
ErbBl+2 
GSK916441 
ErbB2 
P-Y1221/1222 
10µM P -Y992 P Y1068 P-Y1148 P Y1173 (ErbB2) 
GW459135 
++/+++ +++ +++ +++ +++ 
ErbBl 
GW808884 
++/+++ ++/+++ ++/+++ ++/+++ +++ 
ErbB1+2 
GW813324 
++/++ ++/+++ ++/+++ +++ +++ 
ErbB1+2 
GW282974 
_ + + + +++ ErbB1+2 
GSK916441 
+++ ++ ++ ++ +++ 
ErbB2 
The extent of inhibition of the autophosphorylation of five ErbB receptor tyrosine residues 
exhibited by the five ErbB RTK inhibitor (listed by name with inhibitor type underneath) is 
represented and ranked out of three (arbitrary) where -=0 inhibition, += minor inhibition (20- 
30%), ++ = moderate inhibition (50-70%) and +++ = major inhibition (80-100%). P= phospho and 
Y= tyrosine. 
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Data obtained from this and the previous chapter (Chapter 4) present a conundrum 
regarding the pharmacological activity of the ErbB RTKIs used herein. Evidently, whilst 
the ErbBl selective inhibitor GW459135 demonstrated the highest degree of ErbB receptor 
autophosphorylation inhibition, it can not be ignored that, at the higher concentration of 10 
1M, three of the other ErbB RTKIs (GW808884, GW813324 - ErbB1+2 inhibitors and 
GSK916441 - ErbB2 inhibitor) also significantly reduced phosphorylation of tyrosine 
residues involved in the propagation of ERK1l2 signalling. Despite these observations, 
GW808884, GW813324 and GSK916441 showed no indication of inhibiting either EGF- 
induced MUC5AC mRNA expression (although this was inconclusive for GW813324 - 
Chapter 4) or downstream ERKI/2 activity (discussed below - section 5.10.4), even at 10 
µM. However, despite a varying ability to inhibit ErbB receptor tyrosine 
autophosphorylation, all the ErbB RTKIs investigated inhibited EGF-associated DNA 
synthesis at 1 µM (with very similar efficacies), with further reductions occurring at 10 µM, 
indicating that all the compounds were pharmacologically active. 
It is acknowledged that, in this chapter, only the phosphorylation of tyrosine residues 
involved in the manifestation of ERKI/2 signalling were examined. Hence it is possible 
that the ErbB RTKIs used in the present studies may reduce autophosphorylation of 
tyrosine residues which instigate other pathways involved in controlling cell proliferation 
(e. g. Akt, JNK, or PKC pathways), which were not investigated. 
The reasons for this disparity are unclear, but most likely involve pharmacological 
differences between the drugs rather than separate biological effects on ErbB receptor 
signalling. Data obtained from analysing ErbB receptor autophosphorylation showed that 
GW459135, the ErbBl selective inhibitor, had a higher efficacy than the other compounds 
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since autophosphorylation was reduced at 1 µM whereas the other compounds required 
concentrations as high as 10 µM before tyrosine autophosphorylation was attenuated. 
Differences in compound cellular permeability/penetration are unlikely to be an issue 
considering all five ErbB RTKIs inhibited DNA synthesis at 1 µM, with similar efficacy. 
Perhaps the most plausible explanation to describe the differences in pharmacological 
activity of the five ErbB RTKIs involves the concept of off-rates, or rates of dissociation. 
Dissociation of GW572016, another ErbB1+2 RTK inhibitor, requires a conformational 
change in EGFR which occurs slowly, equating to a slow dissociation rate of GW572016 
(Wood et al., 2004). Alternatively, the different structure of GW57201-bound EGFR may 
provide a very tight binding affinity that results in a slow off-rate, and a conformational 
change may not be involved in inhibitor dissociation (Wood et al., 2004). Either way, it is 
likely that GW459135 shares similar properties to GW57201, whereas the other four ErbB 
RTKIs examined may more readily dissociate from the ErbB receptor kinase domain. This 
is reflected in the data concerning EGF-induced MUC5AC mRNA expression (Chapter 4), 
DNA synthesis (Chapter 4), ErbB receptor tyrosine autophosphorylation (section 5.4) and 
ERKI/2 phosphorylation (section 5.8), where drug and stimulus incubation times were 
different. Based on time-course data indicating that activation occurred rapidly and 
diminished over time, particularly ErbB receptor phosphorylation, ErbB receptor and 
ERK1/2 phosphorylation were measured after five minutes (section 5.2). MUC5AC mRNA 
expression was measured after four hours and DNA synthesis was measured after 24 hours. 
Only GW459135 inhibited the biological outputs measured after short incubation times 
such as ErbB receptor autophosphorylation, downstream ERK1/2 phosphorylation and 
MUC5AC mRNA expression with minor or no changes occurring in the presence of the 
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other compounds. However, all ErbB RTKIs investigated herein inhibited DNA synthesis, 
which, through the nature of the process itself required a longer time point. 
Therefore it is possible that the rapid onset blockade of ErbB receptor signalling observed 
for GW459135 (both ErbB receptor and downstream ERK1/2 phosphorylation) was due to 
a more favourable ErbB receptor binding affinity/slow off rate, not matched by the other 
compounds. The ineffective ErbB RTKIs, although undoubtedly pharmacologically active, 
may dissociate more readily than GW459135 and require longer incubation times to elicit a 
pharmacological inhibitory effect on ErbB receptor signalling. Unfortunately, detailed 
information regarding compound structure and dissociation constants was not available, but 
would greatly help explain whether this concept is correct or not. Analysis of EGF-induced 
MUC5AC mRNA expression and ERKI/2 activity after longer incubation with the ErbB 
RTKIs might also merit investigation. 
5.10.5 Effect of ErbB RTKIs on ERK1/2 phosphorylation 
Since ErbB receptor-mediated induction of MUC5AC gene expression is ERKI/2 
dependent (Hewson et al., 2004), intervention of this induction by ErbB RTKIs must 
require the inhibition of ERK1/2 activity. This is exemplified perfectly by data in the 
present thesis whereby the only ErbB RTKI to convincingly attenuate EGF-induced 
MUC5AC mRNA expression (Chapter 4) was also the only inhibitor to block downstream 
ERK1/2 activity (section 5.8). The ErbBl selective inhibitor GW459135 reduced ERK1l2 
phosphorylation back to baseline levels at 1 µM (with no additional inhibition observed at 
10 µM) whilst the other four ErbB RTKIs had no effect, even at the higher concentration of 
10 µM. Other established ErbB RTKIs such as Gefitinib (ZD-1389) and Tarceva (OSI-774) 
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also display ERKI/2 inhibition at similar concentrations (and in a variety of cell lines) (Ono 
et al., 2004; Sutter et al., 2006). 
Of interest is the observation that the ErbB1+2 inhibitor, GW813324, which only partially 
inhibited EGF-induced MUC5AC mRNA expression (Chapter 4), showed no reduction in 
ERK1/2 phosphorylation, even at 10 µM (Fig. 5.12). From this point of view, it is hard to 
justify herein the inhibition of EGF-induced MUC5AC mRNA expression observed for 
GW813324 as being genuine blockade of ErbB receptor signalling, since there was no 
change in the activity of downstream ERKI/2. However, inhibition of ERK1/2 by ErbB 
RTKIs can be time-dependent and require incubation times as long as 48 hours (Hopfner et 
al., 2003; Zanchi et al., 2005), and considering ERKI/2 phosphorylation was only 
measured after only five minutes (as discussed above - section 5.10.3), GW813324 could 
potentially show inhibition of ERKI/2 activity after longer time points, as shown by other 
ErbB RTKIs. Further analysis of the pharmacological actions of GW813324 on ERKI/2 
activity is required to ascertain whether this is the case or not. 
5.11 Chapter Summary 
In this chapter, the ErbB receptor signalling mechanisms involved in EGF-induced 
MUC5AC mRNA expression were investigated and the effects of the five ErbB RTKIs on 
these mechanisms were also explored. 
EGF caused a rapid induction of both ErbB receptor tyrosine autophosphorylation and 
downstream ERKI/2 phosphorylation. It was confirmed that signalling of ERKI/2 was 
essential for EGF-induced MUC5AC mRNA expression, since the ERKI/2 inhibitor PD 
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98059 concentration-dependently attenuated this induction. In light of this observation, data 
generated from analysing EGF-induced ERKI/2 activation in the presence of the ErbB 
RTKIs clarifies why only the ErbBl selective inhibitor (GW459135) convincingly 
attenuated EGF-induced MUC5AC mRNA expression. 
GW459135 was the only compound to inhibit downstream ERK1/2 phosphorylation, and 
also the most potent compound at inhibiting ErbB receptor autophosphorylation. However, 
ErbB receptor autophosphorylation and ERK1/2 activity was measured after a very short 
incubation time (5 minutes - based on time-course data) and all five ErbB RTKIs evidently 
showed pharmacological activity after longer incubation times by inhibiting DNA synthesis 
(measured after 24 hours - Chapter 4). 
The latter phenomenon was attributed to a discrepancy in receptor off-rates whereby 
GW459135 dissociates from the ErbB 1 receptor complex much less readily than the other 
compounds, thus displaying pharmacological blockade at a faster rate than its counterparts. 
However, it must be acknowledge that information provided by GSK implied that 
GW459135 had off-target inhibitory effects on GSK-3ß, a protein that may potentially be 
involved in MUC5AC synthesis. To address this issue, further experiments are required to 
establish the exact mode of action through which GW459135 inhibited EGF- and PMA- 
induced MUC5AC expression. 
208 
CHAPTER 6 
GENERAL DISCUSSION 
The present thesis has highlighted a number of issues that merit more general discussion, 
and these are considered below. 
6.1 Context of current work 
The number of studies documenting the potential role of ErbB receptor signalling in the 
disease pathology of asthma and COPD, particularly in the context of mucin secretion, is 
now quite considerable. Studies have reported elevated ErbB receptor and ErbB receptor 
ligand expression in both asthma and COPD suggest (Amishima et al., 1998; Polosa et al., 
2002; Puddicombe et al., 2000; de Boer et al., 2006), as well as increased ErbBl receptor 
immunoreactivity in the goblet cells of asthmatics (Takeyama et al., 2001 a). These studies 
(amongst others) point to the possibility that ErbB receptors may provide a potential target 
for the treatment of mucus hyperscretion -a concept that has not gone unnoticed by 
pharmaceutical companies such as GSK (who indeed funded the current work). 
The data generated in the current thesis corroborates the already documented in vitro 
observation that MUC5AC synthesis, induced by a number of ErbB receptor signalling 
mechanisms, can be inhibited using small molecule, ErbB RTKIs (Shao et al., 2003; 
Takeyama et al., 2001b; Takeyama et al., 1999). It also confirms the previously reported 
importance of downstream ERKI/2 signalling in EGF-induced MUC5AC mRNA 
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expression (Perrais et al., 2002), since the ERKI/2 inhibitor, PD98059, also blocked EGF- 
induced MUC5AC mRNA expression herein. Taken in context, the data produced in the 
current thesis provides yet further in vitro evidence to suggest that ErbB receptor signalling 
may provide a potential target for reducing mucus hypersecretion. However, this thesis also 
highlighted the fact the interaction between ErbB receptor signalling and MUC5AC 
synthesis is complex, since only one of the ErbB RTKIs tested inhibited EGF-induced 
MUC5AC mRNA expression, despite all compounds showing some degree of inhibition of 
receptor autophosphorylation. 
6.2 Clinical implications 
The symptoms of airway mucus hypersecretion (including increased sputum and decreased 
mucus clearance) manifested in chronic airway inflammatory diseases can be controlled in 
asthma through the administration of glucorticosteroids (GCs) (section 1.4), but a lack of 
sensitivity to GCs is found in both COPD and severe asthma (Barnes et al., 2004; Holgate 
and Polosa, 2006; Wenzel and Busse, 2007). There is, therefore, an unmet need in the 
market for treatments specifically aimed at relieving increased mucus secretion in chronic 
airway inflammatory diseases. 
Data in this thesis (Chapters 4 and 5) support the already published observation that 
inhibition of ErbB receptor signalling attenuates the synthesis of airway mucin (sections 
1.7.2 and 1.7.3). However, it also indicates that compounds that display attenuation of ErbB 
receptor signalling do not necessarily inhibit ErbB receptor-mediated MUC5AC synthesis. 
The clinical implications of the current thesis are therefore very important as the data 
highlights the complexity involved in blocking ErbB receptor signalling related to specific 
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biological functions. Creating small molecule ATP mimics may not necessarily be a simple 
case of finding the most selective compound, but should provide the best strategy for 
inhibition of particular ErbB-receptor controlled processes, for example MUC5AC 
expression. 
The current thesis also begins to outline some of the mechanistic signalling processes 
implicated in ErbB receptor-mediated MUC5AC synthesis. With further characterisation of 
ErbB receptor-mediated MUC5AC expression, it may be possible to eliminate 
autophosphorylation of the specific tyrosine residues involved (e. g. with substrate blockers) 
which would help reduce any possible side effects. To the author's knowledge, an ErbB 
RTKI has yet to be logged for clinical trial with a view to development as a mucus 
hypersecretory treatment, despite the successful deployment of a number of ErbB RTKI 
compounds in the clinical treatment of ErbB receptor-related cancers. The information 
regarding the function of ErbB RTKIs on MUC5AC synthesis generated from this thesis 
will benefit future drug design of potential ErbB RTKIs intended for use as airway anti- 
mucus-hypersecretory treatments. 
Although ErbB RTKIs remain a possible future treatment for mucus hypersecretion, it is 
important to emphasise that completely inhibiting the secretion of mucus, even in patients 
suffering from mucus hypersecretion, would be an undesirable side effect of any 
pharmacological treatment of the symptom. Although mucus hypersecretion is a 
pathological symptom of both COPD and asthma, mucus secretion itself is an important 
homeostatic process, which, under normal circumstances, provides protection against 
inhaled irritants including noxious gases, particulates and bacteria. Complete suppression of 
mucus secretion in the lung would therefore be highly detrimental. 
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6.3 Protein kinase domains 
One topic not discussed previously, but paramount to the current thesis, is the highly 
conserved functionality of protein kinases and, more specifically, the catalytic domain of 
the kinase. The protein kinase family is divided into two major subfamilies: protein 
tyrosine kinases and protein serine-threonine kinases, both of which can be non-receptor or 
receptor associated (like that of the ErbB receptor subfamily) (Hanks and Hunter, 1995). 
Kinases facilitate the transfer of an ATP phosphate group to another protein, generating 
stimulatory or inhibitory effects, and providing an extremely important mechanism of 
regulation for a vast number of signal pathways. 
The number of proteins listed as having a kinase domain is considerable, but the actual 
phosphorylation event itself is carried out by a highly conserved, catalytic peptide sequence 
comprised of two lobes (N-lobe and C-lobe) (Hanks and Hunter, 1995). The majority of 
protein kinase domains require activation before they become catalytically active and the 
multiple stages of control involved in the switching "on" of kinase domains, such as 
binding of allosteric effectors (Pellicena and Kuriyan, 2006), allows for diversity in 
function between kinases. Once the protein kinase domain achieves an active conformation, 
ATP (complexed with a metal ion, generally Mg2) binds in a deep cleft between the two 
lobes of the kinase domain and the peptide substrate (housing the target residue - serine, 
threonine, or tyrosine) binds in an extended conformation close to the 7-phosphate of the 
ATP molecule (Adams, 2001). A centrally located "activation loop" provides a scaffold for 
the substrate and, for most kinases, requires phosphorylation to achieve an active 
conformation, thus providing another regulatory switch for kinase activity. A number of 
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key amino acid residues (aspartame, asparagine, and lysine) housed in the catalytic site are 
arranged in a precise, spatial manner and catalyse the phosphotransfer. These residues are 
unanimously conserved across the entire kinase family (Johnson et al., 1996). 
Many disease pathologies involve aberrant kinase signalling networks and developing 
pharmacological compounds to counteract this atypical activity can help in a clinical 
setting. The similarity in structure and catalytic activity between the kinase domains of all 
protein kinases (receptor and non-receptor associated) provides a framework with which to 
design pharmacological inhibitors. Some of the strategies employed in blocking protein 
kinase signalling are discussed below. 
6.4 Strategies for inhibition of protein kinases 
Based on their structure and function, there are at least three mechanisms for inhibiting 
protein kinase signalling; a pseudo-substrate mechanism, an adenine mimetic mechanism 
(employed by the compounds used herein) and a mechanism that involves locking the 
enzyme into an inactive conformation by using surfaces other than the active site (not 
discussed here). 
Although structure and function across the kinase family of proteins is very similar and 
donation of phosphate groups from ATP molecules is a prerequisite for all kinase activity, 
the development of adenine mimetics as kinase inhibitors remains the most common 
mechanism of pharmacological intervention. This seems a strange concept since the ATP 
binding pocket and catalytic site of the protein kinase domain contain highly conserved 
amino acid residues essential for activity (Taylor et al., 1992) - hence if one protein kinase 
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is blocked with an ATP-binding inhibitor, how is it that other protein kinases are not also 
affected by the same compound? A simple answer to this question is that, whilst the 
catalytic site of the kinase domain remains highly conserved, the ATP-binding site can vary 
between kinases and is also susceptible to multiple layers of regulatory procedures such as 
the binding of allosteric effectors (as mentioned above). In conjunction with this, distal 
recognition elements also help to diversify the function of the protein kinase domain 
(Adams, 2001), allowing proteins containing the kinase domain to have distinct and 
specific roles (despite the machinery behind the kinase activity being the same). This has 
led to a large array of specific kinase inhibitors based on blocking ATP-binding being 
developed over the past decade (section 1.8). 
Blocking complex kinase systems such as that of the ErbB receptor signalling cascade is, 
however, far from straight forward - as exemplified by data in the present thesis. Although 
specific inhibitors can be developed with high affinities for the ErbB receptor of choice, 
these compounds may still be subject to unacceptable side effects clinically, since the 
inhibitory nature of adenine mimetics effects the global signalling of the receptor kinase. 
Signalling systems like the ErbB receptor network employ multiple kinase cascades, 
consequently, completely blocking ATP binding not only silences the aberrant pathway, 
but all signal pathways together. In diseases such as asthma and COPD, where ErbB 
receptors are upregulated (section 1.7), this is perhaps less of a problem, but nonetheless 
side effects may occur due to a global "knock-down" of ErbB receptor activity. 
The future strategy of choice for inhibiting kinase systems, particularly complex receptor 
kinase networks, may therefore be the development of pseudo-substrates - blocking 
peptides designed to selectively inhibit the actual phosphorylation event of specific 
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tyrosine, threonine or serine amino acids (Taylor and Radzio-Andzelm, 1997). Most 
kinases have multiple targets or substrates (particularly ErbB receptors) which induce the 
signalling of specific pathways with specific biological end-points. Pseudo-substrate 
compounds, therefore, offer a mechanism of inhibiting specific kinase signalling pathways, 
dissecting out the abnormal pathway whilst leaving other networks untouched. 
6.5 Future directions 
A number of future research directions have been established from the studies herein and 
are considered below. 
1. In order to clarify the conclusions made herein regarding the difference in efficacies 
between the five ErbB RTKIs (Chapters 4 and 5), detailed analysis of the 
pharmacological properties for each compound is required. In conjunction, it would 
also be useful to study the effects of the ineffective ErbB RTKIs on EGF-induced 
MUC5AC mRNA expression at longer time points. This would ascertain whether the 
lack of attenuation seen for four out of the five inhibitors was indeed due to inhibitor- 
receptor dissociation rates (section 5.10.3). 
2. Further understanding of the signalling processes involved in the ErbB receptor- 
mediated induction of MUC5AC synthesis is essential for the development of future 
ErbB RTKI compounds capable of alleviating increased airway mucus production. 
Studies in this thesis have focused on ErbB receptor tyrosine substrates involved in the 
induction of ERKI/2 signal transduction pathways. However, detailed analysis of the 
ErbB phosphoproteome to map which tyrosine residue-containing substrates are most 
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important for signalling of MUC5AC mRNA expression would be advantageous. This 
could be achieved experimentally by either introducing specific substrate blockers to 
the system, or by direct point mutation of the ErbB receptor tyrosine residues. 
3. The five ErbB RTKIs used herein varied in their ability to inhibit the 
autophosphorylation of specific ErbB receptor tyrosine residues. The highly sensitive 
technique of tandem mass spectrometry (tandem MS - combining fragmentation 
techniques with multiple steps of mass selection or analysis) could be used to create a 
much more sensitive ErbB receptor phosphorylation profile for each compound, 
establishing precisely which ErbB receptor tyrosine residues are effected by each drug. 
4. Finally, the potential of the single ErbBI RTK inhibitor (GW459135) to inhibit mucin 
synthesis has been established herein in vitro. A crucial step in the development of this 
compound is to determine whether the observed in vitro effects also occur in an in vivo 
situation. Since ErbB receptor upregulation occurs both in patients with asthma and 
COPD (section 1.7.1), it would be beneficial to investigate the effects of GW459135 in 
animal models of both diseases. Animal-based models of COPD include porcine 
pancreatic elastase-induced strategies in rats (Birrell et al., 2005b), and models of 
asthma include ovalbumin challenges in mice (Kath et al., 2006) or rats (Birrell et al., 
2005a). In each case, the model selected would require characterisation in terms of 
airway ErbB receptor expression. End points for these studies would include 
assessment of mucin gene expression in tissue, protein expression in tissue and 
bronchoalveolar lavage (BAL) fluid, along with measurement of goblet cell number. 
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